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Abstract
The emergence of multi-drug resistance (MDR) to antimalarial and anticancer drugs has
stimulated a search for novel MDR inhibitors/reversers.  Bisbenzylisoquinoline alkaloids
(BBIQ) are potential agents for reversing MDR, especially when used as synergistic enhancers
of anticancer and antimalarial drugs with improved therapeutic efficacy. Despite numerous
useful biological activities reported for BBIQ’s, the various syntheses of individual members
remained cumbersome and the overall yields are low.  In addition, published methods are non-
stereospecific and produced racemates.
The aim of this project was to develop a synthetic pathway for the preparation of cycleanine, a
natural BBIQ with a symmetrical structure.  The protocols developed for the synthesis of
cycleanine will serve as a template for the synthesis of other BBIQ’s with more complex
structures. The only published total synthesis of cycleanine did not address regioselectivity and
stereoselectivity, furthermore, key steps suffered from extremely low yields of the products.
Our synthetic pathway is a chiral auxiliary-based asymmetric synthesis that generates
enantioselectively a 1,2,3,4-tetrahydroisoquinolines (THIQ) monomers. Cheap, commercially-
available starting materials were used to prepare monomers in a regioselective as well as
stereoselective manner in good yields.  The key feature of this method entails coupling of a
chiral β-phenethylamine and halophenylacetaldehyde using the Pictet-Spengler reaction. Due
to the difficulties encountered during the course of the preparation of monomers, different
methods were tried and formation of unanticipated products rationalised.  Dimeric BBIQ’s are
constituted of monomeric THIQ’s which are reported to have array of biological properties
including MDR reversing activities, therefore, the total synthesis of cycleanine will serve two
purposes.
In this investigation, the THIQ monomers were synthesised by a pathway that avoid harsh
reaction conditions.  Major reactions employed include nucleophilic aromatic substitutiton,
Wittig reaction, hydroboration and IBX oxidation. Some of the steps were attempted on model
compounds to optimise the conditions prior to attempting the reaction on cycleanine
iii
precursors.  Two major contributions toward the synthesis of BBIQ’s were made in this study.
The reaction conditions to control the regioselectivity and enantioselectivity of the Pictet-
Spengler reaction for the preparation of THIQ moiety were developed.  A major drawback of
the published syntheses of BBIQ’s is the harsh conditions and low yields associated with the
Ullmann reaction, which is used in the formation of the diaryl ether bonds.  We have shown
that the microwave-assisted nucleophilic aromatic substitution of aryl fluorides provide a much
superior method for the formation of the key diaryl ether bond.
Although we failed to form the final diaryl ether bond, the pitfalls encountered in the synthetic
pathway are discussed and potential solutions are presented.  The developed synthetic
pathways are of general applicability and therefore can also be employed in the synthesis of
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For thousands of years, infectious diseases have been a major cause of suffering. Despite
important advances in the combating of these diseases, they continue to be a cause of
serious illness and death in the world.  A number of drugs are used against infectious
diseases such as TB, HIV/AIDS, malaria and cancer.  However, their use is limited by high
cost, toxicity and development of microorganisms’ resistance.  Drugs are the mainstay of
the management and prevention of infectious diseases and this is unlikely to change in the
near future.
This chapter reviews the dangers of infectious diseases with a focus on malaria, TB,
hepatitis C virus (HCV) and HIV/AIDS worldwide. Epidemiology, co-infection within
these diseases as well as the current treatments are also outlined.  The impact of resistance
on the current treatments brings us to the aim of the project, that is, the synthesis of
potential multidrug resistance reversers.
1.2 Infectious diseases
The discovery of antibiotics has transformed humanity’s approach to infectious diseases
and that led to optimism that infectious diseases could be controlled. The existence of safe
and effective interventions, such as the development of antibiotics and vaccines, along with
improvements in material standards in terms of housing, nutrition, hygiene, sanitation and
vector control epidemics led many to predict the end of infectious diseases.1 However,
today we know that this optimism was premature since humanity is faced with another
crisis, that is, the ability of microbes to change and adapt.
During the past thirty years, newly discovered infectious diseases such as H1N1 flu (swine
flu), H5N1 flu (bird flu), severe acute respiratory syndrome (SARS), ebola and human
immunodeficiency virus (HIV) have brought unexpected challenges to mankind.2  The
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resurgence and emergence of old diseases such as cholera, malaria and TB (tuberculosis),
which seem to be under control in developed countries, have become a public health
problem in developing countries and are rapidly becoming difficult to treat.  A serious
problem worldwide associated with the resurgence of old diseases is drug resistance.
Furthermore, chronic diseases once thought to be unrelated to infectious diseases are now
linked to bacterial, viral or parasitic agents.  Research indicates that viruses are involved in
15-20% of all human cancers, for example, cervical cancer, a major killer of women
worldwide,3 is caused by the human papilloma virus.
The following paragraphs will concentrate on HIV/AIDS, malaria, TB and HCV, since
these four possesses similarities outlined below.  The global epidemiology of HIV/AIDS,
malaria, TB and cancer overlap because a significant number of HIV-infected individuals
die from TB and they also live in regions where malaria is a problem.  In addition, the




Globally 500 million people are infected by malaria and at least 1 million die each year.4
Although malaria occurs in tropical and subtropical developing countries on all continents,
and today 90% of malaria cases and deaths are recorded in sub-Saharan Africa.  The
individuals most at risk are children under the age of five and pregnant women.5 The
chemotherapy and prophylaxis of malaria have been undermined by the development of
worldwide resistance against drugs of Plasmodium falciparum, a causative agent of human
malaria (Fig. 1.1).
www.malaria.com/info/malaria-countries-map.php
Figure 1.1:  Distribution of malaria.*




HIV is a retrovirus acquired through sexual contact, from mother to child (during
pregnancy, labour or through breast milk), or by contaminated blood, that attacks and
gradually depletes an individual’s immune capacity to fight off deadly infections, leading
to acquired immunodeficiency syndrome (AIDS). It has been estimated that in 2009, 33.3
million people were infected with HIV/AIDS worldwide, with approximately 22.5 million
living in sub-Saharan Africa. Around 1.3 million people died from HIV/AIDS in 2009 in
this region (Fig. 1.2).6 Even though treatment is available, a growing number of
individuals with HIV develop AIDS because of both drug resistance and toxic side effects
of primary drugs.  Furthermore, there is evidence that indicates that the development of
resistance to one inhibitor quickly leads to insensitivity to the entire family of drugs.7
www.who.int/.../en/index3.html
Figure 1.2: HIV prevalence.*
1.3.3 Tuberculosis (TB)
TB, a highly contagious pulmonary infection caused by Mycobacterium tuberculosis,
continuously exists as a leading infectious disease agent that follows poverty and urban
crowding, causing millions of deaths each year. Worldwide, TB remains the world’s
number one bacterial killer, and current trends suggest that TB will still be among the ten
leading deadly diseases in the year 2020.8 The emergence of extremely drug-resistant TB
strains (XDR TB) indicates the survival strategies adopted by the organism to continue
mutating the drug targets. Low income and emerging economic groups are more likely to
be affected.  Africa, more specifically sub-Saharan Africa, has the highest incidence of TB,
with approximately 290/100 000 per year (Fig. 1.3).8 TB cases occur predominantly in the




Figure 1.3:  Estimated HIV prevalence in TB cases.*
1.3.4 Hepatitis C virus (HCV)
Worldwide about 170 million people are infected with HCV with 2-3% chronically
infected9 accounting for 250 000 deaths annually.10  Approximately 20% of the infected
people may develop cirrhosis over a 20 to 50 year period.  These statistics indicate the
need for effective, non-toxic, and affordable treatments for HCV.
1.4 Co-infection of malaria, HCV, TB and HIV/AIDS
HIV and malaria overlap in many countries, particularly in sub-Saharan Africa, Asia, Latin
America and the Caribbean.11  HIV infection can increase the risk and severity of malaria
infection.  Also, individuals in malaria-endemic areas who are considered semi-immune to
malaria can develop clinical malaria if infected with HIV. Likewise, when infected with
malaria, a person’s HIV viral load rises.12
TB is the most common opportunistic infection in people living with HIV worldwide.
Despite being preventable and treatable, TB is the leading killer in HIV-positive
individuals. People with M. tuberculosis infection who are HIV-positive, are at risk of
developing active TB at a rate of 7 to 10% per year, compared to approximately 8% per
lifetime for HIV-negative individuals.8  Thus, HIV infection tends to increase the severity
of TB, while in turn, the host immune response to M. tuberculosis can enhance HIV
replication and may accelerate the natural course of HIV/AIDS.
* Reproduced with permission from WHO.
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HCV is associated with HIV, with an estimated 4 to 5 million people co-infected with
HIV/HCV.13  Due to overlapping transmission routes (transmitted via shared needles and
other injection equipment), HIV accelerates HCV progression.  HIV co-infection
significantly increases the risk of developing serious liver diseases.
1.5 Current treatment recommendations
Chemotherapy is the most important treatment of malaria.  Chloroquine (1.1) resistance in
the most pathogenic malaria species, Plasmodium falciparum, is widespread.  To limit the
development of drug resistance, the World Health Organisation (WHO) currently
recommends that treatment consists of a combination of drugs that act on different parasite
targets and have favourable pharmacokinetic profiles.  Among the recommended drugs, the
use of an artemisin-combination therapy (ACT) containing artemether (1.2) with
lumefantrine or artesunate (1.3) with either mefloquine (1.4) or a combination of














































Figure 1.4: The chemical structures of drugs used for malaria.
The most widely used anti-HIV drugs are nucleoside reverse transcriptase inhibitors
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors
(PIs).  The NRTIs include zidovudine (AZT) (1.7), stavudine (1.8), lamivudine (1.9),
abacavir, emitricitabine, didanosine and tenofovir, the NNRTIs include nevirapine (1.10)
and efavirenz (1.11) and PIs include saquinavir (1.12), ritonavir, tipranavir, among others
(Fig. 1.5).  Antiretroviral treatment is not curative and drug resistance has been reported.
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The current HIV/AIDS treatment known as highly-active antiretroviral treatment
(HAART) has proven to be highly effective and particularly in the prevention of drug
resistance.15 It consists of three agents, normally two NRTIs and either an NNRTI or PI.
However, HAART treatment is limited by several factors such as costs, shelf life, pill
















































Figure 1.5: The chemical structures of some drugs that are currently used for HIV/AIDS
treatment.
The initial treatment of TB takes 6 to 8 months.  This treatment consists of four
medications taken at least three times a week for two months, followed by 4 to 6 months of
two medications daily.  The drugs used are rifampin (R) (1.13), isoniazid (H) (1.14),
ethambutol (E) (1.15) and pyrazinamide (Z) (1.16) which are taken for two months daily or
thrice weekly, followed by four months of HR or six months of HE (Fig. 1.6).16  Treatment
of TB in the presence of HIV is complicated by drug-drug interactions.  Maximal drug
levels or total drug exposure over time of antiretroviral agents may be reduced when these
drugs are co-administered with rifamycins, reducing the efficacy of HAART regimens.
This limits the treatment of people co-infected who need therapy for both conditions.
With HCV, the aim of therapy is to achieve an undetectable HCV 6 months following
therapy and ultimately to reduce hepatic inflammation.  The standard therapy is the
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injection of pegylated interferon with daily ribavirin capsules, with doses administered
according to body weight.17  Although pegylated interferon is considered to be effective
than its predecessor standard interferon, it has limitations to efficacy, tolerability and the
problem of drug resistance remains.
It is unfortunate that many of the new drugs are not only expensive, but have serious side
effects and most will eventually become ineffective due to the rapid mutation of




































Figure 1.6: The chemical structures of drugs used in TB treatment.
The geographical overlap of malaria, HCV, TB and HIV prevalence increase the likelihood
that these diseases co-exist in a large number of individuals. These people will have to use
antimalarial, antitubercular, antiretroviral and antihepatitis C drugs at the same time and
drug-drug interactions may result from concurrent administration of drugs leading to
diminished therapeutic efficacy or increased toxicity.  Many antiretroviral agents and
antimalarial agents commonly used are metabolised by the same cytochrome P450
enzymes, and antituberculars (rafimycins) are known to be cytochrome P450 enzyme
inducers and consequently depending on the drug combinations, the total drug exposure
over time will be altered.
Introduction Chapter 1
8
1.6 Drug resistance and P-glycoprotein homologues
It came as an unpleasant surprise that shortly after the introduction of various classes of
drugs, new pathogenic strains emerged that were no longer susceptible to these drugs.  The
emergence of resistant microorganisms is known to be a consequence of widespread drugs
usage, changes in human ecology, changes in personal behaviour, and human-induced
global changes, which result in the survival of genetically modified organisms that can
reproduce in the presence of a particular drug.18  Modifications can come from
spontaneous mutations, overexpression of certain genes and overproduction of their gene
products or acquisition of genetic material from other microorganisms.  These changes can
confer resistance in several ways, including an enzyme-catalysed reaction that renders the
drug inactive, mutations in the organisms that can result in changes in the biological target,
decreased cell-wall permeability by mutation-induced genetic changes.  Membrane
associated P-glycoproteins (P-gp’s) have been found to be overexpressed in multidrug
resistance (MDR) cancer cells and they are the most common cause of upregulation of
drug efflux.19
P-gp’s are a member of the ATP-binding cassette (ABC) family and plays a role in drug
resistance. P-gp’s homologues are found in important epithelial barriers, such as the
intestinal epithelium, the blood-brain and blood-nerve barrier, the blood-testis barrier and
the materno-fetal barrier, where it prevents drugs in the bloodstreams to cross these
epithelial barriers, thereby contributing to low bioavailability of drugs.21 P-gp’s use two
ATP molecules to extrude one molecule of drug. Initially the drug and ATP binds to the
protein and one ATP is hydrolysed to ADP to efflux the drug. Another ATP is used to
reorient the protein to its original conformation, with the release of ADP to complete a
catalytic cycle (Fig. 1.7).22 In cancer chemotherapy P-gp’s have been found in untreated
malignancies, including neuroblastoma22 and acute myeloid leukemia.23
Figure 1.7:  P-gp-mediated drug transport.21
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In drug-resistant malaria the presence of a similar glycoprotein pump has also been
observed.24 It has also been demonstrated that most of the MDR reversing agents inhibit
the binding of drugs to P-gp, resulting in a lowered efflux and accumulation of drugs in
MDR cells.25 Furthermore, there is evidence that both mefloquine26 and PIs27 can inhibit
drug partitioning by inhibiting P-glycoprotein (P-gp) homologues.  Therefore, P-gp is a
promising target for HIV, TB, HCV and malaria therapies.15
Viruses replicate within cells, therefore, drugs that target replication must penetrate into
infected cells in sufficiently high concentrations to exert their effect.  P-gp’s play a role in
the low intracellular concentration of drugs and P-gp inhibitors, which can be taken
simultaneously with the current drugs, could hopefully increase efficacy as well as
shortening the duration of therapy.
1.7 Bisbenzyltetrahydroisoquinolines as potential MDR reversers
Plants have been used as medicines for millennia and they have been the main medicinal
agents available to humans.  Today most of the people in developing countries still consult
traditional medicine practitioners and use local medicinal plants for primary health care.
The abundant biosynthetic pathways in plants have provided a number of lead structures
























Figure 1.8: Plant-derived products used in the discovery of drugs.
A typical example is , camptothecin (1.17), a monoterpenoid alkaloid isolated from the
Chinese ornamental tree Camptotheca acuminate,28 from which two derivatives, topotecan
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(1.18) and irinotecan (1.19) (a pro-drug), less toxic and more stable than camptothecin
(1.17) (Fig. 1.8), were developed and are currently used for the treatment of colorectal and
ovarian cancers.29 Alkaloids (generally defined as nitrogen-containing natural molecules,
independently of the basic character of the nitrogen) are abundant secondary metabolites in
plants with well-known toxic, hallucinogenic and euphoric properties. In a review by
Teodori et al.,30 several natural compounds with MDR-inhibiting properties, amongst them
alkaloids, were listed. The general features that were reported important for MDR
antagonism, are high lipophilicity, presence of a protonable nitrogen atom and one or more
aromatic rings.30
Among the alkaloids, bisbenzyltetrahydroisoquinolines (BBIQ’s) constitute a broad group
of homodimeric benzylisoquinolines, with more than 400 examples known.31  BBIQ’s
represent 40% of the total number of alkaloids isolated from plants of the Menispermaceae,
hence, they are considered good chemical markers for this family.
As mentioned, it has been suggested that MDR can be reversed by hydrophobic molecules
with two planar aromatic rings and a tertiary basic nitrogen that can be protonated at
physiologic pH.32  A calcium blocker verapamil (1.20), a representative of this class, is
effective against malaria. However, it is toxic at levels high enough to affect MDR









BBIQ’s have attracted the attention of synthetic organic chemists and pharmacologists due
to their complex structures and wide range of biological activities, namely, antibacterial
and antifugal,34 cytotoxic,35 antimalarial,36 anticancer,37 hypotensive38and antiplasmodial39
activities. BBIQ’s as MDR reversers have been documented.40,41,42,43,44,45 Van Dyke46
tested the tetrandrine family of compounds as well as non-tetrandrine compounds to
determine the efficiency of BBIQ’s as MDR reversers against drug resistant strain of P.
falciparum and with cancer cells with MDR in conjugation with primary drugs known to














Configuration R1  R2  R3
Tetrandrine S, S H  Me  Me
Isotetrandrine R, S H  Me  Me
Phaeanthine R, R H  Me  Me
Hernandezine S, S OMe  Me  Me
Pycnamine R, R H Me H
Berbamine R, S H Me H
Fangchinoline S, S H H  Me
Obamegine R, S H H  H
Figure 1.9: Representatives of the tetrandrine family tested for MDR inhibition.
Of the nine tetrandrine-like compounds, only tetrandrine, isotetrandrine, berbamine and
hernandezine potentiate the primary drugs against MDR cells. The non-tetrandrine
compounds tested include cycleanine (1.21), cepharanthine (1.22) and thalicarpine (1.23).
Even though cycleanine (1.21) showed a relative low activity in potentiation of primary
drugs against MDR cells, the lack of cytotoxicity observed with cycleanine is remarkable
among the BBIQ’s tested to date. Moreover, cycleanine have showed activity against












































Figure 1.10:  Non-tetrandrine compounds tested for MDR inhibition.
The inherent antimalarial and/or anticancer activities of BBIQ’s combined with their
ability to reverse MDR, make these compounds interesting candidates for drug discovery.
1.8 Hypothesis and objectives
Despite numerous useful biological activities reported for BBIQ’s, the various syntheses of
individual members remained cumbersome and the overall yields are low. The published
methods are non-stereospecific and produce racemates. The aim of this project was to
develop a synthetic pathway for the preparation of cycleanine (1.21).  Cycleanine (1.21) is
considered to be the least complex member of the BBIQ’s due to its symmetrical nature
and its synthesis is expected to be simple, however, several attempts have met with failure.
The total synthesis of cycleanine (1.21) will serve as a template for the preparation of more
complex BBIQ’s. Furthermore, it will be possible to modify the structure and to find more
effective MDR inhibitors or reversers with low toxicity.
The overall objective of this study relates to the development of synthetic routes for
cycleanine (1.21). The main aims were:
 Planning of efficient methodologies related to cost and time towards total synthesis
of cycleanine (1.21)
 Flexible and versatile strategies which allow synthesis of intermediates
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 Synthesis of the monomeric tetrahydroisoquinoline moiety in stereoselective and
regioselective manner
 Synthesis of highly enantiomerically-pure intermediates
 Regioselective formation of the ether linkage through phenol coupling
 Optimisation of the yields throughout the multistep synthesis
 Employment of simple experimental protocols with mild reaction conditions
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This chapter details the classification of bisbenzyltetrahydroisoquinoline (BBIQ) alkaloids
according to the number of bonds joining the two monomers, with examples focussed
mostly on compounds with diphenyl ether linkages.  Selected previous total syntheses of
BBIQ’s are also outlined. Different synthetic methods for the preparation of the monomers
followed by the protocols to the key diaryl ether linkages are described.
2.2 Classification of bisbenzyltetrahydroisoquinoline alkaloids
Bisbenzyltetrahydroisoquinoline (BBIQ) alkaloids are dimeric compounds assembled from
two benzylisoquinoline or in most cases benzyltetrahydroisoquinoline monomers.  The two
moieties are normally connected by one or more diaryl ether bridges, but in some cases
carbon-carbon bonds or a methylenoxy bridge may also be present.  The BBIQ alkaloids
are classified according to the nature, the number, and the attachment points of the bridges.
In each subgroup, the alkaloids differ by the nature of their oxygenated substituents, the
degree of unsaturation of the heterocyclic rings and the stereochemistry of the two chiral
centres, C-1 and C-1'.    The numbering of the skeleton and the systematic classification
describing the oxygenation and dimerisation patterns of BBIQ’s follow the convention
established by Shamma and Moniot1 (Figure 2.1).  The more highly oxygenated half
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Figure 2.1: Numbering of BBIQ’s.
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Most BBIQ’s are formed by the condensation of coclaurine (2.1) or N-methylcoclaurine
(2.2), with a minority originating from N-methylcoclaurine (2.2) and reticuline (2.3) and
exceptions resulting from the condensation of two reticuline molecules, hence, they can be

















Fundamental types of BBIQ’s can be distinguished according to the number of bonds
binding the two halves and can be further subcategorised according to the position of the
bonds (head or tail).  Presented below are examples of BBIQ’s highlighting the structural
variations that exist within this class of alkaloids and special attention has been given to
those possessing the diphenyl ether moiety.
The simplest members are those in which the two halves are joined together by a tail-to-tail
linkage (the isoquinoline portion is referred as the head and the benzyl portion as the tail)
(Table 2.1).  Most of the BBIQ’s linked tail-to-tail possess the R,R-configuration at C-1
and C-1’ and they are linked by the diphenyl ether linkage, the vasodilator dauricine (2.4)
provides an example of this type.  Malekulatine (2.5), isolated from Hernandia sonora,2
represents a subgroup of alkaloids with a head-to-tail diphenyl ether linkage. No head-to-
head single-bonded BBIQ have been reported to date.



























Dauricine (2.4) Malekulatine (2.5)
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The biscoclaurine alkaloid, cepharanthine (1.22), is a potent agent against the multidrug-
resistant cancer cells that overexpress P-gp.3  It is a member of the alkaloids with head-to-
head and tail-to-tail diphenyl ethers, featuring a unique methylenedioxy group on its
benzylisoquinoline moiety (Table 2.2).  A potent antimalarial agent monterine (2.6)
belongs to a subgroup of alkaloids with diphenyl ether as well as diaryl bonds.  Cycleanine
(1.21), a symmetrical isochondoderine BBIQ containing eight electron-donating sites, is
considered as a true dimer consisting of the same two benzylisoquinoline moieties.
Cycleatjehenine (2.7) belongs to a subgroup of BBIQ’s with the two benzylisoquinoline
moieties linked by diphenoxy head-to-tail and methylenoxy head-to-tail bridges.  This
subgroup possesses a fully unsaturated isoquinoline ring and has been isolated so far only
from Cyclea atjehenisis.4





















































Cycleanine (1.21) Cycleatjehenine (2.7)
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Only a minority of compounds falls within the category where the two monomers are
connected by three bonds (Table 2.3).  Cocsoline (2.8), with a dibenzo-p-dioxin system, is
a representative of this subgroup.  Tiliaresine (2.9) belongs to a subgroup of BBIQ’s in
which the tails are coupled through a direct carbon-carbon bond, rather than through the
more common diaryl ether bridge.  Variants of the compounds displayed in Table 2.3 are
known primarily as arising from the isomerisation at C-1 of the isoquinoline rings, as well
as the degree of O-methylation.

























Cocsoline (2.8) Tiliaresine (2.9)
2.3 Previous synthetic studies of bisbenzyltetrahydroisoquinolines
In general, the original goal of total synthesis to confirm the structure of natural products
has been slowly replaced by the biological importance of the compounds and/or the
discovery of new chemistry along the pathway to the target molecule.  Although various
efforts in a number of laboratories have generated several approaches over the last five
decades, there are only a few successful total syntheses of BBIQ’s.  This suggests that
BBIQ’s are very challenging molecules in terms of synthetic targets and it is evident that a
lot of work still needs to be done in this arena.  The following paragraphs review synthetic
approaches to selected BBIQ’s.
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2.3.1 Synthesis of cycleanine (1.21)
Discovered by Kondo et al.5 from Cyclea insularis (Makino) Diels in 1937, cycleanine
(1.21) proved to be a true dimer with a symmetrical structure involving two diphenyl ether
linkages.  Almost thirty years after its isolation, Tomita et al.6 reported the only published
total synthesis of cycleanine (1.21) (Scheme 2.1). Ullmann reactions were used in the






















































































































Scheme 2.1: Synthesis of cycleanine (1.21).
Fundamental aspects of bisbenzylisoquinolines Chapter 2
22
Condensation of 2.10 and 2.11 utilising N,N’-dicyclohexylcarbodiimide (DCCD) gave a
viscous oily amide, which was further converted to cyclobisamide 2.12 in 17% yield,
thereby setting the stage for the key Bischler-Napieralski cyclisation.  This Bischler-
Napieralski reaction proved to be particularly efficient and well suited to afford a
macrocyclic system with concomitant formation of the two stereogenic centres.  However,
cyclisation of cyclobisamide 2.12 gave cycleanine (1.21) in a low yield (0.067%), together
with two isomers 2.13 (0.23%) and 2.14 (1.9%), showing the lack of regioselectivity as
well as stereoselectivity of this route. This route was also not enantioselective.
2.3.2 Synthesis of isotetrandrine (2.25), tetrandrine (2.26) and phaeanthine (2.27)
The arrival of tetrandrine (first isolation in 1935)7 and its relatives, collectively known as
the tetrandrine family, on the scene in the 1930’s presented a new synthetic challenge.  In
addition to constructing the macrocyclic framework, one must also address the challenge
of obtaining the correct stereoisomers.  Inubushi and co-workers8 were the first to complete
the total synthesis of isotetrandrine (2.25), tetrandrine (2.26) and phaeanthine (2.27) by a
common pathway (Scheme 2.2).
They adopted the strategy of first synthesising the tetrahydroisoquinoline via the Bischler-
Napieralski reaction followed by formation of the diphenyl ether under Ullmann
conditions. The intermediate 2.17 was prepared from the acid 2.15 and amine 2.16 and the
reduced Bischler-Napieralski product 2.18 was resolved by using tartaric acid.  Compound
2.17 has two sites available for cyclisation, but the original publication did not comment on
the regioselectivity of the ring closure. Ullmann reaction between 2.19 and 2.20 gave 2.21
in 50% yield and the second Ullmann reaction between 2.21 and methyl p-
bromophenylacetate afforded compound 2.22 in 48%. Cyclisation of 2.23 under Bischler-
Napieralski reaction furnished 2.24 in 87%.
Reduction of 3,4-dihydroisoquinoline 2.24 under different sets of conditions gave different
products.  Reduction using zinc in ethanol-20% aqueous sulfuric acid followed by
methylation afforded tetrandrine (2.26).  Separation of diastereomers obtained by reduction
using sodium borohydride in methanol at room temperature gave a mixture of
isotetrandrine (2.25) and phaeanthine (2.27). Repetition of reactions in this scheme makes
the route viable, for example, two sequential Ullmann reactions between 2.19 and 2.20 and
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a second one between 2.21 and 2.22, and two Bischler-Napieralski reactions of 2.17 to
2.18 and 2.23 to 2.24.  However, in this route the final stage is equivocal, because the




































































































































Scheme 2.2: Synthesis of isotetrandrine (2.25), tetrandrine (2.26) and phaeanthine (2.27).
Fundamental aspects of bisbenzylisoquinolines Chapter 2
24







































































































































2.30a: R1 = COC6H5, R2 = H, R3 = H
2.30b: R1 = COC6H5, R2 = CH3, R3 = H
2.30c: R1 = COC6H5, R2 = CH3, R3 = H
2.30d: R1 = H, R2 = CH3, R3 = H



















Scheme 2.3: Synthesis of obaberine (2.30e), trilobine (2.33) and isotrilobine (2.34).
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Following their success with the synthesis of isotetrandrine (2.25), tetrandrine (2.26) and
phaeanthine (2.27), Inubushi et al.9 reported the total synthesis of obaberine (2.32),
trilobine (2.33) and isotrilobine (2.34) (Scheme 2.3).  Stimulated by the antitumor effect of
isotrilobine (2.34) against HeLa and HeLa-S3 cells, Ehrlich ascites carcinoma (ascites
tumor) and Sarcoma-180 (solid tumor),10 the group embarked on the total synthesis of
obaberine (2.30e) trilobine (2.33) and isotrilobine (2.34).  The same strategy employed for
the synthesis of the tetrandrine family was used.
The major highlight of this method was the highly regioselective Bischler-Napieralski
cyclisation of the amide 2.28 to give regioisomer 2.29 as the sole product in a yield of
77%. Sodium borohydride reduction of compound 2.29 gave a diastereoisomeric mixture
of 2.30a in 90% yield and a subsequent N-methylation resulted in mixture of compounds
2.30b and 2.30c. Hydrogenation of 2.30c afforded 2.30d and N-methylation with formalin-
NaBH4 furnished obaberine (2.30e) in 30% yield from 2.30d.  Reduction of 2.30b
followed by demethylation gave the per-O-demethylated product 2.31, which set the stage
for the preparation of the dibenzo-p-dioxin nucleus which was formed by the treatment of
2.31 with HBr.  Methylation and a subsequent hydrogenolysis of 2.32 afforded trilobine
(2.33). Trilobine (2.33) was transformed into isotrilobine (2.34) by N-methylation. This is
the only report to date presenting the total synthesis of a BBIQ containing three diphenyl
ether linkages.  Furthermore, this total synthesis demonstrates the power of synthesis to
deliver large numbers of complex structures for biological investigations.
2.3.4 Approach towards macrocyclic BBIQ analogues by Al-Hiari and co-workers
The challenging molecular architecture, coupled with the biological actions of BBIQ’s
prompted Al-Hiari et al.11 to undertake studies toward the total synthesis of a BBIQ
(Scheme 2.4).  Their attempt was based on the incorporation of a sulfur ‘stitch’, which
would hold the BBIQ in an appropriate conformation for cyclisation.  The key intermediate
2.37 was synthesised via bromination of phenoxathiin dioxide 2.36, formed from oxidation
of phenoxathiin 2.35. Regeneration of the sulfone linkage by DIBAL from the dinitro
derivative 2.37 was necessary for ring closure after formylation. Cyclisation of the
diformyl derivative 2.39 to pentacyclic imine 2.40 yielded two more undesired products
(2.40a and 2.40b) where cyclisation occurred in inappropriate positions of 2.39.  Since the
products decompose in solution, they were not separated, hence, after the poor prospects of
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the envisaged Grignard reaction, the mixture was N-derivatised, lithiated and alkylated to
compound 2.41.  Even though this group did not manage to do debenzylation, coupling and



















































































Scheme 2.4: Approach to the total synthesis of BBIQ by Al-Hiari and co-workers.
2.3.5 Synthesis of the laudanosine analogues
Thalicarpine (2.43), a BBIQ comprised of the benzylisoquinoline S-laudanosine connected
with an ether linkage to an aporphine moiety, is active against Walker 256 carcinoma cells
and Lewis lung tumor system.12,13





































Inspired by the complex structure and biological activity of thalicarpine (2.43), the Pyne14
group at Wollongong University investigated the total synthesis of unnatural laudanosine
analogues such as 2.44, 2.45 and 2.50. The preparation of 2.50 involved the Ullmann
condensation of 2.46 to the key biaryl bond in 2.47 early in the synthesis followed by the
construction of the BBIQ.  The biphenyl 2.48 was converted to 2.49 using a standard
Bischler-Napieralski cyclisation with a subsequent reduction-methylation to yield 2.50
(Scheme 2.5).



































































Scheme 2.5: Pyne and co-workers synthesis of thalicarpine analogue.
Following this success, the same group presented the synthesis of similar compounds using
the Mizoroki-Heck and Sonogashira coupling reactions.15 Their approach to the target
compounds with an alkene linker used racemic N-trifluoroacetyl-2’-iodonorlaudanosine
(2.51) as starting material (Scheme 2.6). A palladium-catalysed reaction using Stille’s
conditions between 2.51 and 2.52 gave 2.53 in 79% yield when palladium chloride was
used with palladium acetate providing better yields of 87%. The Mizoroki-Heck reaction
between 2.51 and 2.53 resulted in two geometric isomers which were inseparable by
column chromatography, but the major isomer 2.54 precipitated from MeOH. Base-
catalysed hydrolysis of 2.54 afforded a dimer with an alkene linker 2.55 which after
hydrogenation furnished the target compound 2.56.  This method is short and
straightforward, however, regioselectivity and stereoselectivity problems are not dealt
with.









































100 oC, 36 h  Pd(OAc)2, base
additive, solvent


















Scheme 2.6: Palladium-catalysed synthesis of the novel laudanosine dimer.
Similarly the macrocycle 2.64 was prepared by palladium-catalysed reaction using Stille’s
conditions.  Thus, N-trifluoroacetyl-2’-iodonorlaudanosine (2.51) was condensed with an
alkene 2.52 to furnish 2.58, which was hydrolysed to 2.59. Acylation of secondary
racemic amine 2.59 with succinic anhydride (2.60) gave the amide 2.61. Coupling
between the amide 2.61 and 2’-bromobenzylisoquinoline derivative gave 2.63 in 82%
yield. The desired macrocycle 2.64 was formed in 15% yield under traditional Heck
reaction conditions [Pd(OAc)2, PPh3 and Et3N] (Scheme 2.7).























































































Scheme 2.7: Palladium-catalysed synthesis of the macrocyclic laudanosine.
Prompted by the potential anticancer activity of BBIQ’s, Batenburg-Nguyen et al.16 have
reported the synthesis of laudanosine dimers based on ruthenium-mediated cross-
metathesis (CM) reactions as well ruthenium-catalysed ring closing metathesis (RCM) for
the synthesis of conformationally restricted macrocyclic BBIQ derivatives.  This method
used the same starting compound 2.58, but coupling and ring closing was achieved by
metathesis reactions. The derivative 2.58 was treated with Grubbs I (2.67) catalyst to
afford the homocoupled isomers 2.65 and 2.66 in 72% yield (Scheme 2.8).  Yet, when 2’-
vinyllaudanosine was subjected under the same CM conditions, no homocoupled products
could be obtained.  However, changing from Grubbs I (2.67) to Grubbs II (2.68) catalysts
(Fig 2.3) resulted in increased reactivity of the alkene and more product was obtained.
































N2, reflux, 24 h
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2.58 2.662.65
Scheme 2.8: Ruthenium-mediated cross-metathesis (CM) synthesis of the novel
laudanosine dimers.
RCM was used to construct the target compound 2.45 (Scheme 2.9).  Base-catalysed
deprotection of 2.58 and a subsequent acylation of amine 2.59 with succinic acid (2.60)
afforded the carboxylic acid 2.69. The slow amide coupling reaction (over 3 days) between
2.59 and 2.69 afforded 2.71 in 62% yield.  Intramolecular RCM of 2.70 using Grubbs I
(2.67) catalyst in DCM afforded 2.71 in 35% yield, and reduction of the carbonyl groups












Grubbs' catalyst I Grubbs' s catalyst II
2.67 2.68
Figure 2.2: Grubbs’catalysts 2.67 and 2.68.
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Scheme 2.9: Ruthenium-mediated cross-metathesis (CM) synthesis of the macrocyclic
laudanosine.
Within our group, the isolation of small amounts of BBIQ’s from plant materials by
Helene de Wet17 emphasised the importance to embark on the total synthesis of BBIQ’s to
produce more material needed for biological testing.  In the field of total synthesis of
BBIQ’s Maumela18 (from our group) has made a valuable contribution. Most importantly,
his endeavour led to the development of useful synthetic reactions.  Amongst them are the
improvement of the Ullmann coupling between electron-rich aryl halides and electron-poor
phenols.
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Most BBIQ’s have been prepared by the condensation of two appropriate
benzyltetrahydroisoquinoline monomers to form the biaryl ether.  The following
paragraphs discuss different synthetic methods for the preparation of bisbenzylisoquinoline
monomers, i.e. the Bischler-Napieralski, Pomeranz-Fritsch and Pictet-Spengler reactions.
The method that we used, the Pictet-Spengler reaction, is discussed in greater detail with
special emphasis on reaction mechanism, regioselectivity as well substrates dependence.
Detailed protocols for the preparation of the key diaryl ether linkages are also described.
2.4 Methods for the synthesis of tetrahydroisoquinolines
The 1,2,3,4-tetrahydroisoquinoline (THIQ) scaffold is present in both natural and synthetic
organic compounds with a variety of important biological activities such as antitumour,19,20
antithrombotic,21 antimicrobial,22 P-gp modulators,23  antimalarial,24 hypothermic,25
increased estrogen receptor modulation,26 bradycardic,27 neuroprotective or neurotoxic28
and antiplatelet aggregation.29,30 A number of elegant enantioselective methods, including
the metal-catalysed cyclisation reactions,31 the Pomeranz-Fritsch reaction,32 Bischler-
Napieralski,33 Pictet-Spengler cyclisation34 have been developed to synthesise theses
compounds.  The largest part of the enantioselective approaches is based on asymmetric
hydrogenation of cyclic imines accessed by the Bischler-Napieralski reaction.35
Approaches towards the synthesis of the isoquinoline framework can be categorised into
15 different methods.36,37 The commonly used types in the literature includes strategies
consisting of elaboration of the heterocyclic ring through the formation of one C-C or C-N
bond (Fig. 2.3). However, synthetic protocols of Types 1 (Bischler-Napieralski and Pictet-
Spengler), 2 and 5 (Pomeranz-Fritsch and its modifications) are the most widely used for
the construction of tetrahydroisoquinolines.  These methods allow the synthesis of an
enantiopure 1-substituted-tetrahydroisoquinoline in two steps: cyclisation and creation of
the stereocentre, although only the Pictet-Spengler reaction creates the stereogenic carbon
at C-1 simultaneous with the ring closure.








Figure 2.3: Heterocyclic ring formation of isoquinolines.
2.4.1 Bischler-Napieralski reaction
The Bischler-Napieralski reaction involves the conversion of a N-acyl-β-phenethylamide
(2.72) into its 3,4-dihydroisoquinoline 2.73 in the presence of a Lewis acid, followed by





























Scheme 2.10: Formation of laudanosine via the Bischler-Napieralski reaction.38
2.4.2 Pomeranz-Fritsch reaction
The Pomeranz-Fritsch reaction represents a synthetic method for Type 5 synthesis
entailing cyclisation of benzalaminoacetal under acid-catalysed conditions. The
benzalaminoacetal 2.76 is prepared by condensation of aldehyde and aminoacetal and the
successive cyclisation leads to the isoquinoline 2.77 (Scheme 2.11).  The yields of
isoquinolines vary from zero to more than 80%, with 3-hydroxy and 3-alkoxy bezaldehyde
Fundamental aspects of bisbenzylisoquinolines Chapter 2
35
giving satisfactory results, whereas, 2- or 4-alkoxy derivatives afford the isoquinolines in









Scheme 2.11: The Pomeranz-Fritsch reaction for the formation of isoquinoline 2.77.
2.4.3 Pictet-Spengler reaction
The Pictet-Spengler reaction involves a Mannich-type reaction, wherein β-phenethylamine













Scheme 2.12: The Pictet-Spengler condensation to the 1,2,3,4-tetrahydroisoquinoline 2.80.
The reaction mechanism of the Pictet-Spengler reaction consists of the formation of a
Schiff base as an intermediate which can be cyclised in the presence of the acid.  The
mechanism of the formation of norhydrohydrastinine (2.82) from homopiperonylamine
(2.81) is illustrated in Scheme 2.13.
































Scheme 2.13: Reaction mechanism of the Pictet-Spengler reaction.
Ring closure depends on the nature and position of the aromatic substituents of the β-
phenethylamine moiety of the imine, with the presence of the electron-donating hydroxy or
alkoxy group at the para position of cyclisation essential. Thus, the reaction of
phenethylamine 2.83 with formaldehyde yields only 1,2,3,4-tetrahydro-6-
methoxyisoquinoline (2.84) and no 8-methoxy product was isolated. Oxidation of 2.84










Scheme 2.14: Formation of 4-methoxyphthalic acid.
The product obtained by cyclisation of a 3,4-dialkoxy-β-phenethylamine is always the 6,7-
dialkoxy derivatives and 7,8-dialkoxy derivatives are not formed. A mixture of the two
tetrahydroisoquinoline derivatives is isolated when both ortho positions are activated.  This
reaction is illustrated by the condensation of 1-(3-benzyloxy-4,5-dimethoxybenzyl)-
1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (2.86) with formaldehyde to give two
products 2.87 and 2.88 with 2.88 being the minor isomer due to steric reasons (Scheme
2.15).42


























Scheme 2.15: Regioselectivity in the Pictet-Spengler reaction.
Generally, cyclisation has a tendency to occur at the para position to an alkoxy group, for
example, during synthesis of tetrahydro-ψ-berberine (2.90) from 1-





















Scheme 2.16: Synthesis of tetrahydro-ψ-berberine
On the other hand, if the alkoxy groups are replaced by hydroxy groups as in compound
2.92, then the ring closure proceeds to both ortho and para positions.  Thus, treatment of
tetrahydropapaveroline (2.92) with formaldehyde afforded a mixture of 2.93 and 2.94 in
equal amounts (Scheme 2.17).























Scheme 2.17: Regioselectivity in the presence of free hydroxy groups
The presence of the free hydroxy groups in the benzyl residue activates the ortho position.
In the case where both para and ortho positions are available for cyclisation, Kametani
decided to use bromine as a blocking group to direct cyclisation to ortho position.  Thus,
capaurine (2.96) was synthesised by the Pictet-Spengler reaction of the 1-(2-bromo-4-
methoxy-5-hydroxybenzyl)isoquinoline (2.95), followed by a reductive cleavage of the






















Scheme 2.18: Synthesis of capaurine (2.96).
2.4.4 Asymmetric synthesis of tetrahydroisoquinolines
Most of the 1-substituted THIQ alkaloids in nature possess the 1S absolute configuration,
but there are few with 1R-configuration and the two enantiomers exhibit different
biological activities.  However, the methods described above did not address the absolute
configuration associated with THIQ’s. Enantioselective syntheses of THIQ’s in the
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literature involve mostly the use of chiral auxiliaries.  Asymmetric syntheses of THIQ’s are
based generally on the stereochemical modification of the traditional methods, which are:
1) Metal-catalysed cyclisation reactions
2) Pomeranz-Fritsch reaction
3) Bischler-Napieralski reaction (most enantioselective syntheses involve reduction of
the resulting imine with a chiral hydride reducing agent or asymmetric catalytic
hydrogenation)
4) Pictet-Spengler cyclisation
The following paragraphs intend to discuss these methods briefly.
2.4.4.1 Metal-catalysed cyclisation reactions
The palladium-catalysed coupling reaction of an aryl halide or vinyl halide with an enolate
is a promising procedure to construct the carbon framework of heterocyclic THIQ’s.
Honda et al.45 employed this type of coupling reaction for the synthesis of the basic
skeleton of the tetrahydroisoquinoline in the synthesis of cherylline (2.104) (Scheme 2.19).
The amide 2.100 was prepared in six steps from the alcohol 2.97 via chloride 2.98. The
Schotten-Baumann reaction of amine 2.99 with p-benzyloxyphenylacetyl chloride gave
amide 2.100.  The Pd-catalysed intramolecular coupling reaction of 2.101 in the presence
of 0.1 eq. Pd(dba)2, 1.5 eq. t-BuOK and chiral ligand S-BINAP in refluxing dioxane, gave
2.102 in 42% yield with only 8% ee (based on HPLC).


































































Scheme 2.19: Synthesis of cherylline (2.104).
2.4.4.2 The Pomeranz-Fritsch reaction
The original Pomeranz-Fritsch method has been improved and modified in many ways.  A
useful modification was developed by Bobbit46 as a two-step procedure in which the
Pomeranz-Fritsch imine was hydrogenated in situ to the aminoacetal. Enantiopure N-
sulfinimines have played a role in the asymmetric synthesis of amines, providing access to
synthesis of natural products such as THIQ’s.  Grajewska and Rozwadowska47 reported the
synthesis of S-salsolidine (2.111) based on diastereoselective modification of Pomeranz-
Fritsch methodology (Scheme 2.20). S-salsolidine (2.111) was prepared in a five-step
reaction sequence from condensation of 3,4-dimethoxybenzaldehyde (2.105) with R-N-
tert-butanesulfinylamide (2.106) in the presence of Ti(O-i-Pr)4 to give sulfinimine 2.107 in
84% yield.  Condensation of 2.107 with a Grignard reagent under optimised conditions
afforded sulfinamide 2.108 with 98:2 dr with the absolute configuration being S,
recrystallisation lead to improvement of the de to 99%.  Removal of the N-sulfinyl
auxiliary afforded 2.109, which was alkylated to give the Pomeranz-Fritsch amine 2.110.
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A one-pot hydrolysis and reduction of 2.110 furnished 2.111 in 55% yield. This method












































Scheme 2.20: Synthesis of S-salsolidine (2.111).
2.4.4.3 The Bischler-Napieralski reaction
The Bischler-Napieralski reaction has been the most frequently explored approach to the
asymmetric synthesis of THIQ’s. Reduction of the 3,4-dihydroisoquinoline is crucial for
the stereochemical outcome and this step can be achieved by either diastereoselective or
enantioselective synthesis.
2.4.4.3.1 Diastereoselective synthesis
Hydride reduction or catalytic hydrogenation of chiral 1-substituted 3,4-
dihydroisoquinolines or the corresponding 3,4-dihydroisoquinolinium salts have been
found to give excellent results.  In most cases, a chiral auxiliary was appended to the imine
nitrogen.  Barbier et al.,48 in their synthesis of 1-alkyl, 3-alkyl and 1,3-dialkyl-1,2,3,4-
tetrahydroisoquinolines, used the chiral isoquinolium salt 2.112 (Scheme 2.21).  The
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reaction of salt 2.112 with a Grignard reagent gave 1-substituted dihydroisoquinolines in
quantitative yields. In the preparation of 2.114, the intermediate 2.113 was obtained in
good de (74%) and isolated in 72% yield after recrystallisation.  The absolute
stereochemistry of C-1 in 2.114 was found to be S from the X-ray structure of 2.113,















Scheme 2.21: Synthesis of 1-alkyl-1,2,3,4-tetrahydroisoquinoline 2.114.
2.4.4.3.2 Enantioselective synthesis
Asymmetric synthesis of isoquinoline alkaloids accessed by the Bischler-Napieralski
cyclisation is based on the reduction of the resulting prochiral amine with a chiral hydride
reducing agents or hydrogenation in the presence of chiral catalysts.  Pyo et al.49 used
Noyori’s catalyst, RuCl[(S,S)-TsDPEN](p-cymene)] (2.122S) and RuCl[(R,R)-TsDPEN](p-
cymene)] (2.122R), in the synthesis of S-higenamine and R-higenamine, respectively
(Scheme 2.22). Commercially available amine 2.115 and phenylacetic acid 2.116 were
heated to provide amide 2.117 (94% yield), which was subjected to Bischler-Napieralski
cyclisation to form imine 2.118 in 98% yield. Catalytic asymmetric reduction of 2.118,
gave 2.119 in 62% yield with 99% ee.  Treatment of 2.119 with HBr-AcOH afforded the
salt 2.120 in 84% yield, and subsequent methylation furnished 2.120 in 78% yield in >99%
ee.



























































Scheme 2.22: Synthesis of R-higenamine (2.121).
2.4.4.4 The Pictet-Spengler cyclisation
The Pictet-Spengler reaction is a convenient method for the synthesis of THIQ’s since the
stereogenic centre is generated simultaneously with the ring closure in a one-pot process.
In the syntheses that have been carried out in an asymmetric manner, the chirality transfer
occurred from the chiral auxiliary introduced to either the β-arylethylamine or the aldehyde
component, thus involving a diastereoselective synthesis.
 These methods include the use of 1,4-chirality50 and 1,3-chirality51 transfers (Scheme
2.19).  Optically-active aldehydes and ketones52 tethered to the amino group of β-
phenethylamine53 have found wide use in the syntheses of THIQ’s and other syntheses
include combinations of the above strategies.54






























































Scheme 2.23: Approaches to the stereoselective synthesis of 1-substituted THIQ.
Lee et al.55 subjected the prepared chiral acetylenic sulfoxide 2.123a or 2.123b to a
conjugate addition with 3,4-dimethoxyphenethylamine (2.115) to afford vinyl sulfoxide
2.124, which was cyclised in chloroform with TFA catalysis to form a mixture of 2.126a
and 2.126b (Scheme 2.24). Taking the yield and diastereoselectivity into account, the best
results were achieved in the presence of TFA at 0 ºC. Sulfoxide 2.126a was reductively N-
methylated to 2.127 and then desulfurised with Raney nickel to carnegine [(+)-2.128].  The
higher diastereoselectivity achieved was rationalised by assuming that the imine 2.125a
and the enamine 2.125b are in equilibrium, with the enamine being the predominant
species.





























































2.123a Ar: R1 = Me, R2 = H
























Scheme 2.24: Synthesis of carnegine (2.128)
The same group disclosed an interesting feature when using N-methyl-3,4-dimethoxy-β-
phenethylamine as a starting amine and a nitro derivative as a chiral sulfoxide.  Cyclisation
proceeds with reverse diastereoselectivity.  Raney nickel desulfurisation of the chiral
auxiliary provides S-salsolidine and this is a more convergent way of synthesising this
natural product.
The regiochemical control was investigated by Bates56 in reactions between epinephrine
2.129 and excess formaldehyde or acetaldehyde in aqueous solution between pH of 0.7 to 7
(Scheme 2.25).  At pH 5, a 88:12 ratio of 2.130 and 2.131 was obtained after 2.5 minutes,
however, the product disappeared over the course of several hours due to the presence of
excess formaldehyde, which causes formation of a polymeric substance.  At low pH,
cyclisation occurred almost exclusively para to the activating hydroxy group.  Under
neutral conditions, substantial cyclisation ortho to the activating hydroxy group also takes
place.



















R = R1 = H
2.131
Scheme 2.25: Regioselective synthesis of 1,2,3,4-tetrahydro-4,6,7-isoquinolinetriols 2.130
and 2.131.
Although the 1-substituted tetrahydroisoquinoline alkaloids are readily synthesised in an
asymmetric manner, there is no one general method that would secure preparation of all
types of isoquinoline alkaloids with high optical purity employing simple procedures.
Usually, the applied methodologies suffer from various limitations such as moderate yields
and/or unsatisfactory regio- and stereoselectivity. Therefore, the question of finding more
efficient and/or simpler synthetic strategy still remains a critical challenge to organic
chemists.
2.5 Construction of diaryl ethers
2.5.1 Introduction
The presence of the diaryl ether subunit in a number of synthetically challenging and
medicinally important natural products such as vancomycin57 (2.132, antibiotic), (-)-K-1358
(2.133, angiotensin-converting enzyme inhibitor), bastadin59 (2.134, antitumour agent), the
purely synthetic bioactive agents such as LY29311160 (2.135, LTB4 receptor antagonist) as
well as combretastatin D-261 (2.136, antifungal) (Fig. 2.5), has renewed efforts in
developing strategies for its construction.














































































Figure 2.4: Natural products with a diaryl ether subunits.
As mentioned in the beginning of this Chapter (Section 2.2), bisbenzylsoquinoline
alkaloids are built up of one more diaryl ether linkages.  Various methods for the
preparation of diaryl ethers are known.  However, methods for the construction of diaryl
ethers that are compatible with sensitive functional groups and stereogenic centres in a
variety of complex molecules are needed.  Generally, diaryl ethers can be synthesised by
means of a copper-catalysed Ullmann diaryl ether coupling, palladium-catalysed
Buchwald-Hartwig reaction, nucleophilic aromatic substitution, coupling of phenols with
arylboronic acids, oxidative coupling and nucleophilic aromatic additions to metal-arene
complexes.62 The following sections will concentrate on various methods for construction
of diaryl ethers.
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2.5.2 Intermolecular Ullmann Diaryl Ether Coupling
Since Fritz Ullmann63 and Irma Goldberg64 started their pioneering work on copper-
mediated and catalysed coupling reactions more than a hundred years ago, there has been a
widespread interest in developing methods for the synthesis of diaryl ethers using Cu(I)
catalyst. Diaryl ether formation under Ullmann conditions in the presence of copper
depends strongly on the substitution pattern of both the aryl halide and the phenols.  For
example, Xing et al.65 described the unsuccessful preparation of diaryl ether 2.139 by
coupling 2-benzyloxy-5-methylphenol (2.137) with 1-bromo-2-methoxy-4-methylbenzene
(2.138) in the presence of 5 mol% of (CuOTf)2PhMe and caesium carbonate in pyridine at














Scheme 2.26: Reagents and conditions: i) (CuOTf)2PhMe, Cs2CO3, pyridine, 110 ºC, 24 h.
However, utilising identical reaction conditions, 1-(benzyloxy)-2-bromo-4-methylbenzene
(2.140) reacted with 2-methoxy-4-methylphenol (2.141) to give the diaryl ether 2.139 in















Scheme 2.27: Reagents and conditions: i) (CuOTf)2PhMe, Cs2CO3, pyridine, 110 ºC, 24 h.
Conventional Ullmann reaction usually requires harsh conditions – at least stoichiometric
amounts of copper, large excess of phenols and high temperatures, due to the poor
nucleophilicity of the phenoxide and the low reactivity of the aryl halides involved.66
Addition of a suitable ligand and a base (usually caesium carbonate) enhanced solubility of
the copper ions and consequently more efficient catalysis compared to the classical
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Ullmann coupling reaction, can be achieved at lower temperatures.  Song and co-workers67
reported the use of 2,2,6,6-tetramethylheptane-3,5-dione (TMHD) as a suitable ligand for
coupling various aryl bromides and phenols (Scheme 2.28), with aryl halides possessing
electron-donating groups affording better yield in this modification than in classical
Ullmann procedures.  However, electron-poor phenols did not react to give the desired
products and phenols with ortho methoxy and acetoxy substituents reacted slowly.
Another key problem to Ullmann-type reactions is the racemisation of the chiral centres
present in a system. Cai et al.68 established a mild and nonracemising conditions for
Ullmann-type diaryl ether formation between aryl halides and phenols.  For example,
coupling of 4-iodophenylacetone and N-trityl-L-tyrosine methyl ester catalysed by CuI and












R = Me, Ac, CN, OMe, NMe2 R’ = Me, CO2i-Pr, F, OMe
Scheme 2.28: Reagents and conditions: i) CuCl, THMD, Cs2CO3, NMP, 120 ºC, 24 h.
N,N-dimethylglycine was reported69,70 to be a very effective ligand in dioxane at lower
temperatures (~ 90 ºC), with both electron-rich and poor halides being suitable substrates.
Steric hindrance in reacting substrates disfavoured the reaction and this obstacle was
overcome by using higher temperatures and catalyst and, for example, reaction of 2-
bromotolouene (2.142) and 4-methoxyphenol (2.143) gave good yields of 2.144 at 105 º C.
Also the use of 1,10-phenanthroline as a ligand and potassium fluoride supported on











R = H, Me, OMe, CF3, Br R’ = H, 2-Me, 4-Me
Scheme 2.29: Reagents and conditions: i) 1, 10-phenanthroline (20 mol%), CuI (10%),
KF/Al2O3, toluene or dioxane, 110 ºC, 6-15h.
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Gujadhur and Venkataraman72 reported the use of the Cu(PPh3)3Br complex, which is air
and moisture stable and soluble in most organic solvents, to couple phenols with electron-











R = NO2, Me, CN, OMe, NMe2, CO2Me R’ = Me
Scheme 2.30: Reagents and conditions: i) Cu(PPh3)3Br, Cs2CO3 (3 eq.), NMP, 100 ºC,
48h.
2.5.3 Intermolecular Palladium-Catalysed diaryl ether coupling reactions
Formation of diaryl ether using this method utilises ligands in the presence of catalytic
amount of palladium ions.  The high price of palladium still remains the major drawback
for this method.  Various ligands have been used to obtain diaryl ethers in satisfactory
yields. An example using di-tert-butylphosphino-pentaphenylferrocene is outlined in
Scheme 2.31. A steric effect was observed in the reaction of an aryl halide with ortho
substituents, which react faster (already at 80 ºC) than the unhindered aryl halides which
required heating to 100 ºC.  Contrary to Cu-mediated diaryl ether synthesis, aryl bromides
and chlorides react faster than the aryl iodides.  It was observed that the coupling reaction
utilising 1,1’-bis(di-tert-butylphoshino)ferrocene (D’BPF) as a ligand could be performed
even at room temperature, this is a significant advantage compared to the latest










R = H, Ph, C6H4-p-CF3, C6H4-p-OMe
Scheme 2.31: Reagents and conditions: i) Pd(dba)2, di-tert-butylphosphino-
pentaphenylferrocene, toluene, 40 ºC or 80 ºC, 2-24 h.
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Buchwald and co-workers73 reported formation of diaryl ethers from a wide range of aryl
halides and phenols in high to excellent yields using electron-rich, sterically bulky ligands.
A representative of this method is the chemoselective coupling of 1-bromo-4-
chlorobenzene with 2-isopropylphenol to give 4-chlorophenyl-2-isopropyl phenyl ether in
80% yield.  Substituted phenols, even those with bulky substituents, are excellent
substrates for this reaction. Low yields in the case of aryl halides with electron-
withdrawing groups at the ortho position make this method unfavourable. Furthermore,
many of the ligands developed by Buchwald are either very expensive or not available
commercially.
2.5.4 Nucleophilic aromatic substitution
The formation of diaryl ethers by nucleophilic aromatic substitution with activated
substrates is considered mild and more environmentally benign.  Various electron-
withdrawing functional groups (nitro, triazenyl and methylcarbonyl) were used to activate
the aromatic skeleton towards nucleophilic substitution with phenols.  Wang and co-
workers74,75 developed a microwave-assisted diaryl ether synthesis from electron-deficient











X = F, Cl, Br
R = NO2, CN R’ = OMe, CF3, Cl, NO2, CN
Scheme 2.32: Reagents and conditions: i) K2CO3, DMSO, MW (300W), 5-10 min.
Solvent-free phase-transfer and microwave conditions for the synthesis of diaryl ether were
investigated,76 phase-transfer catalysts investigated includes Bu4N
+Br-, MeOct3N
+Cl- and
18-crown-6. In the presence of the ion pairs microwave influence played a major role in
enhancement of the reaction.   Microwave also enhances the reaction of non-activated
substrates.  The microwave-assisted aromatic nucleophilic substitution was preferable to
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the classic SNAr reaction since it minimised the amount of by-products and the use of
difficult-to-remove polar solvents.
Nucleophilic aromatic substitution was reported in the synthesis of macrocyclic ring of
vancomycin by Zhu and co-workers.77  The macrocycle 2.150 was synthesised in one step

























Scheme 2.33: Reagents and conditions: i) K2CO3, 18-C-6, THF, 50 ºC.
2.5.5 Coupling of phenols with arylboronic acids
Diaryl ethers synthesis by the cross-coupling of phenols and arylboronic acids promoted by
copper(II) was reported independently by Chan et al.78 and Evans et al.79 Recent
advancement of O-arylation with boronic acids gained interests due to the  mild reaction
conditions (room temperature, weak base, ambient atmosphere) and the toleration of
various substrates.  Evans and co-workers79 developed a protocol for phenol arylation with
aryl boronic acids with reasonable yields. In addition, electron-rich aryl boronic acids
performed better than the unsubstituted parent phenylboronic acid.
It was also observed that phenylboronic acid is readily converted to (PhBO)3, which could
be the active species for arylation. Furthermore, it was speculated that the addition of
molecular sieves promotes formation of the borixine form which is more efficient than
coupling with phenylboronic acid.  Petasis and co-workers80 and Sagar et al.81 reported the
conversion arylboronic acid 2.151 into phenols and a subsequent coupling of both species
to form symmetrical diaryl ethers 2.152 in a one-pot reaction. Moreover, this method
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tolerates a great variety of electron-rich and electron-poor substituents and the products are





i, ii or iii
58-97%
2.151 2.152
Scheme 2.34: Reagents and conditions: i) H2O2 (30%), CH2Cl2; ii) Cu(OAc)2, Et3N,
CH2Cl2, ms, 25 ºC; iii)  Cu(OAc)2, Et3N, H2O, CH2Cl2-MeCN, 25 ºC.
Intramolecular coupling of the arylboronic acid 2.153 to yield the macrocyclic diaryl ether
















Scheme 2.35: Reagents and conditions: i) Cu(OAc)2, Et3N, CH2Cl2, ms, 25 ºC.
2.6 Conclusion
Targeting complex structures like BBIQ’s demand more effective reactions in terms of
accomplishing bond constructions and functional group transformation.  A closer look at
syntheses of BBIQ’s, that is, their total synthesis and synthesis of the monomers, unravels
the possible routes and intermediates from which one can choose the most likely route to
succeed. Lack of regioselectivity, stereoselectivity and low yields makes the previous
synthetic routes described unattractive.  Therefore, a process suitable for large scale
preparations of BBIQ’s based on asymmetric synthesis of tetrahydroisoquinoline
monomer, diaryl ether bond incorporated to the pre-existing optical pure
tetrahydroisoquinoline and macrocyclisation of the intermediate will be efficient.  The
rational thinking was to be further advanced so that the stereo- and regiocontrol strategies
are to dominate synthetic planning before being completed.  A judicious choice of optically
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active starting materials as well as high convergent strategy that utilize the same type of
reactions will allow a rapid access to the target compound cycleanine (1.21). In addition, it
was necessary to develop a process that preserved the enantiomeric purity of the readily
epimerisable stereogenic centre s in subsequent reactions.  Furthermore, convenient
purification points had to be established to avoid purification methods that are inconsistent
with large-scale synthesis.
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This chapter outlines our approach towards the synthesis of cycleanine (3.1).* In total
synthesis, retrosynthetic analysis is a key step in devising possible synthetic strategies for
the construction of a target compound. As discussed in Chapters 1 and 2,
bisbenzyltetrahydroisoquinolines (BBIQ’s) have interesting biological activities, yet a
limited number of attempts towards their total syntheses have been published.  The aim of
this investigation was to develop a strategy towards the total synthesis of the BBIQ
cycleanine (3.1). Although this BBIQ is only moderately active in a number of assays, it
has a low toxicity and has a good selectivity index.1  More importantly, although the
diversity of pharmacological effects observed within the BBIQ alkaloids is a function of
the differences in chemical structure, cycleanine (3.1) is a good model compound to
develop synthetic strategies for head-to-tail BBIQ’s due to its symmetrical nature. The
only published total synthesis of cycleanine (3.1) (Scheme 2.1) did not address the
problems of regioselectivity and stereoselectivity. In addition, key steps for this synthesis,
such as the Ullmann condensation and the Bischler-Napieralski reaction, gave low yields
and the final step gave cycleanine (3.1) in an extremely low yield (0.067%).2
A literature review of the synthetic methods for BBIQ’s (Chapter 2) clearly indicates that
the two main challenges in the total synthesis of these compounds are the stereoselective
preparation of the tetrahydroisoquinoline moiety and the regioselective diaryl ether
formation. In our retrosynthetic analysis of cycleanine (3.1), many disconnections were
considered to evaluate all the possibilities before one pathway was selected. Cycleanine
(3.1) contains two stereogenic centres and the initial goal of our synthetic strategy was to
install, stereospecifically, the two stereogenic centres in a way that avoids resolution or
chiral chromatography.
* Cycleanine is numbered cycleanine (1.21) for the structures not showing the absolute stereochemistry in
Chapters 1 and 2 and 3.1 for the structures indicating the stereochemistry.
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3.2 Retrosynthetic analysis
The formidable architecture of BBIQ’s comprises a host of complicated problems that are
certain to challenge the ability of any synthetic chemist. Nature’s likely synthesis of these
natural products suggests several potential avenues to render this target more manageable.
In the literature, a number of synthetic methods for the synthesis of 1,2,3,4-
tetrahydroisoquinolines (THIQ) are reported (see Section 2.4). In our study the synthetic
strategy based on a Pictet-Spengler reaction for the construction of the THIQ monomers
was opted for.  While many disconnections could be considered for the synthesis of
cycleanine (3.1), five main strategies were evident from the viewpoint of a rational
retrosynthetic analysis, as outlined in Scheme 3.1.
Route a could lead to a mixture of two possible isomers since there are two positions
(denoted i and ii in Scheme 3.1) available for cyclisation of 3.2 (see last step in Scheme
2.1).  Following route b, 3.1 could be obtained from 3.3 by a number of methods to form
diaryl ethers. The second diaryl ether functionality could be constructed from two identical
monomers 3.7 (route f). Though 3.1 can be formed directly from 3.7, this condensation
reaction is prone to polymerisation to form side products.  Therefore, following this route,
a stepwise coupling of the two THIQ monomers is advisable.
Routes h and i via b could also be followed, nevertheless, the problem posed by both these
two routes is once again the possible formation of a mixture of regioisomers.  For route h,
condensation of 3.8 and 3.6 could lead to the formation of regioisomers due to the presence
of two positions on 3.8 (denoted i and ii) available for electrophilic aromatic substitution.
Following route i, the presence of two possible modes of cyclisation also poses problems
since 3.9 also contains two possible sites for cyclisation (denoted i and ii in Scheme 3.1).
Route e through b, c and d seemed to be the best option since 3.3 could be formed from 3.5
and 3.4 by a Pictet-Spengler or Bischler-Napieralski reaction and the presence of the free
hydroxy on 3.4 was envisaged to control the site of cyclisation in the formation of 3.3.
Similarly, the site of cyclisation will also be controlled by the presence of a free hydroxy in
3.4 in the formation of 3.7. This approach is preferable for the formation of cycleanine
(3.1) and the main attribute of this strategy is its convergence because of the utilisation of
the same materials (3.4 and 3.6) and reactions (Pictet-Spengler and diaryl ether formation).



















































































































































Scheme 3.1: Retrosynthetic analysis of cycleanine (3.1).
Cycleanine (3.1) is a chiral compound, with a R-configuration at both stereocentres and,
therefore, our challenge in this synthesis was to address the stereoselective synthesis of the
THIQ monomer. A diverse array of enantioselective methods have been developed to
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access homochiral THIQ monomers, mostly involving the use of chiral auxiliaries (see
Section 2.4.4). These methods include




 Asymmetric hydrogenation of cyclic imines accessed by the Bischler-Napieralski
reaction (entails the largest part of the enantioselective synthesis of THIQ).7
The metal-catalysed formation of cherylline (2.104) gave the cyclised product in a low
yield (42%) with low enantioselectivity (8%) due to the presence of the easily enolisable
benzylic proton in the cyclisation product.  Furthermore, palladium is an expensive metal
and this makes this method less attractive.  Although the Pomeranz-Fritsch reaction was
appealing in terms of enantioselectivity during the synthesis of salsolidine (2.111), after
formation of the chiral sulfinamide 2.108, there are two more steps before cyclisation to
the final product and this contribute to the low overall yield of the target product.
The Bischler-Napieralski reaction seemed interesting, nevertheless, the preparation and
isolation of the unstable imine intermediates raised uncertainties.  However, the good
enantioselectivity and yields obtained by this method must be noted. The methods above
allow the synthesis of enantiopure 1-substituted tetrahydroisoquinoline, but only the Pictet-
Spengler reaction creates the stereogenic carbon at C-1 simultaneous with the ring closure,
whereas in other methods two different steps are required. The good yields, good
enantioselectivity and regioselectivity associated with the Pictet-Spengler reaction
motivated us to make this the method of choice in this study (see Section 2.4.4).
A closer look at possible routes (Scheme 3.1) resulted in the development of a strategy for
the diastereoselective and convergent synthesis of cycleanine (3.1) that also controls the
stereochemistry of the molecule at both stereogenic carbons 1 and 1'. The retrosynthetic
analysis depicted in Scheme 3.2 is based on the following disconnections: the macrocyclic
ring 3.1 could be constructed by the intramolecular diaryl ether formation of intermediate
3.3, derived by the condensation of 3.4 and 3.5 by means of a Pictet-Spengler reaction.
Preparation of 3.5 could be achieved by a SNAr reaction, Ullmann coupling or any other
diaryl ether coupling methods of halophenylacetaldehyde 3.6 and THIQ 3.7. If R in 3.4 is
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a chiral auxiliary, a Pictet-Spengler reaction between 3.4 and 3.6 could lead to the
homochiral THIQ 3.7. Therefore, the stereoselectivity of the whole route will be governed
by this condensation.  Furthermore, the Pictet-Spengler reaction would be repeated twice in
the route and the same compounds 3.4 and 3.6 would be employed and this will allow a





































































Scheme 3.2: Preferred retrosynthetic analysis of cycleanine (3.1).
The synthesis was planned according to Scheme 3.3, starting with the coupling of β-
phenethylamine 3.4 and halophenylacetaldehyde 3.6, using the Pictet-Spengler reaction. In
contrast to the previous synthesis of cycleanine (3.1),2 our approach was envisaged to be
chiral-auxiliary based, which will give optical-enriched precursors, while Tomita’s method
was appropriate for racemates. Enantioselectivity was to be controlled by the chiral
auxiliary R* present in the β-phenethylamine 3.4. The reactivity, regio- and
stereoselectivity of the Pictet-Spengler reaction depend greatly on the nature of the starting
chiral auxiliary amine, degree of activation of the cyclising benzene ring of the relevant
imines, the substituents on the phenylacetaldehyde ring as well as the reaction conditions.
In order to assess these factors, different halophenylacetaldehydes 3.6 (X = electron-
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withdrawing or electron-donating) will be prepared in this study. Diaryl ether formation
was planned by means of the coupling of boronic acid 3.10 with the tetrahydroisoquinoline
3.7.  Hydrolysis of the protected aldehyde 3.11, followed by another Pictet-Spengler
reaction between 3.4 and 3.5, should form the desired product 3.3. The final cyclisation to
the macrocylic compound 3.1 was hoped to be achieved via either an Ullmann or a boronic
acid coupling reaction (Scheme 3.3). β-Phenethylamine 3.4 will be utilised for the
preparation of both THIQ monomers, therefore, in the following paragraph the synthesis of









































































removal of chiral auxiliary
N-methylation
Scheme 3.3: Envisaged synthesis of cycleanine (3.1).
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3.3 Preparation of hydroxylated β-phenethylamine 3.4
The first challenge we faced in this project was to construct the stereogenic centre in
compound 3.7 in an enantioselective manner. For the above-mentioned reasons and from a
practical and economical perspective, we reasoned that the Pictet-Spengler reaction would
be our first choice for the synthesis of chiral 3.7. Prior to cyclisation to 3.7, it was
necessary to gain access to the chiral 3.4.  The availability of commercial R- and S-
phenethylamine enantiomers as well as the good diastereoselectivity achieved in the
reduction of the Bischler-Napieralski product containing this chiral auxiliary, prompted us
to use it as chiral auxiliary tethered to our β-phenethylamine. For example, S-α-
methylbenzylamine was found to be an efficient chiral auxiliary in the multistep synthesis
of (-)-tejedine, a seco-bisbenzylisoquinoline alkaloid, where cyclisation and subsequent
reduction gave the THIQ moiety in 40% yield and with 99% de.8 The convenient reductive
removal of the chiral auxiliary at the end of the transformation justifies the choice of this
chiral auxiliary. To control the regioselectivity of the Pictet-Spengler reaction, the
presence of the free hydroxy group on the phenyl ring of 3.4 will play an important role
(Section 2.4.4.4). Furthermore, it is known that diaryl ether formation between phenols
and electron-rich aryl halides is problematic, therefore, a method directed towards the
synthesis of electron-rich phenol 3.7 and an electron-poor halide will be employed. Diaryl
ether 3.11 was envisaged to be formed from THIQ 3.7 and the boronic acid 3.10. In the
next section, the preparation of phenethylamine 3.4 via a phenylacetic acid will be
presented.
3.3.1 Synthesis of phenylacetic acid intermediate
Our first target was the preparation of β-phenethylamine 3.4 with R* = CH(CH3)Ph.
Vanillin (3.12) proved to be an effective starting material for the preparation of β-
phenethylamine 3.4, since the substituents on the aryl ring of 3.4 are similar to the aryl ring
of vanillin (3.12).  The free hydroxy on position three will be introduced first via
bromination, followed by methylation of 4-hydroxy and conversion of the aldehyde to a
chiral amine in subsequent transformations.
Bromination of vanillin (3.12) gave 3-bromovanillin (3.13) in a good yield (93%).
Bromination occurred preferentially at the ortho-position to the free hydroxy group and
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this emphasise the importance of the free hydroxy on C-4. Subsequent copper(I)-assisted
hydrolysis of 3.13 afforded 3.14. The formation of dihydroxy compound 3.14 was
achieved in moderate yield (65%) due to the high solubility of the product in water and as
a result, during workup some of the product was lost in the aqueous layer upon extraction
with ethyl acetate. Selective methylation of 3.14 with methyl iodide resulted in a mixture
of mono- and dimethylated derivatives of 3.14. Therefore, a method for selective
methylation developed by Zhu et al.9 and Pearson et al.10 on selective alkylation of the 4-
OH of gallic acid was employed by utilising the diacetate 3.15 in the presence of MeI and





























































Scheme 3.4: Preparation of acetylated phenylacetic acid.
The increased acidity of the 4-hydroxy group of 3.14 due to the para electron-withdrawing
substituent, renders it more reactive towards alkylation.  The chemoselective methylation
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of 3.14 involves heating of the diacetate 3.15 with K2CO3 and methyl iodide in DMF.  The
selectivity of this reaction is attributed to the hydrolysis of the p-acetate group in 3.15 to
form the intermediate 3.15a, which is stabilised by conjugation.
A nOe experiment on 3.16 confirmed the position of the acetoxy group.  Correlations
between the acetoxy protons and one methoxy group and an aromatic proton were
observed.  Benzaldehyde was homologated to phenylacetic acid by standard methods.
Reduction of 3.16 to the benzyl alcohol 3.17 was achieved in moderate yield (50%),
chlorination to 3.18 in 60% yield, cyanation was accomplished in 55% yield and the















































Scheme 3.5: Preparation of benzylated phenylacetic acid.
Protection of the 5-hydroxy as the O-acetyl in 3.16 suffered drawbacks due to the lability
of the O-acetoxy in subsequent reactions, and compounds 3.17 to 3.20 were obtained in
low yields.  Changing the protecting group to O-benzyl resulted in the exclusive formation
of the desired intermediates (Scheme 3.5).  The methylating reagent was changed to DMS
and a good yield (75%) of the selectively methylated product 3.21 was obtained under
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optimised reaction conditions, together with a minor amount of the dimethylated derivative
of 3.14.  The 1H NMR spectrum of the product 3.21 showed the presence of two methoxy
groups and two meta-coupled aromatic protons.  A nOe experiment confirmed the
positions of the methoxy groups with a strong correlation between only one methoxy group
and a meta-coupled aromatic proton. The reduction-chlorination-cyanation-hydrolysis
sequence gave phenylacetic acid 3.26, with the structures of all the intermediates
confirmed by NMR, m.p. and MS.  Protection of the 3-OH with a benzyl group increased
the yields of the reactions.  An additional five aromatic protons at δH 7.33-7.46 in the 1H
NMR spectrum of 3.22 and the disappearance of a broad OH signal in the IR spectrum,
confirmed the formation of 3.22. The absence of the aldehyde proton at δH 9.64 in the 1H
NMR spectrum of 3.23 and the appearance of a broad OH signal in the IR spectrum
corroborated the formation of 3.23. The change in chemical shift of the methylene protons
from δH 3.64 to 3.54 in the 1H NMR spectrum (Plate 1) as well as the presence of a
carbonyl carbon at δC 176.8 in the 13C NMR spectrum, m.p. 108-100 ºC and the MS (m/z
301.1077 [M-H]-) confirmed the formation of 3.26.  With phenylalcetic acid 3.26 in hand,
a good condensation method with the chiral amine needed be employed.
3.3.2 Condensation of the phenylacetic acid and the chiral amine
Given that S-α-methylbenzylamine was found to be an efficient chiral auxiliary in the
multistep synthesis of (-)-tejedine, where reduction of the intermediate imine gave the S-
configuration of the newly formed stereogenic centre with 99% de,8 we envisaged that the
R-α-methylbenzylamine would also give the R-isomer of the new stereogenic centre of the
THIQ in the Pictet-Spengler reaction. Only one reference where this chiral auxiliary was
used to influence the stereochemistry in the formation of a THIQ by the Pictet-Spengler
reaction, was found.11 In the product, the stereochemistry at C-1 was in accordance to the
selectivity observed for the Bischler-Napieralski reaction.  However, the product in this
reaction is 1-phenylsulfone not a 1-benzyltetrahydroisoquinoline. Both the chiral centres
of cycleanine (3.1) have the R-configuration.  The formation of the chiral β-
phenethylamine will be via the amide formation. As a result, many methods for the
synthesis of amides by direct combination of carboxylic acids and amines have been
investigated. The most common being the conversion of a carboxylic acid moiety to a
more reactive functional group, such as an acyl chloride, mixed anhydride, acyl azide, N-
acylbenzotriazoles, or active esters, or via the in situ activation of the carboxylic group by
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some peptide coupling reagents such as benzotriazol-1-yl-N-oxy-
tris(dimethylamino)phosphonium hexafluorophosphate (BOP)12 and N,N-
dicyclohexylcarbodiimide (DCC).13 The disadvantages of these methods are the modest
yields, expensive coupling reagents and difficulty in removal of the excess reagent and
byproducts.
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (3.30) (DMTMM),14
formed by the reaction of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (3.28) with N-
methylmorpholine (NMM) (3.29), was reported to be an efficient agent for condensing
amines and carboxylic acids (Scheme 3.6).15 DMTMM can be used to couple various
carboxylic acids with either primary or secondary amines to give amides in excellent
yields.  The versatility, solubility (soluble in MeOH, water and EtOH), as well as the
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Scheme 3.6: Formation of DMTMM (3.30).
The order of addition of the reagents is the key to successful preparation of amides in the
presence of DMTMM.  Initially carboxylic acid 3.31 must be added together with amine
3.32 to form a carboxylate anion 3.33, followed by addition of DMTMM (3.30) to give an
activated ester 3.34. In the first step, the amine will play the role of a catalyst in the
coupling of the acid with DMTMM (3.30), leading to the formation of 3.34. In the second
step, the amine reacts as a nucleophile to yield the product 3.35.  As inexpensive cyanuric























Scheme 3.7: Reaction mechanism for amide formation with DMTMM (3.30).
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Condensation of the phenylacetic acid 3.26 with R-1-phenethylamine (3.36) afforded
amide 3.37 in 98% yield with [α]D25 = +42.4 (c = 1.1 MeOH) (Scheme 3.8).  Incorporation
of the chiral amine was very important and this will be discussed in more details in the
section on the Pictet-Spengler reaction.  The expected aromatic protons, that is, a pair of
meta-coupled doublets (δH 6.44 and 6.48) and a multiplet of ten aromatic protons at δH
7.19-7.40 (10H, m, ArH) were evident in the 1H NMR spectrum of 3.37.  Furthermore, the
1H NMR spectrum displayed two methoxy singlets, a broad NH singlet as well as a
methylene singlet and the methyl doublet.  The structure was further corroborated by 13C






























Scheme 3.8: Incorporation of a chiral auxiliary 3.36 to phenylacetic acid 3.26.
Although lithium aluminium hydride (LiAlH4) is a reagent for the reduction of amides to
amines, borane makes a good alternative given that its chemoselectivity is different from
that of LiAlH4. It is known that boranes have the ability to reduce amides in the presence
of esters and their reactivity is driven by the fact that they can accept an electron pair to
their empty p-orbital.
The borane-tetrahydrofuran complex (BH3·THF) is the most reactive of all the borane
complexes due to the weak coordination of borane to THF and this was corroborated by
the fact that reduction of 3.37 using the borane-methyl sulfide complex gave the desired
product 3.38 in a low yield of 10%.  This is in accordance with the findings by Grajewska
and Rozwadowska16 in the synthesis of O-methylbharatamine.  The reaction between the
BH3·THF and the amide produced several intermediates that are ultimately converted to a
borane-amine complex (Scheme 3.9).17  Thus, to reduce the amide to the amine, five
hydride equivalents are required.  Two of the hydrides are used to reduce the amide to the
amine and the other three hydrides are utilised to form the amine-borane complex.  The
high yield and simple isolation of the reduced product have made the borane complex the
reducing agent of choice.
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Reduction of the amide 3.37 with the BH3·THF complex in the presence of BF3·OEt2 gave
amine 3.38 (Scheme 3.8).  The presence of the Lewis acid BF3·OEt2 in the reaction
accelerates the reaction by coordinating with the carbonyl group of 3.37, thereby
increasing the electrophilic character of the carbon.  This lowers the amount of BH3·THF
complex required for the reaction and accelerates the rate of the reaction, hence increasing
the yield of the reaction. The change in chemical shift of the doublet from δH 1.38 to δH
1.34 (methyl group) in the 1H NMR spectrum of 3.38, and also the appearance of the
multiplet of four protons at δH 2.70-2.74 indicates the presence of two methylene groups.
The absence of the carbonyl signal at δC 169.8 in the 13C NMR spectrum of 3.38 as well as


















































Scheme 3.9: Reaction mechanism for amide reduction.
At a later stage when more starting materials were needed, we looked at a shorter reaction
sequence to prepare 3.38, and it was found that compound 3.38 could also be prepared in
three steps from compound 3.22, where compound 3.22 is homologated via enol ether
formation of 3.39 followed by hydrolysis to phenylacetaldehyde 3.40. The main problem
in this reaction sequence, was to get optimised experimental conditions for the hydrolysis
of the enol ether 3.39.  After much experimentation, it was found that hydrolysis
performed in methylene chloride in the presence of formic acid gave the desired product
3.40 in 80% yield. In a subsequent one pot reaction, 3.40 was condensed of with the chiral
amine 3.36 to form the imine and in situ NaBH4 reduction afforded 3.38 in 95% yield.
Direct reductive amination of aldehydes normally uses additives such as catalysts (to
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facilitate formation of imines and to activate C=N for preferential reduction) and
dehydrating agents.18  In our case, since sodium borohydride reduces the imine readily and
the presence of the catalyst was not necessary, it was important to ensure that all the
starting material was consumed prior to addition of NaBH4 to prevent competing reactions.
No dehydrating agent was used in this novel reductive amination sequence of electron-rich
phenylacetaldehyde 3.40.  From a ‘green’ chemistry point of view, this approach is
attractive.  It eliminates the use and generation of hazardous substances such as:
 Corrosive and irritant cyanuric chloride used for preparation of condensing
reagent DMTMM.
 Corrosive and irritant thionyl chloride utilised in synthesis of 3.24.
 Hygroscopic and poisonous sodium cyanide used in the preparation of 3.25.
 Highly flammable moisture-sensitive reducing reagents BH3·THF complex and
BF3·OEt2 which sometimes do not give fully converted amine 3.38.
This method results in a more efficient process by which less synthetic steps are involved
and this reduces the waste associated with the isolation of intermediates involved in
Scheme 3.5.  Furthermore, less by-products are generated and this leads to higher yields.
Formation of phenylacetaldehyde via the enol ether was repeated in the preparation of































Scheme 3.10: Formation 3.38 based on a Wittig reaction.
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Since a phenolic function would be required in the next step to control the regioselectivity
during the Pictet-Spengler cyclisation, it was necessary at this point to deprotect the benzyl
moiety of 3.38. Deprotection of the benzyl ether moiety of 3.38 proved to be difficult with
Lewis acids such as FeCl3
19 and TiCl4.
20  Catalytic hydrogenolysis would be difficult to
conduct since both O-debenzylation and N-debenzylation occurs under the same
conditions.21,22  However, it is generally assumed that O-debenzylation is faster than N-
debenzylation with hydrogen in the presence of palladium on activated carbon (Pd/C)
catalyst.  Under controlled conditions (at ambient pressure and temperature), the O-benzyl
was selectively deprotected furnishing amino alcohol 3.41 in 85% yield after 15 minutes
(Scheme 3.11).  It should be noted that if the reaction is not monitored carefully (TLC), the
N-debenzylated product could be isolated (after 20 minutes). The absence of the
benzyloxy methylene singlet at δH 5.10 in the 1H NMR spectrum of 3.41 as well as the
reduced number of aromatic protons at δH 7.16-7.19 (5H, m), confirmed the formation of
the O-deprotected product 3.41 (Plate 2). With the enantiomerically-pure amine prepared,
it was viable to proceed to the synthesis of phenylacetaldehyde 3.6 to be used in the
subsequent coupling reaction to achieve the desired THIQ. Different synthetic methods for


















Scheme 3.11: Selective O- vs. N-debenzylation.
3.4 Synthesis of phenylacetaldehydes
3.4.1 4-Bromophenylacetaldehyde (3.45)
The aldehyde functionality occupies a central position in functional group chemistry and
numerous procedures have been introduced to generate this functionality ranging from
oxidation of benzylic sites, alcohols, ethers, halides and hydrolysis of acetals.  One of the
methods chosen for the preparation of the target compound 3.45 is the hydrolysis of an
acetal which was prepared from 4-bromobenzaldehyde (3.42), following a Wittig-based
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strategy.23 The reaction of 4-bromobenzaldehyde (3.42) with (methoxy)triphenylphos-
phonium chloride gave the enol ether 3.43 in 90% yield.  The acid-catalysed hydrolysis of
the enol ether 3.43 with HCl did not yield the desired product. It was only after the
completion of the synthesis of this series of phenylacetaldehydes, that the reaction
conditions described on page 71 were developed, and a longer route was followed for the
preparation of these compounds. The enol ether was then treated with p-TsOH in
methanol to the corresponding dimethyl acetal 3.44 (Scheme 3.12).24 Different protocols
employed for the hydrolysis of the acetal are described below.
3.4.1.1 Hydrolysis of acetal 3.44
Acetals are the most important protecting groups for aldehydes.  Regeneration of the parent
carbonyl from acetals by hydrolysis is well known. Classically, hydrolysis has been
performed in the presence of commonly-used acids such as HCl, H2SO4, p-TsOH, HBr,









































Scheme 3.12: Protocols for the hydrolysis of dimethyl acetal 3.44.
Partial hydrolysis has been occasionally mentioned as an inconvenience in the
chromatography of acetals on wet silica gel.25  As the method employs a heterogeneous
reagent, the removal of reagents by filtration when the transformation is complete, was
going to be easy.  However, Amberlyst and wet silica proved to be too mild for our
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compound since only the starting material was isolated, even after utilising different
reaction conditions (different solvents and temperatures).  Even with commonly used acids
such as HCl, H2SO4 and HBr, no reproducible results were obtained and the desired
product was isolated in minor quantities (Scheme 3.12).
Ford and Roskamp26 reported the deprotection of acetals using tin dichloride dihydrate
(SnCl2.2H2O) under neutral, even mildly basic, conditions in methylene chloride.
Deprotection was tried under the same conditions and 50% of the product was isolated,
with the rest being the starting material.  This might be due to the reacetalisation of the
formed product if the reaction is left for long periods of time. This was inhibited by the
addition of sodium bicarbonate, which increased the product formation by only 5%.
Addition of naphthalene, which was reported to lower reaction times and improve the
yields, resulted in an increase of the yields by 20% (from 50% to 70%).26  However,
chromatographic separation of naphthalene and the product 3.45 was not an easy task
because the two compounds have close Rf-values.  Taking into account the above-
mentioned difficulties to obtain the pure target compound, it was therefore decided to
exploit other methods.
3.4.1.2 Oxidation of alcohol 3.47
Oxidation of primary and secondary alcohols to aldehydes can be achieved using a
plethora of reagents (i.e. KMnO4, MnO2, CrO3, SeO2, Br2, etc.) in stoichiometric amounts.
However, precautions must be taken that the aldehyde is not oxidised further to a
carboxylic acid.  Although many methods using a variety of reagents and conditions have
been investigated, the development of selective oxidation using safe, economic and
environmentally benign agents remains a critical challenge in organic synthesis. The
alcohol 3.47 was prepared from 4-bromobenzaldehyde (3.42) via a Wittig olefination
followed by hydroboration and subsequent oxidation gave the anti-Markovnikov alcohol
3.47 as the major product (Scheme 3.13).
Potentially, two regiochemically different products could be formed by hydroboration of
the asymmetrical alkene 3.46.  However, one regioisomer is formed predominantly
because boron preferentially adds to the less-substituted carbon to avoid steric hindrance.
Furthermore, the high regioselectivity can be explained through the mechanism, the
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reaction starts with the interaction of the π-electron pair of the alkene and the electron-
deficient p-orbital of borane.  The transition state with boron at the less-substituted carbon
is energetically favoured because the partial positive charge located at the benzylic carbon
is better stabilised due to delocalisation. It must be noted that good yields (95%) for the
desired anti-Markovnikov product 3.47 were obtained at a low temperature (0 ºC), but an
increase in temperature enhanced the formation of the undesired Markovnikov product.









































Scheme 3.13: Formation and oxidation of phenethyl alcohol 3.47.
Collins reagent (CrO3/pyridine) is one of the most important methods for the preparation of
aldehydes.27  Nevertheless, when the phenethyl alcohol 3.47 was subjected to this
oxidation procedure, traces of the desired product 3.45 were obtained along with 4-
bromobenzaldehyde (3.42) and 4-bromobenzoic acid (3.48) (Scheme 3.13).
The unexpected formation of these side products can be rationalised in the mechanism
proposed below (Scheme 3.14).  The desired product was formed initially and then
immediately attacked by another molecule of Collins reagent.  The key cyclic intermediate
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is formed in a concerted mechanism and the subsequent rearrangement ought to proceed



























Scheme 3.14: Proposed mechanism for the formation of side products during oxidation
using Collins reagent.
Given the general tendency for aldehydes to undergo some degree of aldol self-
condensation under basic or acidic conditions, it was not surprising that the highly
enolisable arylacetaldehyde gave so many problems.  Phenylacetaldehyde is highly
reactive in water at higher temperatures, with two major possible pathways which can
occur, that is, disproportionation (Scheme 3.15) and condensation pathways (Scheme
3.16).28  Disproportionation gives phenethyl alcohol (3.50) and phenylacetic acid (3.52).
Dehydration of phenethyl alcohol leads to styrene (3.51), which in the presence of heat and
acid polymerises to high-molecular weight products. The aldol reaction of dibenzyl ketone













Scheme 3.15: Disproportion pathways for phenylacetaldehyde.
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In the condensation pathway (Scheme 3.16), the initial aldol product 3.55 undergoes
further aldol condensation to 3.56, which then closes with concomitant dehydration to form
triphenylbenzene (3.58) via intermediate 3.57.  Rearrangement of the double bond in 3.55
to 3.59 followed by hydration lead to the reactive intermediates 3.60 and 3.62.  Cleavage
of formic acid from 3.60 gives 1,3-diphenylpropene (3.61), whereas 3.62 decomposes to
either phenylacetaldehyde (3.49) and acetophenone (3.65) or benzaldehyde (3.63) and 2-
phenylpropionaldehyde (3.64) as the side products.  Compound 3.66 is generated via aldol

































Scheme 3.16: Condensation pathway for phenylacetaldehyde.
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In view of the limited number of arylacetaldehydes available commercially and their high
sensitivity to oxidative degradation in the presence of moisture, it was tempting to bypass
the actual isolation of these molecules. However, these would be inappropriate since
formation of THIQ in the Pictet-Spengler reaction does not utilise the same conditions as
formation of arylacetaldehydes.
The use of Dess-Martin periodinane (DMP) (3.68) for oxidation gave the desired product
3.45 in 75% yield. However, preparation of DMP (3.68) requires an additional two steps
with the inert conditions needed for oxidation. o-Iodoxybenzoic acid (IBX) (3.67) has
been widely utilised for the preparation of DMP (3.68), a well-known mild oxidant
affecting the conversion of alcohols to their corresponding carbonyls (Scheme 3.17).29
IBX (3.67) have initially not been used as a reagent in organic synthesis because of its
insolubility in common solvents such as DMF, CH3CN, CHCl3, CH2Cl2, acetone and THF.
Moreover, IBX (3.67) was not commonly used as an oxidant due to the fact that it was
reported to explode on heating. However, it was found that during synthesis of IBX (3.67),
the sample was contaminated with residual bromine, which contributed significantly to the
explosive feature of the sample.  In contrast to DMP (3.68), IBX (3.67) is stable to
moisture and the oxidation does not require dry solvents or an inert atmosphere. The
successful synthetic use of IBX (3.67) as an oxidising agent is carried out in DMSO, the
only solvent in which the reagent readily dissolves.  In recent years, IBX (3.67) has seen a
dramatic increase use as a reagent capable of 1) dehydrogenating ketones, aldehydes and
silyl enol ethers to their corresponding α,β-unsaturated carbonyl compound,30,31,32 2)
facilitating cyclisation of functionalised anilide systems to their heterocyclic
counterparts33,34 and 3) oxidation of benzylic sites.35  Oxidation of phenethyl alcohol 3.47
with IBX gave 4-bromophenylacetaldehyde (3.45) in a good yield of 95%.  Oxidation with
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3.4.2 4-Iodophenylacetaldehyde (3.77)
Different halo-arenes have been reported to give an array of yields in the formation of
diaryl ether linkages.  Generally, aryl iodides are more reactive than aryl bromides in the
Ullmann reaction to form diaryl ethers.  Since we planned to use the Ullmann reaction in













































Scheme 3.18: Preparation of 4-Iodophenylacetaldehyde (3.77) from p-toluidine (3.70).
During the preparation of 4-iodophenylacetaldehyde (3.77), IBX (3.67) was utilised twice
in one reaction sequence (Scheme 3.18) and this is an indication of the reagent’s versatility
and broad potential in further systems.  The benzaldehyde 3.74 could be utilised as a
starting material. However, this starting material is expensive and we decided to prepare it
from the readily available p-toluidine (3.70).  The diazotisation of p-toluidine (3.70) in
anhydrous methylene chloride did not give good results due the low solubility of p-
toluidine (3.70) in the chosen solvent.  Changing the solvent to acetone, in the presence of
excess boron trifluoride to trap the alcohol and water produced during the reaction, the
arenediazonium tetrafluoroborate 3.71 precipitated from the solution as it was formed.  The
anhydrous tetrafluoroborate salt was obtained by a simple filtration and because it is
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sensitive to air, it was immediately iododediazonated with sodium iodide in the presence of
a catalytic amount of iodine to give p-iodotoluene (3.72) in 93% yield.
Chhattise et al.36 reported the benzylic bromination of toluene with NBS as a serendipitous
reaction of aromatic ring bromination.  Their method was employed, but, since acetonitrile
gave the product only after a long reaction time, carbon tetrachloride was opted for as the
solvent of choice. The microwave-assisted bromination of p-iodotoluene (3.72) was
completed after 10 minutes without an initiator to give p-iodobenzyl bromide (3.73) in
70% yield. From a chemistry point of view, NBS offers a major advantage as brominating
reagent because the by-product of this reaction is succinimide and it can be easily
recovered and recycled to NBS. Portion-wise addition of NBS to this reaction was
important since the once-off addition of NBS resulted in a low product yield.  It must be
noted that during prolonged reaction times, the reaction mixture gradually turned purple as
a result of the formation of I2.  This is most likely due to the iodine-bromine exchange
which occurred at a slow rate since none of the deiodinated side product was observed.
Microwave-assisted α-bromination of p-iodotoluene was achieved regioselectively in a
short reaction time in a good yield and no side reactions like aromatic bromination or
iodine-bromine exchanged were observed.
The oxidation of halides to carbonyl compounds can be accomplished by a number of
methods, including N-alkoxypyridinium salts,37 NaIO4-DMF
38 and oxodiperoxovanadate.39
However, most of these methods have disadvantages in terms of acid/base conditions, long
reaction times, poor yields, high temperatures, etc.  The method reported by Moorthy et
al.40 was employed for the oxidation of benzyl bromide 3.73 because IBX was already
prepared for oxidation of the phenethyl alcohols.  Even though a one-pot bromination-
oxidation of iodotoluene was tried, the desired product was achieved in low yields, hence
the sequential two-step procedure was followed.
p-Iodobenzyl bromide (3.73) was rapidly oxidised to give 3.74 in 95% yield.  Oxidation of
benzyl bromide 3.73 was faster than oxidation of phenethyl alcohol 3.76 to 3.77 and this is
attributed to different mechanisms of oxidations (Scheme 3.19). The first reaction follows
a SN2 mechanism, where the first step is the rate-determining step, and hence the
nucleophile is in high concentration, and the leaving group is bromide, which explains why
this reaction is fast.





























Scheme 3.19: Mechanism for the oxidation of benzyl bromide 3.73 to iodobenzaldehyde
3.74.
Accordingly, the reaction may lead to the addition product 3.78, which may subsequently
decompose to the aldehyde 3.74 with liberation of IBA (3.69). A complication associated
with this reaction is the competition IBA (3.69) and IBX (3.67) for the benzyl halide to
form undesirable ethers.  This can be avoided by addition of excess IBX (3.67), because




























Scheme 3.20: Mechanism for the oxidation of phenethyl alcohol 3.76 to
iodophenylacetaldehyde 3.77.
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In the oxidation of the alcohol 3.76 the first step is fast, the subsequent step is the slowest
in the sequence and according to the mechanism, the presence of water slows down the
forward process (Scheme 3.20).
3.4.3 4-Fluoro-3-nitrophenylacetaldehyde (3.84)
From Scheme 3.1, it was possible to construct a diaryl ether bond from two identical THIQ
monomers via nucleophilic aromatic substitution (route f).  However, nucleophilic
aromatic substitution will only be possible with an activated 1-benzyl ring of the THIQ.
This activated THIQ could be constructed by using an activated arylacetaldehyde during
the Pictet-Spengler reaction. For this reason, 3-nitro-4-fluorophenylacetaldehyde (3.84)
(Scheme 3.21) was prepared to give an activated THIQ in the Pictet-Spengler reaction and
this could be used in the nucleophilic aromatic substitution to cycleanine (3.1) in a later
stage of the total synthesis. Nitration of fluorobenzaldehyde 3.80 afforded a single nitro
isomer 3.81 in 75% yield.  The position of the nitro group was confirmed by the NOESY
correlation between the aldehyde proton to two aromatic protons resonating at δH 8.08 (1H,
dd, J = 2.3, 8.3 Hz, H-6) and 8.52 (1H, d, J = 2.3 Hz, H-2). 4-Fluoro-3-nitro styrene (3.82)
was achieved in 95% yield, but it should be noted that good yields for the Wittig
olefination of 3.81 were obtained after long reaction times (5 hours) compared to the
bromo- and iodo-vinylbenzenes derivatives and this can be attributed to the presence of the
strong electron-withdrawing nitro group. Hydroboration-oxidation of 3.82 to the alcohol






























Scheme 3.21: Synthesis of 4-fluoro-3-nitrophenylacetaldehyde (3.84).
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3.4.4 4-Isopropyloxyphenylacetaldehyde (3.89)
To exploit the scope of substrate effects on the Pictet-Spengler reaction, we decided to
prepare the THIQ monomer with the electron-rich 1-benzyl moiety and on this basis 4-
isopropyloxyphenylacetaldehyde (3.89) was prepared (Scheme 3.22). Formation of 3.89
was initiated by protection of the free hydroxy in 3.85 to 3.86 in 84% yield.  The
developed protocol for synthesis of phenylacetaldehydes was also used to give 4-
isopropyloxyphenylacetaldehyde (3.89) in an overall yield of 55% from 4-
hydroxybenzaldehyde. Although the reactions performed with the electron-donating
isopropyloxy group were sluggish, reasonable yields were obtained.  Wittig olefination of
3.86 took 15 hours to afford 3.87 in 90% yield, followed by an overnight hydroboration-
oxidation to 3.87 and subsequent IBX oxidation to 3.89 in 90% yield. IBX (3.70)
oxidised the phenethyl alcohols to aldehydes at room temperature without overoxidation to
the carboxylic acids, no starting materials or C-C bond cleavage was observed.  For all the
products formed (3.77, 3.84 and 3.89), the disappearance of the two triplets due
CH2CH2OH were evident in the
1H NMR spectra and the aldehyde triplet signal was
apparent in all products formed.  The yields for the formation of arylacetaldehydes vary
with the halogen used, with the iodo being more reactive and giving higher yield at shorter
reaction times (98%, 30 min) followed by bromo (95%, 1.5 h) and the fluoro (85%, 5 h)



























Scheme 3.22: Synthesis 4-isopropyloxyphenylacetaldehyde (3.89).
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3.4.5 The anticipated synthesis of 3-benzyloxy-4,5-dimethoxyphenylacetic acid
(3.26) via IBX (3.67) oxidation
The good results obtained in the oxidation of phenethyl alcohols (Scheme 3.12, 3.17, 3.20
and 3.21) encouraged us to attempt the synthesis of phenylacetic acid 3.26 using IBX
(3.70). Synthesis of the phenylacetic acid was envisaged as indicated in Scheme 3.22.
The envisaged synthesis of 3.26 according to Scheme 3.22 promised higher yields and
shorter reaction times compared to synthesis of 3.26 following Scheme 3.6. The reaction
of phenethyl alcohol 3.91 with IBX (3.70) was attempted. However, to our disappointment
the oxidation of 3.91 to 3.92 gave the desired product in 10% yield.  This could be
attributed to coordination of the substrate to IBX (3.70), which may undermine the desired
reaction course.  The phenethyl alcohol 3.91 coordinates to the iodine centre via the lone
pair of electrons on the ethereal oxygen thus changing the course of the reaction and the
desired product is not formed. All reactions performed on 3.22 to 3.91 gave the products
in low yields (Scheme 3.23), this could be due to the electron-rich character of subsequent
compounds.  Compound 3.90 was achieved in 60% yield compared to 95% yield of the
iodo derivative 3.77.  Oxidation of 3.90 to 3.91 was obtained in moderate yield of 55%,


































Scheme 3.23: Envisaged synthesis of 3-benzyloxy-4,5-dimethoxyphenylacetic acid (3.26)
via IBX oxidation.
The importance of IBX (3.67) methodology stems from the fact that all the above-
mentioned transformations are quite general and can be easily applied to a magnitude of
synthetic strategies.    The mild and chemoselective nature of IBX (3.67), coupled with the
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high reaction yields that frequently accompany its employment, has rendered this reagent
as a unique and powerful tool in chemical synthesis.
3.5 Regio- and stereoselective synthesis of 1,2,3,4-tetrahydroisoquinoline (THIQ)
derivatives.
With the two starting materials 3.41 and different phenylacetaldehydes available for the
formation of THIQ, the best conditions for synthesis of THIQ’s were investigated. It has
been reported that the Pictet-Spengler41 strategy is the straightforward and synthetically
efficient protocol for the synthesis of tetrahydroisoquinoline alkaloids.  In this study, the
Pictet-Spengler methodology was employed because fewer steps are involved. Though
efficient, regioselectivity and stereoselectivity are known to be major drawbacks of the
Pictet-Spengler reaction.
Although Pictet and Spengler originally reported the formation of the parent THIQ by
heating of a mixture of 2-phenethylamine and formaldehyde in the presence of
concentrated hydrochloric acid at reflux (150 ºC), a number of attempts to reproduce the
synthesis of the parent THIQ in this prototype reaction have failed.  For example, Clemo
and Swan42 reported the formation of large amounts of bis(2-phenylethylamine)methane
along with the traces of THIQ under the reaction conditions originally described. The
presence of the catalytic amount of the acid facilitates the ring closure in the Pictet-
Spengler reaction. The preferred protic acid for the Pictet-Spengler reaction include HCl,
formic acid, perchloric acid, phosphoric acid, trifluoroacetic acid (TFA),
trifluoromethanesulfonic acid, to mention a few. The reactivity, regio- and
stereoselectivity of the Pictet-Spengler reaction depend greatly on the nature of the starting
chiral auxiliary amine, the degree of activation of the cyclising benzene ring of the relevant
imines as well as the reaction conditions.  The following paragraphs details the substrate
effects, regio- and stereoselectivity of the products formed by the Pictet-Spengler reaction.
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3.5.1 Regioselective analysis.
One problem which arises in the application of the Pictet-Spengler reaction is the
regiochemical control when there is more than one site for cyclisation (Scheme 3.24).
Hence this gives rise to two regioisomers if the site of the closure is not controlled.  For



















Scheme 3.24: Regioisomers formed in the Pictet-Spengler reaction.
The synthesis of symmetrical THIQ’s44 is well known and in this case the regioselectivity












Scheme 3.25: Synthesis of a symmetric THIQ via the Pictet-Spengler reaction.
Cho et al. 45 employed a halogen blocking group so that cyclisation can be directed to one
position (Scheme 3.25), in this case 3.98 gives only 3.99.  However, introduction of the
blocking group add two more steps to the total synthesis, that is, addition as well as














Scheme 3.26: Employment of a blocking group in the Pictet-Spengler reaction.
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Cyclisation has generally been reported to proceed para46 to the activating 3-alkoxy or 3-
hydroxy group, thereby generating 6-alkoxy- or 6-hydroxytetrahydroisoquinolines. For
example, condensation of dopamine with formaldehyde proceeds with preferential
formation of 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline over the 7,8-dihydroxy isomer,
due to the pronounced directing effect of the activating OH group to the para- rather than
ortho-position as a result of the steric hindrance. 47  Cyclisation of 3.100 afforded












Scheme 3.27: Directing effect of OH group in the Pictet-Spengler reaction.
Due to the prominent directing effect of a free hydroxyl group, in this study the β-
phenethylamine with a free hydroxy group was utilised. In the reaction conditions were
optimised by using 4-bromophenylacetaldehyde (3.6) because fewer steps are involved
during its preparation as compared to the other three arylacetaldehydes. The condensation
reaction of β-phenethylamine 3.41 and phenylacetaldehyde 3.45 via the imine intermediate
3.103 could form two possible regioisomers 3.104 and 3.105 could form (Scheme 3.28).
The predominant formation of the desired regioisomer 3.104 was essential since the
separation of the isomers can be a tedious process, especially for large scale preparations.
























































Scheme 3.28: Regioisomers isolated in the Pictet-Spengler reaction between 3.41 and 3.45.
In this study, CH2Cl2 was used as the solvent and HOAc was chosen as the catalyst to
promote formation of the iminium cation in the Pictet-Spengler reaction. During the
formation of the iminium intermediate, water is also formed and this could slow the
formation of the final product.  Thus, molecular sieves were added to improve the rate as
well as the yields of the reaction. The highly polar 2,2,2-trifluoroethanol (TFE) was also
used as a co-solvent.  The unique properties brought about by the presence of three fluoro
substituents in this solvent were expected to dramatically modify the course of the reaction.
The electron-withdrawing character of CF3 confers high acidity to the hydrogen of the
hydroxy group with a pKa value of 12.4.  Furthermore, TFE possesses a very strong
hydrogen bond donor power (α = 1.51).  Previously, TFE was used in the Pictet-Spengler
reaction to influence the stereochemistry of the reaction, but to the best of our knowledge,
this is the first time that it is used to control the regioselectivity of the Pictet-Spengler
reaction.48
When the amine 3.41 and the aldehyde 3.45 reacted at 25 ºC in the absence of TFE and
HOAc, no reaction occurred after 12 hours (Table 3.1, Run 1). Addition of TFE as a co-
solvent did not provide the desired product (Table 3.1, Run 2). Addition of a catalytic
amount of HOAc (0.01 eq.) and reduction of TFE (CH2Cl2:TFE 2:1) at 25 ºC resulted in a
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formation of the mixture of the two regioisomers 3.104 and 3.105 in a 1:1 ratio (Table 3.1,
Run 3, Plate 3).  Reduction of the co-solvent from a 1:1 ratio to a 7:1 (CH2Cl2:TFE) ratio
and increasing the HOAc (0.1eq.), resulted not only in an increased yield of the reaction,
but also to the formation of 3.104 as the major product (Table 3.1, Run 6).  The results
from runs 3-5 clearly demonstrated that the hydroxy group of the 3,4-dimethoxy ring was
activated by the presence of TFE, due to the high hydrogen bond donor ability of TFE and
its high ionising power.  High concentration of TFE in the reaction mixture (low pH)
resulted in cyclisation para to the hydroxy group and this is in agreement with results
reported by Bates where cyclisation occur exclusively in the para position.  Furthermore, a
high concentration of TFE in the solution can result in the formation of the dimeric TFE
complex in the transition state, which will make the ortho position to the OH group less















Figure 3.1:  Hydrogen bonding due to the presence of TFE in the Pictet-Spengler reaction.
A decrease in temperature from 25 ºC to 0 ºC resulted in a change in ratio to 1:6, with
3.105 being the major isomer (Table 3.1, Run 5, Plate 4).  This indicates that lower
temperatures retard cyclisation in the desired position, hence decreased the formation of
the desired product. In refluxing CH2Cl2 in the presence of molecular sieves and lower
amounts of TFE, to our delight the desired regioisomer 3.104 was formed as a major
product (Table 3.1, Run 6). Increase in the reaction times from 12 h to 18 h in refluxing
CH2Cl2 resulted in the formation of 3.104 as a sole product (Table 3.1, Run 7, Plate 5).
Overall, under optimised conditions [CH2Cl2:TFE = 7:1, HOAc (0.1 eq.), reflux, molecular
sieves, 18 h], the desired product 3.104 was obtained in 78% yield. When this reaction
mixture was heated for a longer period (24 h) and with a high concentration of HOAc (1
eq.), the yield of the product was decreased from 78% to 45% (Table 3.1, Run 8). This
indicated that HOAc rapidly induced the cyclisation and at the same time slowly
decomposed the products due to prolonged exposure to the acid (Plate 6).  This was also
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experienced when product was in contact with CDCl3, which is slightly acidic for a long
time.  These results suggested that the ratio of regioisomers is thermodynamically rather
than kinetically controlled.  At this stage, we were not sure what the stereochemistry at C-1
of 3.104 and 3.105 was, but based on results obtained later (Section 3.7), the
stereochemistry at C-1 was assigned as S.
Table 3.1:  Effects of time, temperature and co-solvent on the yields and ratio of the
regioisomers of the Pictet-Spengler reaction.






1 CH2Cl2 - 25 12 - -
2 CH2Cl2/TFE
(1:1)
- 25 12 - -
3 CH2Cl2/TFE
(2:1)
HOAc (0.01 eq.) 25 12 50 1:1
4 CH2Cl2/TFE
(2:1)
HOAc (0.1 eq.) 25 12 55 2:3
5 CH2Cl2/TFE
(2:1)
HOAc (0.1 eq.) 0 12 65 1:6
6 CH2Cl2/TFE
(7:1)





reflux 18 78 100:0
8 CH2Cl2/TFE
(7:1)
HOAc/ms  (1 e.q) reflux 24 45 decomposition
aYields are for isolated products obtained after chromatography (Hexanes/EtOAc)
bRatios were determined by 1H NMR spectroscopic integration
The results achieved are in good agreement with the reported studies by Manabe et al.49
and Eynden et al.,50 but it is important to note that in their case, the formation of one
regioisomer was attributed to steric control. Nevertheless, in our investigation the product
formed at higher temperature was governed by electronic factors as well as the steric
control. Ortho-cyclisation may also be favoured by dipolar attraction between the iminium
cation and phenolate anion. Looking at the NMR shifts of the different aromatic protons of
compound 3.41, it is apparent that the proton ortho to the free hydroxy at δH 6.18 (1H, d, J
= 1.8, H-6) is more electron-rich than the para proton at δH 6.33 (1H, d, J = 1.8 Hz, H-2),
since it resonates up-field and more energy is needed for cyclisation to occur at H-2.
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The ratio of regioisomers 3.104 and 3.105 formed in the Pictet-Spengler reaction depends
on the reaction conditions, i.e. temperature, the amount of the co-solvent and time as
shown in Table 3.1.  The reactions conducted under milder conditions gave low
regioselectivity, while the reactions under forced conditions showed high regioselectivity,
for example, the ratio of 3.104 and 3.105 was 1:1 at 25 ºC and at reflux 100:0.  The
structures of products 3.104 and 3.105 were determined by spectral analyses (MS, IR, 1H,
13C, NOESY). The 1H NMR of 3.104  exhibited ten aromatic protons, a singlet (H-5) at δH
6.22, methine H-1 at δH 4.35, two methoxy groups, methine quartet (δ 3.63) and methyl
doublet (δH 0.96) from the chiral auxiliary and six aliphatic protons (three pairs of
methylene protons). The presence of ten aromatic protons instead of five protons in the
starting material, methine H-1, splitting patterns of the diastereotopic H-α protons and the
methylene protons indicate the presence of the newly chiral centre at C-1 and these
corroborate formation of 3.104. The aromatic region (δH 6.22 - 7.45) of the 1H NMR
spectrum exhibited two separate spin systems, an AA'BB' and ABC. Analyses of 13C
NMR, DEPT and HSQC revealed the presence of two methine, one methyl, three
methylene and eight quaternary carbons.  The HMBC spectrum permitted the construction
of structure showing correlations from H-5 to C-6, C-4, C-4a; H-1 to C-8a, C-6, C-7; H-α
to C-1, C-9, C-10; H-10 to C-9, C-11, C-12; H-11 to C-9,C-10, C-12.The assigned
structure was also supported by the MS data (m/z 482.1333 [M+H]+). The difference
between 3.104 and 3.105 structures was determined by NOESY.  In the NOESY spectrum
of 3.104 (Plate 7), the signal of the H-5 singlet at δH 6.22 showed a correlation to the C-6
methoxy protons at δ 3.80, whereas for 3.105 no correlation to a methoxy signal was
observed. In addition, the methine proton (H-1) of 3.105 appears at higher chemical shifts
due to the shielding effect of the methoxy group at C-8.
3.5.2 Effects of substrates
Thus, the general consensus hitherto has been that the Pictet-Spengler cyclisation is
sensitive to the aromatic substituents of the 2-arylethylamine moiety of the imine.
Furthermore, an electron-donating hydroxy or an alkoxy group at the para-position of the
cyclisation site, is the minimum requirement for a facile reaction.51  Because a methoxy
group on the aromatic ring is a strong electron-donating group, the imine 3.107, which
bears two methoxy groups, can be regarded as an activated substrate.  This imine readily
undergoes cyclisation to give the corresponding THIQ 3.110 in a high yield.  The imine
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3.107 is protonated in HOAc to give the iminium cation 3.108, which cyclises in the rate-





























Scheme 3.29: Iminium cation formed in the Pictet-Spengler reaction.
The influence of substituents on the phenylacetaldehyde ring was also investigated
(Scheme 3.29, Table 3.2).  It was noted that the reaction yields increased in the presence of
the electron-withdrawing halides by increasing the electrophilicity of the aldehyde.
Formation of THIQ 3.113 required longer reaction times and lower yields were obtained in
comparison to the THIQ with halides substituents (Table 3.2, Entry 4). Although the
phenylacetaldehydes with bromine and iodine substituents did not show a big difference in
terms of the yields, the reaction of the bromo derivative took longer than the reaction of the
iodo derivative (Entries 1 and 2, Table 3.2).  The fluoro-nitro substituents gave lower yield





















3.45: R1 = Br, R2 = H
3.77: R1 = I, R2 = H
3.84: R1 = F, R2 = NO2
3.89: R1 = OiPr, R2 = H
3.104: R1 = Br, R2 =H (78%)
3.111: R1 = I, R2 = H (80%)
3.112: R1 = F, R2 = NO2 (72%)
3.113: R1 = OiPr, R2 = H (70%)
Scheme 3.30: Effects of R1 and R2 substituents on phenylacetaldehyde on the formation of
THIQ .
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Table 3.2.  Effects of R1 and R2 substituents on the time and reaction yields of the Pictet-
Spengler reaction.
Entry R1 R2 Time (h) Yield (%)
1 Br H 18 78
2 I H 12 80
3 F NO2 24 72
4 OiPr H 20 70
No intermolecular side products were formed since the iminium cation intermediate
formed is a weak electrophile and it requires a reactive nucleophile and this favours
intramolecular cyclisation to a heterocyclic ring over intermolecular reactions. The Pictet-
Spengler cyclisation proceeded exclusively in a 6-endo fashion and no products derived
from the 5-exo alternative were observed.  Furthermore none of the uncyclised products
were isolated.
3.5.3 Stereochemical and conformational analyses
The use of chiral auxiliaries to control stereochemistry played a major role in the
development of stereoselective syntheses for natural products. One way to control the
stereochemistry of tetrahydroisoquinolines at C-1 is to incorporate a chiral auxiliary on the
nitrogen. Based on results published on the Bischler-Napieralski reaction,8 we initially
anticipated that the chiral auxiliary with a R-configuration will result in the R-configuration
at the new chiral centre.
In a X-ray crystallographic study discussed later (page 107), it was found that the
heterocyclic ring of the THIQ has a half-chair conformation, with the substituent (4-
bromobenzyl) at C-1 and the bulky benzyl group at nitrogen trans to each other.  The
stereochemistry of the newly formed chiral centre was proven to be S from the X-ray
structure of compound 3.131. Compound 3.131 was prepared from isoquinoline 3.104
and, therefore, the stereochemistry at C-1 of 3.104 must also be S.  Compound 3.104 has
two stereocentres and if the Pictet-Spengler reaction was not stereoselective, the result
would be a mixture of diastereomers.  The NMR spectra of 3.104 clearly showed that it
consisted of one diastereomer only and that the reaction proceeded with high
stereoselectivity.
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The Bischler-Napieralski reaction gives the same isomer as the starting chiral auxiliary,
therefore, the results found from X-ray indicates that different mechanisms are followed
during cyclisation when the Pictet-Spengler reaction is employed instead of the Bischler-
Napieralski reaction. The stereochemical outcome of the Pictet-Spengler reaction and the
Bischler-Napieralski reaction can be explained by Houk’s computational studies.52  Both
reactions are cases of an 2-aza-allyl system and Houk’s investigation found that for these
systems, one conformation is preferred due to allylic 1,3-strain.  Thus it is important to













Scheme 3.31: The most stable conformer of open chain allylic system.
For simple alkenes, the preferred conformation is the one with the hydrogen in the plane of
the alkene.  The relative sizes of the R2 and R3 substituents differentiate the diastereotopic
faces on the double bond (Scheme 3.31). When R1 = Me the equilibrium lie in favour of
3.114b and if R3 is bigger than R2, the attack will occur from the less sterically hindered
side.  For heterosubstituted allylic systems, experimental asymmetric induction and
spectroscopic measurements suggest that the conformer 3.115b is markedly favoured over

















Scheme 3.32: The most stable conformer of heterosubstituted allylic system.
We applied Houk’s model to rationalise the stereochemical outcome of the Bischler-
Napieralski and  the Pictet-Spengler reactions.  In these two reactions the reacting prochiral
groups and the inducing stereocentres are part of the same molecule.  The two entities are
separated by two bonds equivalent to 1,3-asymmetric induction.   Both these reactions
require nucleophilic attack to an imine.  Nucleophilic attack on imines, as in the case with
carbonyls, follows the Bürgi-Dunitz trajectory,53 as the nucleophile approaches the C=N
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carbon atom, the two alkyl substituents R2 and R3 bend away and the C=N distance
becomes longer.  The nucleophile approaches along a line which is not perpendicular to the




Figure 3.2: Nucleophilic approach to C=N carbon atom.
The Bischler-Napieralski reaction entails formation of a new stereocentre on a cyclic six-
membered ring substrate (Scheme 3.33).    Since the C=N double bond is set in a rigid six-
membered ring, only two rotations are possible for this structure: 1) rotation around C-N
bond linking the N to the stereogenic centre and 2) rotation around C-C bond linking the
stereocentre and the aromatic moiety.  This conformational rigidity ensures the high levels
of stereocontrol. The mechanism accounting for this success is the stereocontrolled
formation of the iminium ion-borohydride ion pair prior to reduction, followed by the
hydride ion attack of the activated iminium moiety with the generation of the new chiral




















Scheme 3.33: Diastereoselective synthesis of THIQ 3.117 via the Bischler-Napieralski
reaction.
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The single stereogenic centre appended to the nitrogen atom controls the effectiveness of
the asymmetric induction by creating different steric environments at the two
diastereofaces of the iminium. The R-diastereomer was postulated to arise from transition
state of the 3.116b which is more stable than 3.116a favouring a si-attack by a hydride ion.
The si-face is the least hindered face and in this conformer 1,3-allylic strain is minimised.
The attack from the si-face will lead to the R-benzyltetrahydroisoquinoline.
The Pictet-Spengler reaction represents asymmetric induction of an open chain allylic
system.  For the efficient asymmetric induction in the open-chain situations, two conditions
have to be met. Firstly, the number of energetically favourable conformations of the bonds
connecting the prochiral group and the inducing stereogenic centre has to be restricted so
that one conformation is available in the transition state.  Secondly, in this conformation
the different groups on the stereogenic centre must differentiate the diastereotopic faces of
the reacting prochiral group.  This differentiation can be accomplished by using a large
group at the controlling stereocentre that shields the approach on one side of the prochiral
group.  The main aim is to control the conformation around the bond between the inducing
centre and the reacting prochiral C=N group, e.g. around a 3.118b and to control the
geometry of the C=N bond.
The preference for the formation of diastereomer 3.104 by Pictet-Spengler cyclisation of
iminium 3.118b was not consistent with the stereoselective outcome of Pictet-Spengler
reaction reported previously.55  Therefore, an effort was made to rationalise these findings.
Scheme 3.34 depicts two possible diastereoisomers that can be formed depending on the
faces exposed. The iminium cation can adopt the E-3.118 or the Z-3.118a configuration
via the enamine intermediate and when discussing the stereochemical outcome of Pictet-
Spengler cyclisation both isomers must be considered. Normally the E-isomer is more
stable than the Z-isomer. For the E-isomer, the attack will be from the si-face and this will
result in the R-configuration at the newly formed stereogenic centre of compound 3.118c,
which is not the isolated isomer. However, from the results obtained, it was clear that the
Pictet-Spengler cyclisation proceeded via the Z-isomer. We propose that the presence of
TFE influences the reaction selectivity by forming a coordinated TFE complex (Figure
3.1), which will prevent formation of the E-isomer in the transition state.  This change in
selectivity in the presence of TFE was also observed by Zhu and co-workers48 in the
synthesis of ecteinascidin.




















































Scheme 3.34: Mechanism for the diastereoselective synthesis of THIQ 3.118a via the
Pictet-Spengler reaction.
The preferential formation of isomer 3.118a was rationalised according to Houk’s model.
According to Houk’s model the allylic hydrogen of the chiral auxiliary will be in the same
plane as the C=N bond as in conformer A. It must be noted that molecule 3.118b is not
frozen in conformer A and changes in the rotation around bond b is possible to form
conformer B.  However, conformer B is destabilised by allylic 1,3-strain56 (C-Me bond
eclipsing the double bond).  The difference in population of the conformers A and B is a
significant factor affecting the level of asymmetric induction of this reaction and this
favours the re-attack resulting in the S-isomer as the major product and the results indicates
that the reaction proceed from the Z-isomer of the starting material.
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3.5.4 Conclusion
We have described a highly efficient regioselective and stereoselective synthesis of THIQ
derivatives using the N-phenethyl chiral auxiliary to control the stereochemistry and the
hydroxy group to control regiochemistry of the Pictet-Spengler reaction. The mechanism
was proposed in order to account for the stereochemical outcome of the Pictet-Spengler
cyclisation. Effects of substrates on the reaction yield were examined and it was found that
electron-rich substrates react slowly giving lower yields compared to electron-deficient
phenylacetaldehydes.  The ease of formation of enantiomerically pure β-phenethylamine
3.22 combined with the ability to synthesise phenylacetaldehydes with a variety of
substituents, makes this method efficient for the preparation of other THIQ’s.  Moreover,
both the R and S isomers of THIQ are found in naturally occurring biological active
alkaloids, therefore, our study proposes a solution to the highly stereoselective synthesis of
both isomers. Also, our study compares favourably with previous methods in terms of
efficiency and potential scope.
3.6 Synthesis of boronic acid 3.10
The substitution of an aryl halide by a nucleophile that takes place with catalysis by a
transition-metal complex is generally referred to as a cross-coupling reaction if it follows
the mechanistic course of oxidative addition, transmetallation and reductive elimination.
The Suzuki-Miyaura cross-coupling reaction is one of the most versatile procedures
developed in the 20th century.57 Since its discovery many improvements have been made,
for example, Evans et al.58 reported a useful boronic acid phenol cross-coupling that
expand the versatility of the Suzuki coupling reaction.  The chemistry of boronic acids
continues to be a growth area in synthetic methodology.  Arylboronic acids are useful in
synthesis by coupling reactions with phenols,59 amines,60  amides and imides,61 and N-
heterocycles62,63 to give the corresponding O- or N-arylated products.
The remarkably simple resolution by Evans et al.58 allows formation of diaryl ethers from
phenols and boronic acids catalysed by Cu(II) acetate at ambient temperature.  Since the
target compound cycleanine (3.1) comprises two asymmetric centres, it was envisaged that
the centres could be inert to these reaction conditions.  The mild reaction conditions of this
method prompted us to use it, therefore, it was necessary to prepare an arylboronic acid.  A
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typical preparation of an arylboronic acid involves a reaction between an organoborate and
an organometal (Li or Mg), usually prepared by magnesium insertion or lithium-halogen
exchange (LHE) of the corresponding aryl halides (Scheme 3.35).64 Both methods were
employed in this study.




Scheme 3.35: Preparation of boronic acids by magnesium insertion or lithium-halogen
exchange.
3.6.1 Lithium-Halogen Exchange (LHE)
The LHE reaction, discovered by Wittig et al.65 and Gilman co-workers66 is the most
versatile method used to generate organolithium compounds. The LHE reaction provides
access to many unstable organolithium intermediates because it is rapid even at low
temperatures (lower than -70 ºC). Bromobenzene (3.119) was used in a model reaction as
a unsubstituted aryl halide.  Conventional protocol was employed, that is bromobenzene
(3.119) was treated with n-butyllithium at -78 ºC followed by triisopropyl borate and then





Scheme 3.36: Formation of phenylboronic acid (3.118) from bromobenzene via LHE.
The resultant phenylboronic acid (3.120) was then coupled with the THIQ 3.104 to yield






















Scheme 3.37: Formation of diaryl ether 3.121 via boronic acid coupling.
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While optimising the reaction conditions, we were interested to see the effects of
substituents on the benzene ring since the targeted diaryl ether 3.11 is para-substituted.
For this reason, 4-bromoanisole (3.122) was subjected to the same reaction conditions and
to our delight the yields were improved from 50% in bromobenzene (3.119) to 60% in 4-
bromoanisole (3.122) and it was envisaged that the same conditions could be used for our








Scheme 3.38: Formation of boronic acid from bromoanisole (3.123) via lithium-halogen
exchange.
The reaction of 1-bromo-4-(2,2-dimethoxyethyl)benzene (3.44) with BuLi and B(OMe)3
followed by acid quench and aqueous workup with concomitant deprotection of the
dimethoxyethyl group did not give the desired product 3.10 and only non-identifiable










Scheme 3.39: Formation of boronic acid from 1-bromo-4-(2,2-dimethoxyethyl)benzene
(3.44) via lithium-halogen exchange.
Li et al.67 reported that the order of addition of the reagents was the key to a successful
preparation of arylboronic acids. The addition procedure was reversed, and 1-bromo-4-
(2,2-dimethoxyethyl)benzene (3.44) was added to a solution of n-BuLi followed by
addition of B(OMe)3. The boronate ester was even changed to triisopropyl borate with no
success.  Furthermore, the sequence was changed again where n-BuLi was added to a
solution of 1-bromo-4-(2,2-dimethoxyethyl)benzene (3.44) and B(OiPr)3 followed by acid
quenching, but this also did not give better results.  The activating ability of the methoxy
group with bromoanisole can be explained in terms of the inductive effect but for the
dimethoxyethyl group this is not obvious as its electronegative properties are weak.  It
should be noted that BuLi/THF deprotonates acidic hydrogens faster than bromine-lithium
exchange and this could be the reason for isolation of non-identifiable products.  Although
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halogen-lithium exchange is reported to be an excellent method for the preparation of
organolithium compounds, which readily undergo transmetallation to provide a variety of
organometallic reagents, this protocol did not work well for the preparation of the target
compound 3.11 and an alternative method was employed.
3.6.2 Preparation of arylmagnesium reagents
Organomagnesium reagents first prepared by Grignard over 100 years ago, still occupy a
central place in organic chemistry and have excellent reactivity towards a wide range of
electrophiles.  The most common method used to prepare organomagnesium compounds is
the direct reaction of magnesium metal with organic halides.  The reactivity of
organomagnesium reagent is strongly dependent on the reaction temperature  Thus
performing the halogen-magnesium exchange at temperatures below 0 ºC has the potential





Scheme 3.40: Formation of phenylboronic acid from bromobenzene via the Grignard
reaction.
Although slower than I/Mg, Br/Mg exchange is sufficiently fast below 0 oC for the
preparation of functionalised aryl magnesium bromides that bear electron-withdrawing
groups.  Therefore Br/Mg exchange is suitable for the preparation of Grignard reagents that
contain sensitive functional groups.  The exchange rate depends strongly on the electron










Scheme 3.41: Formation of boronic acid from bromoanisole via the Grignard reaction.
Model reactions on bromobenzene (3.119) and bromoanisole (3.122) with magnesium
triisopropyl bromide produced better yields of 3.120 (70%) and 3.123 (95%), respectively
Results and Discussion Chapter 3
103











Scheme 3.42: Formation of boronic acid from 4-bromo-1-(dimethoxymethyl)benzene via
the Grignard reaction.
Even though the organoboranes give promising results, many of these reagents are difficult
to purify because they are waxy solids.  The situation is complicated by the formation of










This equilibrium has no bearing on the coupling process, but it can influence the reaction
stoichiometry, since it is difficult to determine the concentration of boronic acid versus
boroxine in a mixture and there is no simple assay to assess the amount of total boronic
acid available.  Consequently, many literature protocols employ excess boronic acid to
ensure a complete conversion of the electrophilic component of the reaction, clearly an
inefficient use, of what might be the most expensive component of the reactions.
Moreover, as Brönsted acids, boronic acids react readily with a variety of bases and
nucleophiles, and because of their electron-deficient character are easily oxidised.
Because many organic functional group transformations involve bases, nucleophiles and
oxidants, we sought to look for an alternative procedure for the formation of the diaryl
ether.  These factors together with the difficulty in the preparation of this reagent, led us to
consider nucleophilic aromatic substitution as a possible method for the diaryl ether
synthesis.  Moreover, successful use of IBX in oxidation reactions and frustrations
encountered during formation of the diaryl ether bond using boronic acids, led to
reconsideration of our synthetic plans where SNAr was considered to be the solution to the
frustrations.
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3.7 Formation of diaryl ether 3.131 via nucleophilic aromatic substitution
A number of years ago intensive studies on diaryl ether synthesis involved nucleophilic
SNAr reactions of activated aryl halides were carried out, but due to the success of
palladium, copper and boronic acid mediated chemistry, the progress in this field has
slowed down.  Despite that, some new extensions of the classical nucleophilic aromatic
substitution methods to diaryl ethers have been developed.  Aryl halides that have one or
more strongly electronegative groups (nitro, methylcarbonyl) para or ortho to the halogen
are considered to be activated and undergo nucleophilic substitution with phenols under
relatively mild conditions.
Microwave irradiation has become increasingly popular in recent years to improve the
yield and shorten reaction times in a variety of reactions.  Wang and co-workers68
developed a convenient microwave-assisted version of diaryl ether synthesis from electron-
deficient phenols and aryl halides.  This technology has also been explored for nucleophilic
substitution of haloheterocycles with sodium phenoxide on pyridine, quinoline,
isoquinoline, pyrazine and pyrimidine systems by Cherng.69
Aryl halides do not undergo nucleophilic substitution reactions by SN1 and SN2
mechanisms, instead certain aryl halides do undergo nucleophilic substitution by
nucleophilic aromatic substitution, where substitution occurs at a carbon of an aromatic
ring by a nucleophilic mechanism.  In our study, we employed fluorobenzaldehyde (3.80)
as an aryl halide because the fluorides are the most reactive substrates in nucleophilic
aromatic substitution. The mechanism of this reaction is illustrated in Scheme 3.43. The
electron-withdrawing aldehyde group para to the halide accelerates the reaction because
the transition state resembles the Meisenheimer complex and this aldehyde also stabilises
this complex by resonance.  Fluorine also stabilises the negative charge by its electron-
withdrawing polar effect, which is greater than the polar effect of other halogens.  The loss
of the halide is not rate limiting and thus the leaving-group ability does not determine the
reaction rate.























Scheme 3.43: Mechanism of the nucleophilic aromatic substitution reaction.
Prior to coupling of THIQ 3.104 with aryl fluoride 3.80, the reaction conditions were
optimised with the model reaction of phenol (3.124) and fluorobenzaldehyde (3.80).  The
model reactions illustrated in the Scheme 3.44 below gave good yields, and better reaction
conditions were formulated.  Nucleophilic aromatic substitution between 3.80 and 3.124
gave 3.125, which was homologated via Wittig olefination to 3.126 followed by
hydroboration-oxidation to 3.127 and a subsequent IBX oxidation afforded 3.128, which
was condensed with 3.129 under Pictet-Spengler conditions to afford the desired product in



































Scheme 3.44: Model reaction for the formation of the diaryl ether and subsequent
reactions.
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The structures of all the compounds were confirmed by NMR, IR and MS.  Nine aromatic
protons in the 1H NMR spectrum as well as MS data (m/z 199.0759 [M+H]+) confirmed the
formation of 3.125.  The absence of the aldehyde proton at δH 9.85 and the presence of the
vinyl protons at δH 5.19 and 5.65 in the 1H NMR spectrum proved the formation of 3.126.
The 1H NMR spectrum of 3.127 exhibited two triplets at δH 2.79 (2H) and δH 3.85 (2H) and
MS data (m/z 215.1073 [M+H]+) and these correlate to the structure of 3.127.  The
presence of the doublet at δH 3.59 (2H) and the triplet at δH 9.67 (1H) in the 1H NMR
spectrum as well as carbonyl carbon at δC 199.2 in the 13C NMR spectrum confirmed
formation of 3.128.  The results of 1H NMR spectroscopic analysis are consistent with the
structure of compound 3.130.  The aromatic region (δH 5.99-7.35) of the 1H NMR
spectrum exhibits two separate spin systems, an AA'BB' and ABC.  Analyses of 13C NMR,
DEPT and HSQC reveal the presence of one methine, three methylene and seven
quaternary carbons.  The HMBC spectrum permitted the construction of structure showing
correlations from H-5 to C-6, C-4, C-4a; H-8 to C-8a, C-1, C-6, C-7; H-α to C-1, C-9, C-
10; H-10 to C-9, C-11, C-12.  H-5 and H-8 were differentiated on the basis of nOe
analysis.  A NOESY correlation between H-5 and H-4 and one methoxy protons is
observed and for H-8 there is a correlation only to the methoxy protons.  The MS data (m/z
376.1913 [M+H]+) corroborate formation of compound 3.130.
Prompted by above-mentioned promising results, we coupled our electron-rich THIQ
3.104 with the electron-poor aryl fluoride 3.80 under microwave conditions [CEM,
Discover®, at 100 W (100 ºC)] in the presence of K2CO3 in DMF for 15 minutes gave
3.131 in 85% yield. The presence of the singlet signal at δH 9.88 in the 1H NMR spectrum
and the carbonyl carbon at δC 190.7 in the 13C NMR, together with the IR signal at 34796
cm-1 revealed the presence of the aldehyde in compound 3.131 (Plate 8).  The MS (m/z
586.1594 [M+H]+) data corroborated formation of 3.131. The phenol 3.104 showed good
tolerance in the coupling process since the product was obtained in high yield (85%)
without epimerisation along with 10% starting aryl halide (Plate 8). In a control
experiment, the same reaction mixture was heated at 120 oC overnight using an oil bath
and the product was obtained in 60% yield with 20% starting phenol and 10% starting aryl
halide as well as other minor diastereomers present.  This observation demonstrates the
advantage of microwave radiation over conventional heating techniques.  The chosen aryl
halide is readily available commercial, and proved to be the good reagent because for SNAr
reactions, electron-poor fluorides are considered the most reactive. Two noteworthy trends
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are apparent.  Firstly, reaction under microwave condition give higher yields at shorter
reaction times compared to the bench-top reaction.  Secondly, microwave conditions
afforded only one diastereomer.  In summary, microwave heating can be quite effective in
improving the yields and decreasing the reaction times of SNAr ether synthesis.
Until this point, the absolute stereochemistry at C-1 for THIQ was not known since
attempts to recrystallise THIQ monomers were unsuccessful.  This necessitated the
recrystallisation of the intermediates in order to determine the absolute stereochemistry.
However, recrystallisation of diaryl ether 3.131 in chloroform afforded colourless crystals
which were suitable for X-ray diffractrometry. The crystal structure of 3.131 confirmed
the stereochemistry of the newly formed chiral centre (Figs 3.3 and 3.4).
Figure 3.3: Thermal ellipsoid plot for the 4-[1-(4-bromobenzyl)-6,7-dimethoxy-2-(1-
phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.131) (50% probability
level), with H atoms not labelled for clarity.
Figure 3.4: Unit cell contents
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The X-ray structure is summarised as follows: Orthorhombic, P212121, a = 8.166 (5) Å, b =
17.376 (5) Å, c = 20.387 (5) Å, V = 2893 (2) Å3, Z = 4, μ = 1.46 mm−1, T = 293 K. In the
crystal structure of 3.131 one crystallographically independent molecule is found in the
asymmetric unit. The crystal structure contains no short van der Waals contacts less than
the sum of the van der Waals radii. However, the crystal packing is loosely stabilised by a
single intermolecular O···H—C interaction between adjacent molecules [O···H—C distance
of 2.65 (1) Å]. The heterocyclic ring adopts a half chair conformation with the N1-benzyl
moiety in an equatorial and C1 benzyl with p-bromine in an axial position. The adopted
conformer shifts C3 out of the plane by 0.317 (3) Å, hence minimises the A1,3 strain
between the axial methine proton at C1 and the equatorial methylene proton at C3. The
N1-benzyl moiety deviates from planarity by −0.341 (2) Å. The endocyclic torsion angle
C1-C8a-C4a-C4 is 3.0 (4)° but C4a-C8a-C1-N1 is −19.1 (4)° which is constricted, most
likely this is related to the substitution pattern on C1 and N1, the two bulky benzyl groups
play a role in this respect. The remaining torsion angles are consistent with the half-chair
conformation. The crystal structure, in accordance with conclusions from NMR
interpretations, confirmed the absolute configuration of the two chiral centres C1 and the
incorporated chiral auxiliary as S and R, respectively, with heterocyclic ring adopting the
half-chair conformation.
The intermediate 3.135 was assembled from 3.131 in three steps, following protocols
developed in the course of the synthesis of the above-mentioned compound 3.130.  Wittig
olefination of 3.131 to 3.132 followed by boron oxidation to 3.133 and the subsequent IBX
oxidation gave the desired 3.134 in the overall yield of 46% yield (Scheme 3.44).
Alternatively, 3.135 was achieved via formation of the enol ether 3.134 in 68%, and this
method provides a better option for synthesis of macrocyclic phenylacetaldehydes in
excellent yield.  The structures of intermediates 3.132, 3.133, 3.134 and 3.135 were readily
determined by MS, IR, 1H- and 13C- NMR analyses.  The MS (m/z 584.1801 [M+H]+) data
established the molecular formula of compound 3.132 as C34H34
79BrNO3. The aromatic
region of 1H NMR spectrum exhibits two AA'BB' spin systems and a singlet of one proton
of H-5.  The presence of the vinyl protons at δH 5.19 and 5.62 confirmed formation of
3.132.




























































































































Scheme 3.45: Redesigning the synthetic plan according to nucleophilic aromatic
substitution.
The 1H NMR spectrum of 3.133 exhibited one triplet of two protons at δH 3.71 and second
triplet overlapping with H-α, H-3 and H-4 at δH 2.72-2.92.  The broad OH signal in the IR
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spectrum at 3429 cm-1 is consistent with the structure of compound 3.133.  Compound
3.134 was obtained as a yellow oil, [α]D25 = + 33.4 (c = 1.1, CHCl3).  The presence of the
extra methoxy protons at δH 3.68 as well as two cis protons at δH 5.20 and 6.19 (J = 10.5
Hz) and two trans protons at δH 5.80 and 6.95 (J = 16.9 Hz) in the 1H NMR spectrum
(Plate 9) as well as the MS (m/z 612.1750 [M+H]+) data are in agreement with the structure
of 3.134.  The presence of the triplet at δH 9.85 in the 1H NMR spectrum (Plate 10) and the
carbonyl carbon at δC 199.9 in the 13C NMR, together with the IR signal at 3496 cm-1
revealed the presence of the aldehyde in compound 3.135.  The MS (m/z 601.1750
[M+H]+) data corroborated formation of 3.135. The key coupling of 3.41 and 3.135
forming of the second THIQ moiety via the Pictet-Spengler reaction gave the desired 3.136
in low yields due to the formation of other side products.  In part, this may be attributed to
the slower reaction of 3.41 with 3.135 due to the increased electrondensity on the
phenylacetaldehyde, resulting from the p-phenoxy substituent.  Furthermore, these
disappointing results may be due to the previously reported instability of the
phenacetylaldehyde which may undergo disproportionation reactions to yield the
phenylacetic acid and phenethyl alcohol in the presence of acid.  In addition, during the
synthesis of the THIQ monomer, it was found that prolonged contact of the THIQ with the
acid resulted in the decomposition of the product.
In designing a macrocyclisation method, we sought to address the following issues:
 Increasing the yield of cyclisation product
 Avoiding the harsh conditions
 Enhancing the versatility (flexibility) of cyclisation procedure
 Prevent epimerisation during the ring-closure process
Cyclisation is usually disfavoured because of loss of entropy and of strain associated with
the ring formation.
To investigate the macrocyclisation method, a model reaction was carried out.  The
reaction relies on the intermolecular Ullmann condensation of the side product 3.105 since
it resembles the THIQ 3.104.  However, this reaction was troublesome and resulted in
decomposition of the material (Scheme 3.46).  Although the Ullmann reaction on the odel
compound 3.105 was not successful, we decided to use the actual intermediate 3.136 to
close the ring. The model reaction on 3.105 entailed an intermolecular reaction. Since
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intramolecular reactions are often easier to accomplish than the intermolecular reactions,
there was a chance that intramolecular Ullmann reaction on 3.136 might succeed. The
intermediate 3.136 was subjected to the modified Ullmann coupling conditions, where
3.136 was heated at 110 ºC in NMP, using CuCl and TMHD as catalysts and Cs2CO3 as a
base, but to our disappointment the starting material decomposed and only unidentifiable
products were isolated.  Due to time constraints, we could not synthesise more of 3.136 in
order to find the suitable reaction conditions for macrocyclisation to 3.137, and this will be


























     110 oC
3.105
3.138
Scheme 3.46: Model reaction for coupling via the Ullmann condensation reaction.
In summary, we successfully synthesised a bisbenzyltetrahydroisoquinoline 3.136 in 13
steps employing vanillin as the starting material. Our synthesis features the regio- and the
diastereoselective synthesis of a THIQ by Pictet-Spengler cyclisation. The stereochemistry
of the newly-formed chiral centre at C-1 was established by the X-ray structure of 3.131
prepared by the efficient microwave-assisted SNAr reaction.  The developed Wittig
homologation used in formation of 3.22 and the Pictet-Spengler reaction used in the
synthesis of THIQ’s were employed to form a bisbenzyltetrahydroisoquinoline 3.136.
Although we failed to form the final diaryl ether bond, the developed synthetic strategy can
also be employed in the construction of other complex intermediates in the synthesis of
natural products containing diaryl ethers. The use of the Wittig and Pictet-Spengler
reactions more than once using the same materials and conditions renders our total
synthesis efficient and practical.
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Unit cell dimensions a = 8.166 (5) Å μ = 1.46 mm−1
b = 17.376 (5) Å
c = 20.387 (5) Å 0.50 × 0.35 × 0.35 mm




Crystal size 0.50 × 0.35 × 0.35 mm
θ Range for data collection 2.7-32.0°
Reflections collected 9093
Independent reflections 9093
Refinement method Full-matrix least squares F2
Goodness-of-fit-on F2 0.104
Largest diff. peak and hole 0.22 and -0.43 e Å-3
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Table 3.4: Fractional atomic coordinates and isotropic or equivalent isotropic
displacement parameters (Å2) for 4-[1-(4-bromobenzyl)-6,7-dimethoxy-2-(1-phenylethyl)-
1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
x  y  z Uiso*/Ueq
C1 1.2059 (3) 0.26161 (14)  0.26842 (13) 0.0383 (6)
C008 1.3011 (3) 0.24389 (14) 0.32427 (13) 0.0413 (6)
C009 0.8383 (3) 0.23449 (15) 0.21565 (13) 0.0434 (7)
H009 0.8480 0.2738 0.2499 0.052*
C010 0.9876 (4) 0.03463 (14) 0.43606 (12) 0.0498 (7)
C011 1.1326 (3) 0.19768 (14) 0.22679 (13) 0.0393 (6)
H011 1.0843 0.1600 0.2569 0.047*
C012 1.0531 (3) 0.29478 (14) 0.14837 (13) 0.0429 (7)
H01A 0.9689 0.3095 0.1172 0.051*
H01B 1.1519 0.2834 0.1238 0.051*
C013 1.1236 (4) 0.00251 (16) 0.40727 (14) 0.0534 (7)
H013 1.1382 -0.0505 0.4091 0.064*
C014 1.2163 (3) 0.12642 (15) 0.37331 (12) 0.0412 (6)
C015 1.3705 (3) 0.29928 (15) 0.36329 (13) 0.0445 (7)
C016 1.0865 (3) 0.36231 (14) 0.19415 (13) 0.0439 (6)
H01C 1.1432 0.4024 0.1701 0.053*
H01D 0.9831 0.3833 0.2093 0.053*
C017 1.2630 (3) 0.15534 (15) 0.18634 (15) 0.0482 (7)
H01E 1.3117 0.1913 0.1556 0.058*
H01F 1.3488 0.1377 0.2156 0.058*
C018 1.1690 (4) 0.01789 (16) 0.17826 (14) 0.0521 (7)
H018 1.1896 0.0129 0.2229 0.062*
C019 0.9707 (4) 0.11386 (15) 0.43467 (14) 0.0586 (8)
H019 0.8815 0.1365 0.4554 0.070*
C020 1.0840 (4) 0.16022 (16) 0.40296 (14) 0.0544 (8)
H020 1.0704 0.2133 0.4018 0.065*
C021 1.2377 (4) 0.04652 (14) 0.37604 (14) 0.0484 (7)
H021 1.3288 0.0237 0.3567 0.058*
C022 1.1886 (3) 0.33920 (15) 0.25280 (12) 0.0386 (6)
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Table 3.4 (continued): Fractional atomic coordinates and isotropic or equivalent isotropic
displacement parameters (Å2) for 4-[1-(4-bromobenzyl)-6,7-dimethoxy-2-(1-phenylethyl)-
1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
C023 0.7151 (3) 0.26126 (15) 0.16526 (13) 0.0433 (6)
C024 1.2612 (3) 0.39548 (14) 0.29113 (13) 0.0447 (7)
H024 1.2482 0.4469 0.2795 0.054*
C025 1.3524 (3) 0.37742 (16) 0.34602 (13) 0.0451 (6)
C026 1.1968 (3) 0.08759 (15) 0.14888 (13) 0.0421 (6)
C027 0.6956 (3) 0.22157 (17) 0.10664 (14) 0.0511 (7)
H027 0.7595 0.1784 0.0983 0.061*
C028 1.1591 (4) 0.09358 (17) 0.08228 (14) 0.0557 (7)
H028 1.1744 0.1405 0.0612 0.067*
C029 0.5057 (4) 0.34958 (18) 0.12872 (19) 0.0696 (9)
H029 0.4420 0.3930 0.1364 0.083*
C030 0.6183 (4) 0.32544 (17) 0.17611 (17) 0.0582 (8)
H030 0.6283 0.3527 0.2152 0.070*
C031 1.4057 (4) 0.50843 (16) 0.37079 (16) 0.0648 (9)
H03A 1.4464 0.5171 0.3272 0.097*
H03B 1.4665 0.5393 0.4013 0.097*
H03C 1.2920 0.5223 0.3727 0.097*
C032 0.4886 (4) 0.3103 (2) 0.07177 (18) 0.0708 (9)
H032 0.4141 0.3268 0.0403 0.085*
C033 1.1108 (4) -0.04590 (16) 0.14387 (14) 0.0498 (7)
H033 1.0952 -0.0929 0.1647 0.060*
C034 1.0996 (4) 0.03167 (16) 0.04670 (14) 0.0569 (8)
H034 1.0753 0.0366 0.0023 0.068*
C035 1.0774 (3) -0.03722 (15) 0.07863 (15) 0.0475 (7)
C036 0.5828 (4) 0.2454 (2) 0.06072 (15) 0.0645 (9)
H036 0.5699 0.2177 0.0220 0.077*
C037 1.6224 (4) 0.2802 (2) 0.41653 (19) 0.0833 (11)
H03D 1.6589 0.2449 0.3834 0.125*
H03E 1.6676 0.2654 0.4581 0.125*
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Table 3.4 (continued): Fractional atomic coordinates and isotropic or equivalent isotropic
displacement parameters (Å2) for 4-[1-(4-bromobenzyl)-6,7-dimethoxy-2-(1-phenylethyl)-
1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
H03F 1.6581 0.3312 0.4057 0.125*
C038 0.8604 (5) -0.0128 (2) 0.46706 (17) 0.0701 (9)
C039 0.7805 (4) 0.1591 (2) 0.24695 (16) 0.0665 (9)
H03G 0.7958 0.1176 0.2165 0.100*
H03H 0.6665 0.1632 0.2580 0.100*
H03I 0.8429 0.1493 0.2860 0.100*
N1 1.0000 (3) 0.22487 (10) 0.18308 (9) 0.0387 (4)
O1 0.8586 (3) -0.08179 (14) 0.46942 (11) 0.0860 (8)
O002 1.3324 (2) 0.16681 (10) 0.33938 (9) 0.0472 (5)
O003 1.4509 (2) 0.27856 (11) 0.42008 (9) 0.0558 (5)
O004 1.4237 (2) 0.42944 (10) 0.38719 (9) 0.0586 (5)
Br01 1.00439 (4) -0.124178 (17) 0.028924 (16) 0.07177 (12)
H100 0.772 (4) 0.0128 (18) 0.4850 (16) 0.076 (12)*
Table 3.5: Atomic displacement parameters (Å2) for 4-[1-(4-bromobenzyl)-6,7-dimethoxy-
2-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
U11 U22 U33 U12 U13 U23
C1 0.0399 (14) 0.0337 (14) 0.0412 (15) -0.0009 (12) -0.0015 (12) 0.0009 (11)
C008 0.0469 (15) 0.0301 (14) 0.0468 (16) -0.0003 (12) -0.0020 (13) 0.0020 (12)
C009 0.0450 (16) 0.0443 (16) 0.0410 (16) -0.0039 (13) 0.0003 (13) -0.0091 (12)
C010  0.0643 (18) 0.0427 (14) 0.0425 (15) -0.0088 (17) 0.0007 (16) 0.0014 (11)
C011 0.0413 (14) 0.0330 (14) 0.0437 (16) -0.0016 (12) -0.0028 (13) -0.0020 (12)
C012 0.0417 (15) 0.0456 (16) 0.0414 (15) 0.0002 (12) 0.0015 (12) 0.0046 (12)
C013 0.072 (2)  0.0317 (14) 0.0561 (19) -0.0027 (15) -0.0105 (17) 0.0015 (14)
C014 0.0492 (15) 0.0343 (13) 0.0401 (15) -0.0031 (14) -0.0086 (13) 0.0030 (12)
C015 0.0533 (16) 0.0415 (16) 0.0387 (16) -0.0033 (13) -0.0048 (14) 0.0014 (12)
C016 0.0481 (15) 0.0371 (15) 0.0465 (16) -0.0017 (12) -0.0037 (13) 0.0065 (12)
C017 0.0474 (16) 0.0410 (15) 0.0561 (18) 0.0025 (13) -0.0026 (14) -0.0050 (13)
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C018 0.067 (2) 0.0489 (18) 0.0402 (16) 0.0031 (15) 0.0020 (15) -0.0006 (13)
C019 0.072 (2) 0.0481 (17) 0.0559 (18) 0.0038 (17) 0.0169 (16) 0.0050 (13)
C020 0.077 (2) 0.0326 (15) 0.0533 (19) 0.0056 (15) 0.0050 (16) -0.0019 (13)
C021 0.0574 (17) 0.0321 (15) 0.0558 (18) 0.0034 (14) -0.0059 (15) 0.0002 (13)
C022 0.0421 (15) 0.0338 (14) 0.0401 (16) -0.0028 (12) 0.0023 (12) 0.0003 (11)
C023 0.0383 (14) 0.0454 (16) 0.0464 (16) -0.0015 (13) 0.0046 (13) -0.0004 (13)
C024 0.0528 (17) 0.0298 (14) 0.0517 (18) -0.0044 (12) 0.0025 (14) 0.0027 (12)
C025 0.0494 (15) 0.0406 (15) 0.0453 (16) -0.0072 (14) -0.0021 (13) -0.0019 (13)
C026 0.0412 (15) 0.0405 (15) 0.0446 (17) 0.0083 (13) 0.0032 (13) -0.0052 (12)
C027 0.0506 (16) 0.0541 (17) 0.0486 (18) 0.0023 (14) -0.0036 (14) 0.0000 (14)
C028 0.072 (2)  0.0431 (16) 0.0521 (18) -0.0026 (15) -0.0032 (17) 0.0024 (14)
C029 0.0439 (16) 0.0647 (19) 0.100 (3) 0.0100 (19) 0.005 (2) 0.0195 (19)
C030 0.0515 (18) 0.0575 (19) 0.066 (2) 0.0027 (16)  0.0107 (17) -0.0059 (16)
C031  0.079 (2) 0.0435 (18) 0.072 (2) -0.0247 (16) 0.0004 (18) -0.0082 (15)
C032 0.0506 (18) 0.084 (2) 0.078 (2) -0.004 (2) -0.006 (2) 0.033 (2)
C033 0.0646 (18) 0.0366 (16) 0.0481 (18) -0.0007 (14) 0.0050 (15) 0.0017 (13)
C034 0.077 (2) 0.0496 (18) 0.0441 (18) 0.0045 (16) -0.0075 (16) -0.0037 (14)
C035 0.0489 (15) 0.0386 (15) 0.0551 (18) 0.0073 (13) -0.0011 (14) -0.0116 (13)
C036 0.0632 (18) 0.083 (2) 0.0474 (19) -0.0104 (19) -0.0061 (17) 0.0018 (17)
C037 0.060 (2)  0.110 (3) 0.079 (3) -0.002 (2) -0.015 (2) 0.024 (2)
C038 0.092 (3) 0.066 (2) 0.053 (2) -0.008 (2) 0.009 (2) 0.0034 (18)
C039 0.0524 (19)  0.083 (2) 0.064 (2) -0.0160 (18) 0.0008 (16)  0.0142 (17)
N1 0.0378 (10)  0.0391 (10) 0.0392 (11) -0.0004 (12) 0.0001 (12) -0.0020 (8)
O1 0.125 (2) 0.0548 (14)  0.0783 (16) -0.0319 (14) 0.0235 (16) -0.0042 (13)
O002 0.0477 (11) 0.0322 (10) 0.0618 (12) 0.0008 (9) -0.0013 (10) 0.0072 (9)
O003 0.0666 (13) 0.0612 (12) 0.0395 (11) -0.0115 (10) -0.0128 (10) 0.0073 (9)
O004 0.0757 (13) 0.0409 (11) 0.0593 (13) -0.0134 (10) -0.0136 (11) -0.0067 (9)
Br01 0.0784 (2) 0.05399 (18) 0.0829 (2) -0.0007 (2) -0.0145 (2) -0.02055 (15)
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Table 3.6: Geometric parameters (Å, °) for 4-[1-(4-bromobenzyl)-6,7-dimethoxy-2-(1-
phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
C1-C022 1.393 (3) C021-H021 0.9300
C1-C008 1.413 (4) C022-C024 1.385 (4)
C1-C011 1.521 (3) C023-C030 1.385 (4)
C008-C015 1.372 (4) C023-C027 1.389 (4)
C008-O002 1.398 (3) C024-C025 1.380 (4)
C009-N1 1.488 (3) C024-H024 0.9300
C009-C023 1.511 (4) C025-O004 1.364 (3)
C009-C039 1.531 (4) C026-C028 1.396 (4)
C009-H009 0.9800 C027-C036 1.377 (4)
C010-C013 1.375 (4) C027-H027 0.9300
C010-C019 1.384 (4) C028-C034 1.386 (4)
C010-C038 1.469 (4) C028-H028 0.9300
C011-N1 1.479 (3) C029-C032 1.354 (4)
C011-C017 1.535 (4) C029-C030 1.398 (4)
C011-H011 0.9800 C029-H029 0.9300
C012-N1 1.471 (3) C030-H030 0.9300
C012-C016 1.524 (3) C031-O004 1.420 (3)
C012-H01A 0.9700 C031-H03A 0.9600
C012-H01B 0.9700 C031-H03B 0.9600
C013-C021 1.363 (4) C031-H03C 0.9600
C013-H013 0.9300 C032-C036 1.384 (4)
C014-O002 1.368 (3) C032-H032 0.9300
C014-C020 1.370 (4) C033-C035 1.366 (4)
C014-C021 1.400 (3) C033-H033 0.9300
C015-O003 1.379 (3) C034-C035 1.375 (4)
C015-C025 1.410 (4) C034-H034 0.9300
C016-C022 1.512 (4) C035-Br01 1.914 (3)
C016-H01C 0.9700 C036-H036 0.9300
C016-H01D 0.9700 C037-O003 1.403 (4)
C017-C026 1.503 (4) C037-H03D 0.9600
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Table 3.6 (continued): Geometric parameters (Å, °) for 4-[1-(4-bromobenzyl)-6,7-
dimethoxy-2-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
C017-H01E 0.9700 C037-H03E 0.9600
C017-H01F 0.9700 C037-H03F 0.9600
C018-C026 1.370 (4) C038-O1 1.200 (4)
C018-C033 1.395 (4) C038-H100 0.92 (3)
C018-H018 0.9300 C039-H03G 0.9600
C019-C020 1.387 (4) C039-H03H 0.9600
C019-H019 0.9300 C039-H03I 0.9600
C022-C1-C008 116.8 (2) C027-C023-C009 120.6 (3)
C022-C1-C011 122.7 (2) C025-C024-C022 121.9 (2)
C008-C1-C011 120.5 (2) C025-C024-H024 119.1
C015-C008-O002 118.0 (2) C022-C024-H024 119.1
C015-C008-C1 122.8 (2) O004-C025-C024 125.3 (3)
O002-C008-C1 119.2 (2) O004-C025-C015 116.1 (2)
N1-C009-C023 108.8 (2) C024-C025-C015 118.5 (2)
N1-C009-C039 111.3 (2) C018-C026-C028 117.0 (3)
C023-C009-C039 110.0 (2) C018-C026-C017 122.0 (2)
N1-C009-H009 108.9 C028-C026-C017 121.0 (3)
C023-C009-H009 108.9 C036-C027-C023 120.8 (3)
C039-C009-H009 108.9 C036-C027-H027 119.6
C013-C010-C019 118.4 (3) C023-C027-H027 119.6
C013-C010-C038 121.8 (3) C034-C028-C026 121.9 (3)
C019-C010-C038 119.8 (3) C034-C028-H028 119.0
N1-C011-C1 113.0 (2) C026-C028-H028 119.0
N1-C011-C017 109.7 (2) C032-C029-C030 120.6 (3)
C1-C011-C017 112.1 (2) C032-C029-H029 119.7
N1-C011-H011 107.2 C030-C029-H029 119.7
C1-C011-H011 107.2 C023-C030-C029 120.4 (3)
C017-C011-H011 107.2 C023-C030-H030 119.8
N1-C012-C016 113.2 (2) C029-C030-H030 119.8
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Table 3.6 (continued): Geometric parameters (Å, °) for 4-[1-(4-bromobenzyl)-6,7-
dimethoxy-2-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
N1-C012-H01A 108.9 O004-C031-H03A 109.5
C016-C012-H01A 108.9 O004-C031-H03B 109.5
N1-C012-H01B 108.9 H03A-C031-H03B 109.5
C016-C012-H01B 108.9 O004-C031-H03C 109.5
H01A-C012-H01B 107.8 H03A-C031-H03C 109.5
C021-C013-C010 121.6 (3) H03B-C031-H03C 109.5
C021-C013-H013 119.2 C029-C032-C036 119.5 (3)
C010-C013-H013 119.2 C029-C032-H032 120.2
O002-C014-C020 123.3 (2) C036-C032-H032 120.2
O002-C014-C021 116.3 (2) C035-C033-C018 118.0 (3)
C020-C014-C021 120.4 (3) C035-C033-H033 121.0
C008-C015-O003 120.0 (2) C018-C033-H033 121.0
C008-C015-C025 119.2 (2) C035-C034-C028 118.3 (3)
O003-C015-C025 120.7 (2) C035-C034-H034 120.8
C022-C016-C012 112.3 (2) C028-C034-H034 120.8
C022-C016-H01C 109.2 C033-C035-C034 122.1 (3)
C012-C016-H01C 109.2 C033-C035-Br01 119.4 (2)
C022-C016-H01D 09.2 C034-C035-Br01 118.5 (2)
C012-C016-H01D 109.2 C027-C036-C032 120.4 (3)
H01C-C016-H01D 107.9 C027-C036-H036 119.8
C026-C017-C011 113.5 (2) C032-C036-H036 119.8
C026-C017-H01E 108.9 O003-C037-H03D 109.5
C011-C017-H01E 108.9 O003-C037-H03E 109.5
C026-C017-H01F 108.9  H03D-C037-H03E 109.5
C011-C017-H01F 108.9 O003-C037-H03F 109.5
H01E-C017-H01F 107.7 H03D-C037-H03F 109.5
C026-C018-C033 122.6 (3) H03E-C037-H03F 109.5
C026-C018-H018 118.7 O1-C038-C010 125.9 (4)
C033-C018-H018 118.7 O1-C038-H100 117 (2)
C010-C019-C020 121.4 (3) C010-C038-H100 117 (2)
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Table 3.6 (continued): Geometric parameters (Å, °) for 4-[1-(4-bromobenzyl)-6,7-
dimethoxy-2-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
C010-C019-H019 119.3 C009-C039-H03G 109.5
C020-C019-H019 119.3 C009-C039-H03H 109.5
C014-C020-C019 118.9 (3) H03G-C039-H03H 109.5
C014-C020-H020 120.6 C009-C039-H03I 109.5
C019-C020-H020 120.6 H03G-C039-H03I 109.5
C013-C021-C014 119.3 (3) H03H-C039-H03I 109.5
C013-C021-H021 120.3 C012-N1-C011 109.8 (2)
C014-C021-H021 120.3 C012-N1-C009 112.54 (19)
C024-C022-C1 120.7 (2) C011-N1-C009 114.62 (19)
C024-C022-C016 119.7 (2) C014-O002-C008 118.4 (2)
C1-C022-C016 119.6 (2) C015-O003-C037 115.3 (3)
C030-C023-C027 118.2 (3) C025-O004-C031 116.8 (2)
C022-C1-C008-C015 1.9 (4) O003-C015-C025-C024 -175.6 (2)
C011-C1-C008-C015 179.7 (2) C033-C018-C026-C028 2.1 (4)
C022-C1-C008-O002 -175.3 (2) C033-C018-C026-C017 -178.7 (2)
C011-C1-C008-O002 2.5 (4) C011-C017-C026-C018 -79.8 (3)
C022-C1-C011-N1 -19.1 (4) C011-C017-C026-C028 99.4
C008-C1-C011-N1 163.2 (2) C030-C023-C027-C036 -0.1 (4)
C022-C1-C011-C017 105.5 (3) C009-C023-C027-C036 179.6 (3)
C008-C1-C011-C017 -72.2 (3) C018-C026-C028-C034 -1.4 (4)
C019-C010-C013-C021 -2.1 (4) C017-C026-C028-C034 179.4 (3)
C038-C010-C013-C021 177.1 (3) C027-C023-C030-C029 -0.7 (4)
O002-C008-C015-O003 -8.0 (4) C009-C023-C030-C029 179.6 (3)
C1-C008-C015-O003 174.7 (2) C032-C029-C030-C023 0.5 (5)
O002-C008-C015-C025 174.7 (2) C030-C029-C032-C036 0.4 (5)
C1-C008-C015-C025 -2.6 (4) C026-C018-C033-C035 -1.5 (5)
N1-C012-C016-C022 46.4 (3) C026-C028-C034-C035 0.1 (4)
N1-C011-C017-C026 -58.3 (3) C018-C033-C035-C034 0.1 (4)
C1-C011-C017-C026 175.2 (2) C018-C033-C035-Br01 177.9 (2)
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Table 3.6 (continued): Geometric parameters (Å, °) for 4-[1-(4-bromobenzyl)-6,7-
dimethoxy-2-(1-phenylethyl)-1,2,3,4-tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.124).
C013-C010-C019-C020 2.5 (4) C028-C034-C035-C033 0.5 (4)
C038-C010-C019-C020 -176.7 (3) C028-C034-C035-Br01 -177.3 (2)
O002-C014-C020-C019 178.2 (2) C023-C027-C036-C032 1.1 (4)
C021-C014-C020-C019 -1.1 (4) C029-C032-C036-C027 -1.3 (5)
C010-C019-C020-C014 -0.9 (4) C013-C010-C038-O1 -1.8 (5)
C010-C013-C021-C014 0.2 (4) C019-C010-C038-O1 177.4 (3)
O002-C014-C021-C013 -177.9 (2) C016-C012-N1-C011 -63.4 (3)
C020-C014-C021-C013 1.4 (4) C016-C012-N1-C009 65.5 (3)
C008-C1-C022-C024 -0.5 (4) C1-C011-N1-C012 47.7 (3)
C011-C1-C022-C024 -178.2 (2) C017-C011-N1-C012 -78.2 (2)
C008-C1-C022-C016 -179.2 (2) C1-C011-N1-C009 -80.1 (3)
C011-C1-C022-C016 3.0 (4) C017-C011-N1-C009 154.00 (19)
C012-C016-C022-C024 165.4 (2) C023-C009-N1-C012 54.4 (3)
C012-C016-C022-C1 -15.8 (3) C039-C009-N1-C012 175.8 (2)
N1-C009-C023-C030 -128.3 (2) C023-C009-N1-C011 -179.2 (2)
C039-C009-C023-C030 109.6 (3) C039-C009-N1-C011 -57.9 (3)
N1-C009-C023-C027 52.0 (3) C020-C014-O002-C008 -11.5 (4)
C039-C009-C023-C027 -70.1 (3) C021-C014-O002-C008 167.8 (2)
C1-C022-C024-C025 -0.3 (4) C015-C008-O002-C014 99.6 (3)
C016-C022-C024-C025 178.5 (2) C1-C008-O002-C014 -83.0 (3)
C022-C024-C025-O004 -178.0 (2) C008-C015-O003-C037 103.5 (3)
C022-C024-C025-C015 -0.4 (4) C025-C015-O003-C037 -79.2 (3)
C008-C015-C025-O004 179.6 (2) C024-C025-O004-C031 -1.8 (4)
O003-C015-C025-O004 2.3 (4) C015-C025-004-C031 -179.6 (2)
C008-C015-C025-C024 1.7 (4)
Hydrogen-bond geometry (Å, °)
D—H···A D—H H···A D···A D—H···A
C036—H036···O1i 0.93 2.66 3.432 (5) 141 (1)
Symmetry codes: (i) −x+3/2, −y, z−1/2.
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CHAPTER 4
Conclusions and Future Work
4.1 Conclusions
In this study, we have been able to
 Develop a concise route for the synthesis of  a β-phenethylamine derivative
containing a chiral auxiliary
 Prepare a series of phenylacetaldehydes in high yields
 Develop reaction conditions to control the regioselectivity and diastereoselectivity
of the Pictet-Spengler reaction
 Provide proof for the stereochemistry of the prepared benzyltetrahydroisoquinoline
by X-ray crystallography
 Form a diaryl ether from the parent tetrahydroisoquinoline by a microwave-assisted
SNAr reaction
 Prepare bisbenzyltetrahydroisoquinoline 3.136.
We have developed a novel procedure for the synthesis of an enantiomerically-pure β-
phenethylamine derivative, which comprise carbon homologation of the aldehyde 3.22 by
a Wittig reaction, followed by hydrolysis of enol ether 3.39 to phenylacetaldehyde 3.40,
and a subsequent reductive amination to 3.41.  This method proved to be an efficient
approach since it reduces the steps and hazardous wastes associated with the isolation of
intermediates involved in standard procedures and high yields are obtained.  In order to
control the regioselectivity of Pictet-Spengler reaction in the formation of THIQ 3.104, the
C-3 hydroxy group was strategically position in 3.41 to facilitate the ring closure in the
ortho-position and to control stereochemistry, a chiral auxiliary was embedded on the
nitrogen of β-phenethylamine.  A variety of phenylacetaldehyde, reaction partners of β-
phenethylamine for the Pictet-Spengler reaction, were prepared with the yields varying
according to substituents.  Phenylacetyladehydes with bromo- and iodo-substituents were
prepared in higher yields at shorter reaction times (95% and 98%, respectively) as
compared to the fluoro and electron-rich substrates, which were formed with longer
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reaction times but with high yield (85% and 90%).  The ease of formation of
enantiomerically pure β-phenethylamine 3.22 combined with the ability to synthesise
phenylacetaldehydes with a variety of substituents, makes the Pictet-Spengler reaction
efficient for the preparation of other THIQ’s.
The reaction conditions to control the regioselectivity and diastereoselectivity of the Pictet-
Spengler reaction were developed.  High yields in short reaction times were obtained.
However, the highly selective formation of the desired isomer 3.104 was not
straightforward.  The electronic and steric properties of the β-phenethylamine and
phenylacetaldehyde reaction partners have been examined extensively in order to provide
an efficient cyclisation towards the THIQ’s.  The stereochemistry of the newly chiral
centre at C-1 was established by the X-ray structure of 3.131 prepared from the parent
THIQ 3.104 and a mechanism was proposed for the stereochemical outcome of the Pictet-
Spengler reaction.  In most cases, starting materials were efficiently prepared using well-
known reactions in a limited number of steps from commercially available reagents.
Various functional groups are tolerated in subsequent reactions.  THIQ monomers have
shown to have an MDR activity1 which was the original motivation for total synthesis of
cycleanine (3.1).  If interesting products can be formed in synthetically useful yields and
diastereomeric ratios, this methodology can be extended to the formation of other THIQ’s
of biological importance.
Despite the unsuccessful macrocyclisation of compound 3.136, some progress was made in
the right direction.  The microwave-assisted SNAr formation of diaryl ether 3.131, using a
reactive aryl fluoride and the electron-rich phenol 3.104 was achieved in high yields and
short reaction times without racemisation of the product.  Recrystallisation of diaryl ether
3.131 afforded colourless crystals which were suitable for X-ray diffractrometry and the
crystal structure of 3.126 established the stereochemistry of C-1 in 3.104.  The developed
C-C Wittig homologation and the Pictet-Spengler reaction used in the previous steps were
employed to form a bisbenzyltetrahydroisoquinoline 3.136 in low yields due to the
thermolability of phenylacetaldehydes in acid conditions.  The intramolecular Ullmann
reaction of 3.136 to 3.137 was unsuccessful.
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4.2 Future Work
Future efforts should be concentrated toward the synthesis of precursors with iodo
substituents, since molecules with iodo group are reported to be more reactive in coupling
reactions to form diaryl ethers (Scheme 4.1).  The developed methods can be used to form
the intermediates to cycleanine (3.1) and iodo derivatives assure high yields and short








































































Scheme 4.1: Proposed reaction for coupling via the Ullmann coupling method.
Alternatively, the approach to cycleanine (3.1) can be achieved via a SNAr coupling
reaction in a one-pot reaction (Scheme 4.2).  The readily prepared THIQ 3.112 with the
nitro-activating group can undergo a facile intramolecular SNAr to provide a macrocyclic
precursor 4.5, which can be easily reduced to 4.6 and N-methylated to the target cycleanine
(3.1).






































Scheme 4.2: Proposed reaction for coupling via the nucleophilic aromatic substitution.
The most striking feature of our approach towards total synthesis of cycleanine (3.1) is its
reliance on only the simplest of reagents to carry out what seemed to be rather complex
chemical transformations.  We managed to overcome the daunting regiochemical and
stereochemical problems associated with the synthesis of cycleanine (3.1), and the only
pending issue is formation of the macrocyclic ring.  These challenges give impetus to the
development of new synthetic technologies and strategies to address stereocontrol and
macrocyclisation problems.  Total synthesis of cycleanine (3.1) provided a tough challenge
and synthetic methods developed here can be used by those who wish to continue with the
synthesis of BBIQ’s.
4.3 Reference






Reactions requiring anhydrous conditions were performed under nitrogen using clean
oven-dried glassware.  All reagents were purchased from FLUKA, ALDRICH or MERCK
and used without further purification, unless otherwise specified.  Anhydrous solvents
were obtained from a Pure-Solv Solvent Purification System supplied by Innovative
Technology, Inc. This system removes water and oxygen to produce dry deoxygenated
high-purity solvent, by passing room temperature solvents through columns containing
activated alumina and copper under low nitrogen pressure to remove trace impurities.
A chromatotron (model 7924, Harrison Research) was used for centrifugal
chromatography. Flash column chromatography was performed on a glass column (5 cm
diameter) charged with 100 g of Merck Kieselgel 60 (230-400 mesh) for every 1 g of the
crude material.  The crude product was dissolved in a minimum of the appropriate solvent,
applied to the column and eluted with the solvent of choice.  Qualitative thin-layer
chromatography (TLC) was performed on pre-coated Merck plastic sheets (silica gel PF254,
0.25 mm).  After development, compounds were detected under UV (254 nm) followed by
staining the plates with vanillin-H2SO4 or iodine. Yields reported refer to isolated material
determined to be pure by NMR spectroscopy and thin-layer chromatography (TLC), unless
specified otherwise in the text.
All 1H and 13C NMR spectra were recorded on a Bruker DRX-400 at 30 ºC.  Chemical
shifts are reported in ppm relative to residual solvent peak [CDCl3 7.26 ppm (
1H) and 77.0
ppm (13C), or CD3OD, 3.31 ppm (
1H) and 49 ppm (13C)  or DMSO-d6, 2.5 ppm (
1H) and
39.5 ppm (13C)].  Structures were determined by analysis of 2D (HSQC, HMBC, COSY)
and nuclear Overhauser effect (NOE) spectroscopy.  All high-resolution mass
spectroscopic data were collected on a TOF Waters LCT Premier mass spectrometer using
electrospray ionisation in the positive or negative mode. Infrared (IR) spectra were
recorded neat on a Bruker Alpha FT-IR spectrometer. Melting points were measured on
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Kofler hot-stage melting point apparatus and are uncorrected. Optical rotations were
measured with a Perkin Elmer polarimeter with a cuvette of 1 cm path length.
Table 5.1: Abbreviations used in describing 1H NMR signal multiplicities.


























A mixture of Br2 (7.4 ml, 60 mmol) in glacial acetic (25 ml) was added dropwise to a
stirred solution of vanillin (20.0 g, 130 mmol) in glacial acetic acid (160 ml) over a period
of 20 min.  The reaction was stirred for 1 h and monitored by TLC.  The precipitate formed
during the process was filtered and washed several times with water to give a yellow
powder.  The dried powder was recrystallised to give bromovanillin (3.13) (24.9 g, 93%)
as white crystals (from ethanol), m.p. 164-165 ºC (lit.1 163-164 ºC).
1H NMR (CDCl3): H 3.98 (3H, s, OCH3), 6.54 (1H, s, br, OH), 7.36 (1H, d, J = 1.5 Hz, H-
6), 7.64 (1H, d, J = 1.5 Hz, H-2), 9.79 (1H, s, CHO).
13C NMR (CDCl3): δC 56.2 (OCH3), 107.9, 108.1, 130.0, 130.1, 147.6, 148.8 (6 x ArC),
189.6 (CHO).
HRESIMS (negative ionisation mode), m/z found 228.9491 [M-H]-, calculated for
C8H7
79BrO3 228.9500.
IR: υmax (neat)/cm-1: 3507, 3168, 1661, 1583, 1460, 1426, 1295, 1258, 1149, 1014, 949,
854, 792.







A mixture of bromovanillin (3.13) (25.0 g, 109 mmol), NaOH (28.6 g, 700 mmol) and
copper powder (2.6 g, 41 mmol) in H2O (100 ml) were refluxed for 24 h.  Sodium
hydrogenphosphate (9.2 g, 65 mmol) was added during the last hour of reflux, and the
mixture was cooled to room temperature, filtered to remove the precipitate of cupric
hydrogenphosphate and acidified with HCl.  The mixture was extracted with EtOAc (3 x
50 ml) and the combined organic layers were stirred with activated carbon and filtered.
The filtrate was washed with a saturated EDTA solution followed by brine, water and dried
(MgSO4). The EtOAc layer was concentrated to give 3,4-dihydroxy-5-
methoxybenzaldehyde as a solid product (11.8 g, 65%).  The crude product was
recrystallised from toluene as brownish crystals, m.p. 133-135 ºC (lit.2 132-133 ºC).
1H NMR (CDCl3): δH 3.96 (3H, s, OCH3), 5.44 (1H, s, br, OH), 5.94 (1H, s, br, OH), 7.08
(1H, d, J = 1.5 Hz, H-6), 7.14 (1H, d, J = 1.5 Hz, H-2), 9.78 (1H, s, CHO).
13C NMR (CDCl3): δC 56.6 (OCH3), 107.9, 108.1, 130.0, 130.1, 147.6, 148.8 (6 x ArC)
189.7 (CHO).
HRESIMS (negative ionisation mode), m/z found 167.0423 [M-H]-, calculated for C8H7O4
167.0422.
IR: υmax (neat)/cm-1 3504, 3093, 1725, 1655, 1595, 1511, 1468, 1343, 1296, 1261, 1192,





The mixture of 3,4-dihydroxy-5-methoxybenzaldehyde (3.14) (20.0 g, 119 mmol),
dimethyl sulfate (11.3 ml, 119 mmol), sodium carbonate (13.9 g, 130.8 mmol) in acetone
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(100 ml) were heated at reflux for 4 h.  The reaction mixture was then cooled to room
temperature and filtered.  The acetone was removed under vacuum and the reaction
mixture was poured into water and extracted with EtOAc.  The EtOAc layer was washed
with brine, water and dried over anhydrous MgSO4.  Removal of the solvent under vacuum
afforded 3.21 (16.2 g, 75%) as a yellowish solid.  The product was recrystallised from
toluene:heptane (2:1) and 3-hydroxy-4,5-dimethoxybenzaldehyde (3.21) was obtained as
yellowish crystals with m.p. 65-66 ºC (lit.2 64-65 ºC).
1H NMR (CDCl3): H 3.93 (3H, s, OCH3), 4.00 (3H, s, OCH3), 5.93 (1H, s, OH), 7.06 (1H,
d, J = 2.0 Hz, H-6), 7.12 (1H, d, J = 2.3 Hz, H-2), 9.87 (1H, s, CHO).
13C NMR (CDCl3): δC 55.9 (OCH3), 60.8 (OCH3), 103.7, 111.6, 131.9, 140.1, 149.7, 152.7
(6 x ArC) and 191.4 (CHO).
HRESIMS (positive ionisation mode), m/z found 205.0476 [M+Na]+, calculated for
C9H10O4 205.0477.
IR: υmax (neat)/cm-1: 3507, 3310, 2249, 1720, 1676, 1611, 1584, 1351, 1234, 1131, 1100,






To a solution of 3.21 (12.0 g, 65.9 mmol) in abs. EtOH (10 ml) were added K2CO3 (10.1 g,
73.2 mmol) and KI (43.8 g, 264 mmol).  Freshly distilled benzyl chloride (9.3 ml, 73.1
mmol) was added dropwise and the resulting suspension was stirred under reflux for 2 h.
The reaction mixture was cooled to room temperature and water was added.  After
evaporation of EtOH under vacuum, the solution was poured into 2 M NaOH solution (30
ml).  The aqueous solution was extracted several times with CH2Cl2.  The combined
CH2Cl2 extracts were concentrated under reduced pressure to yield 3.22 (17.6 g, 98%) as
pale yellow crystals (from petroleum ether) m.p. 52-53 ºC (lit.3 50-51 ºC).
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1H NMR (CDCl3): δH: 3.93 (3H, s, OCH3), 3.96 (3H, s, OCH3), 5.19 (2H, s, OCH2Ph),
7.14 (1H, d, J = 1.5 Hz, H-6), 7.17 (1H, d, J = 1.5 Hz, H-2), 7.33-7.46 (5H, m, ArH), 9.64
(1H, s, CHO).
13C NMR (CDCl3): δC: 56.3 (OCH3), 61.0 (OCH3), 71.2 (OCH2), 106.6, 109.2, 127.3 (2C),
128.1, 128.6 (2C), 131.6 (2C), 136.4, 152.6, 153.8 (12ArC) and 190.9 (CHO).
HRESIMS (positive ionisation mode), m/z found 295.0947 [M+Na]+, calculated for
C16H16O4 295.0946.
IR: υmax (neat)/cm-1: 3030, 2955, 2245, 1725, 1684, 1500, 1325, 1230, 1112, 877, 989,
725.





To the well-stirred solution of benzaldehyde 3.22 (20.0 g, 73 mmol) in EtOH (100 ml),
NaBH4 (8.3 g, 220 mmol) was slowly added at 0
oC.  After stirring for 1.5 h, the excess
NaBH4 was destroyed by careful addition of 10% HCl.  EtOH was evaporated and the
residue extracted with EtOAc.  The EtOAc layer was washed with saturated solution of
NaHCO3 and water, dried over MgSO4 and concentrated under vacuum to afford pure
benzyl alcohol 3.23 (19.2 g, 96%) as an oily substance.
1H NMR (CDCl3): δH 3.81 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.53 (2H, s, CH2OH), 5.07
(2H, s, OCH2Ph), 6.56 (1H, d, J = 1.7 Hz, H-6), 6.60 (1H, d, J = 1.7 Hz, H-2), 7.28-7.42
(5H, m, ArH).
13C NMR (CDCl3): δC 55.9 (OCH3), 60.7 (OCH3), 65.1 (CH2OH), 70.8 (OCH2), 104.0,
106.2, 127.1 (2C), 127.7, 128.4 (2C), 136.6, 136.9 (2C), 152.3, 153.3 (12 x ArC).
HRESIMS (positive ionisation mode), m/z found 297.1104 [M+Na]+, calculated for
C16H18O4 297.1103.
IR: υmax (neat)/cm-1: 3427, 3028, 2938, 1591, 1503, 1453, 1429, 1233, 1114, 1065, 1007,
957, 837, 737, 694.
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Thionyl chloride (26.0 g, 218 mmol) in anhydrous CHCl3 (15 ml) was added to the
solution of alcohol 3.23 (20.0 g, 73 mmol) in anhydrous CHCl3 (25 ml) at 0 ºC.  The
solution was stirred for 1 h at the same temperature, poured into ice and extracted with
CHCl3.  The CHCl3 extract was washed with saturated NaHCO3 solution, brine, water and
evaporated.  Flash column chromatography (hexanes:EtOAc, 8:2) gave benzyl chloride
3.24 (18.1 g, 85%) as pale yellow crystals from petroleum ether m.p. 68-69 ºC (lit.4 67-68
ºC).
1H NMR (CDCl3): δH 3.87 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.51 (2H, s, CH2Cl), 5.13
(2H, s, OCH2Ph), 6.63 (1H, d, J = 1.8 Hz, H-6), 6.67 (1H, d, J = 1.8 Hz, H-2), 7.32-7.46
(5H, m, ArH).
13C NMR (CDCl3): δC 44.6 (CH2Cl), 56.0 (OCH3), 60.7 (OCH3), 71.0 (OCH2), 105.9,
107.7, 127.2 (2C), 127.8, 128.4 (2C), 132.7 (2C), 136.8, 152.3, 153.4 (12ArC).
HRESIMS (positive ionisation mode), m/z found 315.0767 [M+Na]+, calculated for
C16H17O3Cl 315.0766.






A mixture of benzyl chloride 3.24 (15.0 g, 54 mmol) and sodium cyanide (13.3 g, 271
mmol) in dimethyl sulfoxide (50 ml) were heated at 80 oC for 5 h.  The reaction mixture
was poured into water and extracted with EtOAc.  The EtOAc extract was washed several
times with water, brine, evaporated and subjected to flash column chromatography
(hexanes:EtOAc, 7:3) to give phenylacetonitrile 3.25 (10.8 g, 70%) as a yellowish oil.
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1H NMR (CDCl3): δH 3.64 (2H, s, CH2CN), 3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 5.12
(2H, s, OCH2Ph), 6.52 (1H, d, J = 1.8 Hz, H-6), 6.57 (1H, d, J = 1.8 Hz, H-2), 7.31-7.45
(5H, m, ArH).
13C NMR (CDCl3): δC 23.5 (CH2CN), 56.1 (OCH3), 60.8 (OCH3), 71.1 (OCH2), 105.2,
107.1, 117.7, 125.1, 127.2 (2C), 127.9, 128.5 (2C), 136.6, 138.1, 152.6, 153.7 (13C,
12ArC and CN).
HRESIMS (positive ionisation mode), m/z found 306.1109 [M+Na]+, calculated for
C17H17O3N 306.1106.
IR: υmax (neat)/cm-1 3020, 2938, 2233, 1591, 1505, 1453, 1429, 1334, 1235, 1112, 1002,
919, 819, 737, 697.





To the solution of phenylacetonitrile 3.25 (10.0 g, 35 mmol) in MeOH (100 ml) was added
25% aq NaOH (35 ml) and the reaction was refluxed until the evolution of ammonia has
ceased (pH paper, 24 h).  The mixture was concentrated under vacuum and the aqueous
residue was washed with ether.  The aqueous layer was acidified with 15% aq HCl and
extracted with EtOAc.  The EtOAc extract was washed with brine, water and evaporated to
give the acid 3.26 as colourless crystals (9.8 g, 92%), m.p. 108-110 ºC (from toluene-light
petroleum) (lit.5 108-109 ºC).
1H NMR (CDCl3): δH 3.54 (2H, s, CH2COOH), 3.84 (3H, s, OCH3), 3.85 (3H, s, OCH3),
5.11 (2H, s, OCH2Ph), 6.51 (1H, d, J = 1.9 Hz, H-6), 6.56 (1H, d, J = 1.9 Hz, H-2), 7.31-
7.43 (5H, m, ArH).
13C NMR (CDCl3): δC 41.2 (CH2CO2H) 56.1 (OCH3), 60.8 (OCH3), 71.2 (OCH2), 106.8,
108.6, 127.3 (3C), 127.8, 128.5 (3C), 136.9, 152.4, 153.4 (12ArC) and 178.6 (CO2H).
HRESIMS (negative ionisation mode), m/z found 301.1077 [M-H]-, calculated for
C17H18O5 301.1075.
IR: υmax (neat)/cm-1 3030, 2944, 2631, 2248, 1707, 1685, 1591, 1456, 1332, 1317, 1233,
1179, 1149, 1110, 1026, 1002, 737.
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NaHCO3 (8.5 g, 0.1 mol) followed by 2,4,6-trichloro-1,3,5-triazine (3.27) (9.3 g, 0.05 mol)
were added to the solution of MeOH (28 ml) and H2O (2.5 ml) at 0 ºC.  The reaction
mixture was stirred for 1 h at room and as the temperature raised, CO2 evolved.  After
evolution of CO2 has ceased, the mixture was refluxed for 30 min and then cooled to room
temperature.  Water (100 ml) was added to the white precipitate formed, filtered, washed
with water and dried in vacuo to give CMDT (3.28) as white crystals (6.5 g, 74%) m.p. 73-
74 ºC (from H2O) (lit.
6 72-76 ºC).











N-methylmorpholine (NMM) (3.29) (2.85 ml, 26 mmol) was added dropwise to a solution
of 3.28 (5.0 g, 28 mmol) in THF (80 ml) at room temperature.  After stirring for 30 min at
room temperature, the white solid formed was filtered and washed with THF (2 x 50 ml)
and dried in vacuo to give DMTMM (3.30) (100%, 7.15 g) m.p. 117 ºC (from THF) (lit.7
116 ºC).
1H NMR (CD3OD): δH 3.56 (3H, s, NCH3), 3.88 (4H, m, CH2), 4.09 (2H, m, CH2), 4.20
(6H, s, OCH3) and 4.55 (2H, m, CH2).











To a solution of (R)-(-)-1-phenylethylamine (3.36) [(0.4 ml, 33 mmol), [α]D25 = + 35.3 (c =
1.1) in MeOH)] and phenylacetic acid 3.26 (7.0 g, 23 mmol) in CH3OH:H2O (10:1, 50 ml)
was added DMTMM (23 mmol) and the mixture was stirred overnight at room
temperature.  The resulting residue was poured into water and extracted with ether.  The
ether layer was washed successively with saturated Na2CO3, water, 10% aq. HCl, water
and brine, and dried (MgSO4).  Evaporation of the solvent afforded amide 3.37 (9.1 g,
98%) as a white solid.
1H NMR (CDCl3): δH 1.38 (3H, d, J = 6.9 Hz, CHCH3), 3.47 (2H, s, CH2CO), 3.81 (3H, s,
OCH3), 3.86 (3H, s, OCH3), 5.08 (2H, s, OCH2Ph), 5.09 (1H, q, J = 6.9 Hz, CHCH3), 5.62
(1H, br d, NH), 6.44 (1H, d, J = 1.8 Hz, H-6), 6.48 (1H, d, J = 1.8 Hz, H-2), 7.19-7.40
(10H, m, ArH).
13C NMR (CDCl3): δC 21.6 (CH3CH), 44.0 (CH2CO) 48.6 (CHNH), 56.1 (OCH3), 60.8
(OCH3), 71.0 (OCH2Ph), 106.4, 108.4, 125.9 (3C), 127.1 (3C), 127.3, 127.9, 128.5 (3C),
130.2, 136.8, 143.0, 152.5, 153.6 (18ArC) and 169.8 (CO).
HRESIMS (positive ionisation mode), m/z found 428.1840 [M+Na]+, calculated for
C25H27O4N 428.1838.
IR: υmax (neat)/cm-1 3635, 3025, 2960, 2644, 2178, 1677, 1643, 1231, 1111, 1007, 989,
739, 696.
[α]D25 = + 42.4 (c = 1.1, MeOH).










Method A: Reduction of 3.37
BF3
.Et2O (12.9 g, 91 mmol) complex was slowly added to a solution of acetamide 3.37
(8.0 g, 20 mmol) in anhydrous THF (25 ml) followed by the addition of  BH3
.THF (1 M,
1.8 g, 120 mmol) complex at room temperature, and the reaction mixture was refluxed for
1 h.  After cooling the mixture to room temperature, the excess reagents were decomposed
with 6 N HCl.  The aqueous solution was washed with EtOAc, basified with 10% KOH
and extracted with CH2Cl2.  The CH2Cl2 was washed with water and evaporated to give
amine 3.38 (4.6 g, 60%) as an oily substance.
Method B: Condensation with 3.36 followed by in situ reduction.
A solution of (R)-(-)-1-phenylethylamine (3.36) [(0.13 ml, 10.5 mmol), [α]D25 = + 35.3 (c =
1.1) in MeOH)] was gradually added to a solution of phenylacetaldehyde 3.40 (3.0 g, 10.5
mmol) in CH3OH (30 ml) cooled with ice and the mixture was stirred overnight at room
temperature.  Sodium borohydride (0.34 g, 10.5 mmol) was gradually added with cooling,
and the mixture was then stirred for 3 h at room temperature and then added to aqueous
sodium hydrogen carbonate (20 ml). Methanol was removed under reduced pressure and
the resulting residue was poured into water and extracted with ether.  The ether layer was
washed successively with water and brine, and dried (MgSO4).  Evaporation of the solvent
afforded amine 3.38 (3.9 g, 95%) as an oily substance.
1H NMR (CDCl3): δH 1.34 (3H, d, J = 6.9 Hz, CHCH3), 1.71 (1H, br d, NH), 2.70-2.74
(4H, m, CH2CH2NH), 3.76 (1H, q, J = 6.9 Hz, CHCH3), 3.81 (3H, s, OCH3), 3.89 (3H, s,
OCH3), 5.10 (2H, s, OCH2Ph), 6.41 (1H, d, J = 1.8 Hz, H-6), 6.47 (1H, d, J = 1.8 Hz, H-2),
7.23-7.46 (10H, m, ArH).
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13C NMR (CDCl3): δC 23.9 (CH3CH), 36.2 (CH2CH2NH), 48.3 (CH2CH2NH), 55.7
(OCH3), 55.8 (CHNH), 60.5 (OCH3), 70.4 (OCH2Ph), 105.8, 107.6, 126.2 (2C), 126.5,
126.9 (2C), 127.4, 128.0 (2C), 128.1 (3C), 135.3, 136.9, 145.2, 151.9, 153.0 (18ArC).
HRESIMS (positive ionisation mode), m/z found 414.2047 [M+Na]+, calculated for
C25H29O3N 414.2045.
IR: υmax (neat)/cm-1 3439, 2918, 1643, 1587, 1505, 1451, 1427, 1332, 1233, 1114, 1028,
1007, 989, 761, 735, 697.





To a suspension of (methoxymethyl)triphenylphosphonium chloride (7.3 g, 21.3 mmol) in
dry THF (10 ml), t-BuOK (3.3 g, 29.7 mmol) was added at 0 0C for 15 min.  Then
benzaldehyde 3.22 (5 g, 16.9 mmol) was added and stirred for 8 h.  The reaction mixture
was concentrated under vacuum and partitioned between water and Et2O.  The aqueous
layer was extracted with Et2O (2 x 20 ml), the combined organic layer was washed with
water and brine, dried and concentrated under vacuum.  Flash column chromatography
(hexanes:EtOAc, 7:3) gave 3.39 (4.2 g, 90%) as a yellow oil.
1H NMR (CDCl3): δH1H NMR (CDCl3): δH: 3.31 (3H, s, OCH3 trans), 3.75 (3H, s, OCH3
cis), 3.86 (12H, s, 4 x OCH3), 5.13 (4H, s, 2 x OCH2Ph), 5.73 (1H, d, J = 13.0 Hz trans),
6.07 (1H, d, J = 7.2 Hz cis), 6.47 (1H, d, J = 1.7 Hz, H-6), 6.84 (1H, d, J = 1.7 Hz, H-2),
6.93 (2H, m, ArH) 7.32-7.46 (10H, m, ArH),
13C NMR (CDCl3): δC 56.0 (OCH3 trans), 56.1 (OCH3 cis), 55.4 (OCH3), 60.7 (OCH3),
60.9 (OCH3), 61.0 (OCH3), 71.1 (OCH2 trans), 71.2 (OCH2 cis), 102.9, 104.8, 105.1,
105.6, 106.1, 107.9, 127.2 (2C), 127.4 (2C), 127.7, 127.8, 128.4 (2C), 128.5 (2C), 131.5,
132.1, 137.2, 137.3 (2C), 137.5, 147.5, 148.6, 152.1, 152.6, 153.0 and 153.4.
HRESIMS (positive ionisation mode), m/z found 300.1259 [M+Na]+, calculated for
C18H20O4 323.1256.
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Formic acid (10 ml) was added to a solution of 3.39 (4.5 g, 14.9 mmol) in CH2Cl2 (30 ml)
The reaction mixture was stirred for 48 hr at the room temperature, then diluted with water
followed by the extraction with CH2Cl2, the organic layer was washed several times with
water and concentrated to give 3.40 (3.1 g, 80%) as a colourless solid.
1H NMR (CDCl3): δH1H NMR (CDCl3): δH: 3.57 (2H, d, J = 2.4 Hz, CH2CHO), 3.86 (3H,
s, OCH3), 3.88 (3H, s, OCH3), 5.11 (2H, s, OCH2Ph), 6.42 (1H, d, J = 1.7 Hz, H-6), 6.46
(1H, d, J = 1.7 Hz, H-2), 7.29-7.44 (5H, m, ArH), 9.68 (1H, t, J = 2.4 Hz, CHO).
13C NMR (CDCl3): δC 50.6 (CH2CHO), 56.2 (OCH2), 60.9 (OCH3), 71.3 (OCH3), 107.1,
109.1, 127.2 (2C), 127.3, 127.9, 128.5 (2C), 136.9, 138.3, 152.8, 153.9 and 199 (CHO).
HRESIMS (positive ionisation mode), m/z found 309.1105 [M+Na]+, calculated for
C17H18O4 309.1103.









To a solution of 3.38 (4.5 g, 12 mmol) in 95% EtOH (20 ml) was added 10% Pd/C (2.0 g,
19 mmol) and the mixture was hydrogenated at atmospheric pressure at room temperature
for 30 min.  The mixture was filtered through a pad of celite and the filtrate was
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concentrated.  The residue was purified by column chromatography (hexanes:EtOAc, 9:1)
to afford 3.41 (3.07 g, 85%) as a brown oil.
1H NMR (CDCl3): δH 1.35 (3H, d, J = 6.7 Hz, CHCH3), 2.66-2.68 (4H, m, CH2CH2NH),
3.76 (1H, q, J = 6.9 Hz, CHCH3), 3.76 (3H, s, OCH3), 3.79 (3H, s, OCH3), 6.23 (1H, d, J =
1.8 Hz, H-6), 6.39 (1H, d, J = 1.8 Hz, H-2), 7.24-7.30 (5H, m, ArH).
13C NMR (CDCl3): δC 23.8 (CH3CH), 36.0 (CH2CH2NH), 48.4 (CH2CH2NH), 55.7
(OCH3), 58.1 (CHNH), 60.7 (OCH3), 104.2, 108.5, 126.5, 126.9, 128.4 (2C), 134.0, 135.8,
149.4, 152.4 (10ArC).
HRESIMS (positive ionisation mode), m/z found 302.1757 [M+H]+, calculated for
302.1756.
IR: υmax (neat)/cm-1 3591, 3459, 3188, 2987, 1643, 1595, 1468, 1433, 1239, 1111,1084,
983, 834, 780, 739, 696, 677.




To a suspension of (methoxymethyl)triphenylphosphonium chloride (1.2 g, 3.4 mmol) in
dry THF (10 ml), t-BuOK (0.46 g, 4.09 mmol) was added at 0 0C for 15 min.  Then 4-
bromobenzaldehyde (0.5 g, 2.7 mmol) was added and stirred for 15 min.  The reaction
mixture was concentrated under vacuum and partitioned between water and Et2O.  The
aqueous layer was extracted with Et2O (2 x 20 ml), the combined organic layer was
washed with water and brine, dried and concentrated under vacuum. Flash column
chromatography (hexanes:EtOAc, 7:3) gave 3.43 as a mixture of the cis and trans isomers
(0.52 g, 90%) as a yellow oil.
1H NMR (CDCl3): δH 3.68 (3H, s, OCH3 trans), 3.78 (3H, s, OCH3 cis), 5.17 (1H, d, J
=7.0 Hz cis,), 5.74 (1H, d, J = 13.0 Hz trans), 6.16 (1H, d, J = 7.0 Hz cis), 7.03 (1H, d, J =
13.0 Hz trans), 7.09 (2H, d, J = 8.5 Hz, H-2,6), 7.36-7.40 (4H, m) and 7.44 (2H, d, J = 8.5
Hz, H-3,5).
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13C NMR (CDCl3): δC 56.5 (OCH3), 60.7 (OCH3), 103.9 (CH(OCH3)) 104.5 (CHOCH3),
118.8  (CH2CHOCH3), 119.0  (CH2CHOCH3), 126.5 (2C),  129.6 (2C), 131.1 (2C), 131.5
(2C), 134.7, 135.3, 148.4, 149.2 (12ArC).
HRESIMS (positive ionisation mode), m/z found 212.9916 [M+H]+, calculated for
C9H9
79BrO  212.9915.






The solution of 3.43 (0.12 g, 0.55 mmol), p-TsOH (0.11g, 0.55 mmol), and molecular
sieves (0.1g) in MeOH were heated under reflux for 3 h.  The reaction mixture was poured
into water and extracted with EtOAc.  The EtOAc extract was washed with water, brine
and evaporated to give 3.44 (0.12 g, 95%) as bright yellow oil.
1H NMR (CDCl3): δH 2.85 (2H, d, CH(OCH3)2, J = 5.6 Hz), 3.33 (6H, s, CH(OCH3)2),
4.45 (1H, t, CH2CH(OCH3)2, J = 7.0 Hz,), 7.11 (2H, d, J = 8.3 Hz, H-2,6), 7.40 (2H, d, J =
8.3 Hz, H-3,5).
13C NMR (CDCl3): δC 38.9 (CH(OCH3)2), 53.3 (2C, (OCH3)2), 104.8 (CH2CH), 120.1, (C-
1), 131.0 (2C, C-2,6), 131.2.1 (2C, C3,5), 135.8 (C-4).
HRESIMS (positive ionisation mode), m/z found 244.0099 [M+H]+, calculated for
C10H12O2
79Br 244.0098.
IR: υmax (neat)/cm-1 3020, 2923, 2858, 1737, 1459, 1242, 1196, 1171, 1030, 979, 832,
755, 680.




t-BuOK (1.9 g, 16.7 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (5.2 g, 13.9 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of 4-bromobenzaldehyde (2.0 g, 10.8 mmol) in dry THF (5ml).  The
mixture was stirred at room temperature for 1h (TLC). The reaction mixture was
concentrated under vacuum and partitioned between water and Et2O.  The organic layer
was washed with water, brine and dried over MgSO4 and concentrated. Purification by
column chromatography (hexanes:EtOAc, 95:5) gave 3.46 as a colorless oil (1.9 g, 95%
yield).
1H NMR (CDCl3): δH 5.29 (1H, d, J = 10.8 Hz CH2CH, cis), 5.76 (1H, d, J = 17.1 Hz
CH2CH, trans), 6.67 (1H, dd, J = 17.1, 10.8 Hz CH2CH),   7.28 (2H, d, J = 8.4 Hz, H-2,6)
7.46 (2H, d, J = 8.4 Hz, H-3,5 ArH).
13C NMR (CDCl3): δC 114.5 (CHCH2), 121.6 (C-1), 127.8 (2C, C-2,6), 131.6 (2C, C-3,5),
135.8 (CHCH2) and 136.5 (C-4).
HRESIMS (positive ionisation mode), m/z found 182.9809 [M+H]+, calculated for
C8H7O
79Br 182.9809.





.S(CH3)2 (5.5 mmol, 5M) was added at 0 ºC to a solution of 3.46 (1.0 g, 5.4 mmol) in
dry THF (10ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0 ºC
and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2 (15.2
mmol) were added dropwise over 30 min, then stirred at room temperature for 3 h.  Upon
completion of the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the
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organic layer was washed with water, brine and dried over MgSO4 and concentrated.
Purification by column chromatography (hexanes:EtOAc, 8:2) gave 3.47 as colourless oil
in (1.0 g, 95%).
1H NMR (CDCl3): δH  2.50 (1H, s, br, OH), 2.77 (2H, t, J = 6.6 Hz CH2CH2OH), 3.76 (2H,
t, J = 6.6 Hz CH2CH2OH), 7.08 (2H, d, J = 8.4 Hz, H-2,6), 7.41 (2H, d, J = 8.4 Hz, H-3,5).
13C NMR (CDCl3): δC 38.5 (CH2CH2OH), 63.5 (CH2CH2OH), 120.2 (C-1), 130.8 (2C, C-
2,6), 131.6 (2C, C-3,5) and 137.7 (C-4).
HRESIMS (positive ionisation mode), m/z found 200.9917 [M+H]+, calculated for
C8H7O
79Br 200.9915.
IR: υmax (neat)/cm-1 3371, 2938, 1675, 1525, 1487, 1349, 1317, 1143, 1071, 1043, 953,
804, 722, 675.











Potassium bromate (4.0 g, 24 mmol) was added over 0.5 h to a vigorously stirred mixture
of 2-iodobenzoic acid (4.0 g, 16 mmol) in H2SO4 (2M, 38 ml) cooled to 55 ºC in an ice
bath.  The reaction mixture was stirred for 3.5 h at 65 ºC, and then cooled and filtered.  The
white precipitate formed was washed with H2O (500 ml) followed by cold ethanol (500 ml)
to give a white powder.  The product was recrystallised from ethanol and IBX (3.67) was
obtained as white crystals (3.9 g, 88%) with m.p. 232-233 ºC (lit.2 233 ºC).8
1H NMR (DMSO): δH 7.84 (1H, t, J = 8.3 Hz, H-3), 7.98 (1H, t, J = 8.3 Hz, H-2), 8.02
(1H, d, J = 12.8 Hz H-4), 8.14 (1H, d, J = 12.8 Hz, H-1).
13C NMR (DMSO): δC 125.5 (C-1), 130.6 (C-4), 131.6 (C-4a), 134.9 (C-3), 134.9 (C-2),
147.0 (C-1a) and 168.0 (C-5).
HRESIMS (negative ionisation mode), m/z found 278.9154 [M+H]-, calculated for
C7H4O6I 278,9154.
IR: υmax (neat)/cm-1 3358, 2979, 1591, 1476, 1245, 1170, 1078, 1040, 930, 755, 694,
653.





Method A: Oxidation of 3.47
IBX (3.67) (1.4 g, 5 mmol) was dissolved in DMSO (20ml) and the dissolution of IBX
(3.67) required 10-15 min.  The phenylethanol 3.47 (0.85 g, 4.3 mmol) dissolved in DMSO
(5ml) was added and the reaction was stirred at rt for 1.5 h (TLC). Upon completion of the
reaction the mixture was diluted with water followed by the extraction with EtOAc, the
organic layer was washed several times with water and concentrated to a give the desired
product. Compound 3.45 was isolated as a colourless oil (0.81 g, 95% yield).
Method B: Hydrolysis of 3.43
Formic acid (10 ml) was added to a solution of 3.43 (0.50 g, 2.4 mmol) in CH2Cl2 (30 ml)
The reaction mixture was stirred for 48 hr at the room temperature, then diluted with water
followed by the extraction with CH2Cl2, the organic layer was washed several times with
water and concentrated to give 3.45 (0.44 g, 95%) as a colourless solid.
1H NMR (CDCl3): δH 3.66 (2H, d, J = 2.4 Hz, CH2CHO), 7.10 (2H, d, J = 8.2 Hz, H-2,6),
7.49 (2H, d, J = 8.2 Hz, H-3,5), 9.74 (1H, t, J = 2.4 Hz, CHO).
13C NMR (CDCl3): δC 49.7 (CH2CHO), 121.5 (C-1), 130. 7 (C-4), 131.2 (C-2,6), 132.1 (C-
3,5 ArC)  and 198.5 (CHO).
HRESIMS (positive ionisation mode), m/z found 198.9757 [M+H]+, calculated for
C8H7O
79Br 198.9758.
IR: υmax (neat)/cm-1 3289, 2938, 1705, 1586, 1487, 1436, 1345, 1168, 1069, 1050, 942,
806, 757, 694, 651.





A solution of p-toluidine (10.0 g, 93 mmol) in dry ether (10 ml) was added dropwise to
BF3
. Et2O (52.0 g, 373 mmol) chilled in dry acetone (-15 ºC) under nitrogen, followed by
addition of a solution of tert-butylnitrite (16.0 g, 163 mmol) in dry ether (10ml) over a
period of 30 min. The chilled mixture was stirred an additional 10 min, and the cold bath
was allowed to warm to 5 ºC over 20 min.  Diethyl ether was added to the chilled
precipitate formed during the process and the solid product was filtered and washed several
times with chilled Et2O and air-dried to give diazonium salt 3.71. A solution of diazonium
salt 3.71 (8.0 g, 40 mmol) in CH3CN was then added dropwise to the solution of NaI (6.0
g, 45 mmol) and I2 (1 g, 4 mmol) in CH3CN.  The mixture was then stirred at rt for 1 h,
then Na2S2O3 (2 M, 20 ml) was added to the mixture. The resultant solution was extracted
with CH2Cl2 (3 x 25 ml) and the organic phase was washed with brine and dried over
Na2SO2.  The crude product was purified by column chromatography with
(hexanes:EtOAc, 8:2) to give p-iodotoluene (3.72) (8.7 g, 93%) as a yellow powder.
1H NMR (CDCl3): H 2.45 (CH3), 6.93 (2H, d, J = 8.5 Hz, H-2,6), 7.61 (2H, d, J = 8.5
Hz, H-3,5).
13C NMR (CDCl3): δC 21.3 (CH3), 94.9 (C-1), 130.7 (2C, C-2,6), 136.9 (C-4), 137.9
(2C, C-3,5).
HRESIMS (positive ionisation mode), m/z found 232.9464 [M+H]+, calculated for C7H5OI
232.9463.
IR:  υmax (neat)/cm-1 3030, 29234, 2850, 1660, 1461, 1364, 1301, 1255, 1055, 979, 673.
5.2.22 4-Iodobenzyl bromide (3.73)
I
CH2Br
NBS was added in 3 equal portions (3 x 0.8 g, 14 mmol) over 10 minutes to a solution of
p-iodotoluene (3.1 g, 14 mmol) in refluxing CCl4 (30 ml) under incandescent irradiation
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(100W).  The mixture was cooled to rt and filtered and washed twice with hexane to give
p-iodobenzyl bromide (3.73) (2.9 g, 70%) white crystals (from hexane) m.p. 77-79 ºC (lit.9
78.5-79.5 ºC).
1H NMR (CDCl3): H 4.44 (2H, s, CH2), 7.15 (2H, d, J = 8.5 Hz, H-2,6), 7.69 (2H, d, J =
8.5 Hz, H-3,5).
13C NMR (CDCl3): δC 32.4 (CH2Br), 94.1 (C-1), 130.8 (2C, C-2,6), 137.4 (C-4), 137.5
(2C, C-3,5).
HRESIMS (positive ionisation mode), m/z found 296.8776 [M+H]+ calculated for
C7H6IBr 296.8775.





IBX (3.67) (4.8 g, 17 mmol) was dissolved in DMSO (10 ml) and the dissolution of IBX
(3.67) required 10-15 min.  Benzyl bromide 3.73 (1.7 g, 5.6 mmol) dissolved in DMSO (5
ml) was added to the reaction mixture and stirred at room temperature for 15 min (TLC).
Upon completion of the reaction the mixture was diluted with water followed by the
extraction with ethyl acetate, the organic layer was washed several times with water and
concentrated to a white solid, recrystallised from ethanol m.p. 76-78 ºC (lit.10 76-77 ºC) to
give 3.74 (1.2 g, 95% yield) as white crystals.
1H NMR (CDCl3): H 7.15 (2H, d, J = 8.3 Hz, H-2,6), 7.69 (2H, d, J = 8.3 Hz, H-3,5) 9.98
(1H, s, CHO).
13C NMR (CDCl3): δC 102.7 (C-1), 130.7 (2C, C-2,6), 135.6 (C-4), 138.4 (2C, C-3,5),
191.4 (CHO).
HRESIMS (positive ionisation mode), m/z found 232.9464 [M+H]+, calculated for C7H5OI
232.9463.
IR: υmax (neat)/cm-1 3029, 2944, 2850, 1705, 1660, 1476, 1395, 1301, 1265, 1054, 980,
675.




t-BuOK (0.93 g, 8.35 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (2.6 g, 6.95 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of 4-iodobenzaldehyde (3.74) (1.3 g, 5.4 mmol) in dry THF (5ml).
The mixture was stirred at room temperature for 30 minutes (TLC). The reaction mixture
was concentrated under vacuum and partitioned between water and Et2O.  The organic
layer was washed with water, brine and dried over MgSO4 and concentrated. Purification
by column chromatography (hexanes:EtOAc, 95:5) gave 3.75 (1.2 g, 98%) yield as a
yellowish oil.
1H NMR (CDCl3): δH 5.17 (1H, d, J = 10.6 Hz, cis CH2CH), 5.66 (1H, d, J = 17.5 Hz,
trans CH2CH), 6.55 (1H, dd, J = 17.5, 10.6 Hz CH2CH), 7.05 (2H, d, J = 8.4 Hz, H-2,6),
7.56 (2H, d, J = 8.4 Hz, H-3,5).
13C NMR (CDCl3): δC 114.2 (CHCH2), 120.3 (C-1), 127.2 (2C, C-2,6), 130.9 (2C, C-3,5),
135.1 (CHCH2) and 136.2 (C-4).
HRESIMS (positive ionisation mode), m/z found 230.9671 [M+H]+, calculated for C8H7I
230.9670.
IR:  υmax (neat)/cm-1 3051, 2877, 1701, 1690, 1582, 1483, 1245, 1169, 1117, 1089, 1058,





.S(CH3)2 (5.5 mmol, 5M) was added at 0 ºC to a solution of 3.75 (1.2 g, 5.4 mmol) in
dry THF (10ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0 ºC
and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2 (15.2
mmol) were added dropwise over 30 min, then stirred at 0 ºC for 3 h.  Upon completion of
the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the organic layer was
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washed with water, brine and dried over MgSO4 and concentrated. Purification by column
chromatography (hexanes:EtOAc, 8:2) gave 3.76 (1.3 g, 98%) yield as a colourless oil.
1H NMR (CDCl3): δH 2.82 (2H, t, J = 6.5 Hz, CH2CH2OH), 3.85 (2H, t, J = 6.5 Hz,
CH2CH2OH), 7.00 (2H, d, J = 8.2 Hz, H-2,6), 7.65 (2H, d, J = 8.2 Hz, H-3,5).
13C NMR (CDCl3): δC 38.7 (CH2CH2OH), 63.3 (CH2CH2OH), 91.6 (C-1), 131.1 (2C, C-
2,6), 137.6 (2C, C-3,5) and 138.3 (C-4).
HRESIMS (positive ionisation mode), m/z found 248.9776 [M+H]+, calculated for C8H7OI
248.9776.





IBX (3.67) (1.4 g, 5 mmol) was dissolved in DMSO (20ml) and the dissolution of IBX
(3.67) required 10-15 min.  The phenylethanol 3.76 (1.1 g, 4.3 mmol) dissolved in DMSO
(5ml) was added and the reaction was stirred at room temperature for 30 minutes (TLC).
The reaction mixture was diluted with water followed by the extraction with EtOAc, the
organic layer was washed several times with water and concentrated to a give the desired
product. Compound 3.77 was isolated as a yellow oil (1.1 g, 98% yield).
1H NMR (CDCl3): δH 3.64 (2H, d, J = 2.4 Hz, CH2CHO), 7.03 (2H, d, J = 8.6 Hz, H-2,6),
7.41 (2H, d, J = 8.6 Hz, H-3,5) and 9.72 (1H, t, J = 2.4 Hz, CHO).
13C NMR (CDCl3): δC 49.5 (CH2CHO), 121.3 (C-1), 129.9 (C-4), 131.9 (C-2,6), 132.0 (C-
3,5)  and 199.5 (CHO).
HRESIMS (positive ionisation mode), m/z found 246.9618 [M+H]+, calculated for C8H7OI
246.9619.
IR: υmax (neat)/cm-1 3277, 2935, 1715, 1577, 1490, 1430, 1380, 1188, 1049, 1065, 925,
811, 766, 685, 642.






A mixture of H2SO4 (c) (20 ml) and nitrite free HNO3 (2.7 ml) cooled to -5 ºC, were treated
dropwise with para-fluorobenzaldehyde (3.80) (5.0 g, 40.2 mmol) with the temperature
kept below 5 ºC.  The mixture was allowed to stand for 48 hours at room temperature, then
poured on  ice (500 g) and the precipitate formed was filtered to yield 3.81 (5.1 g, 75%)
yield as yellowish solid, which was recrystallised (from Et2O) to give yellow crystals m.p.
46-47 ºC (lit.11 46.5 ºC).
1H NMR (CDCl3): δH 7.32 (1H, d, J = 8.3 Hz, H-5), 8.08 (1H, dd, J = 2.3, 8.3 Hz, H-6),
8.52 (1H, d, J = 2.3 Hz, H-2), 9.95 (1H, s, CHO).
13C NMR (CDCl3): δC 117.3 (C-5), 125.6 (C-2), 133.7 (C-1), 140.1 (C-3), 138.5 (C-6),
163.8 (C-4) and 191.4 (CHO).
HRESIMS (positive ionisation mode), m/z found 170.0253 [M+H]+, calculated for
C7H4NO3F 170.0254.





t-BuOK (1.9 g, 16.7 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (5.2 g, 13.9 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of 4-fluoro-3-nitrobenzaldehyde (3.81) (1.8 g, 10.8 mmol) in dry
THF (5ml).  The mixture was stirred at room temperature for 5 h (TLC).  Upon completion
of the reaction the mixture was concentrated under vacuum and partitioned between water
and Et2O.  The organic layer was washed with water, brine and dried over MgSO4 and
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concentrated. Purification by column chromatography (hexanes:EtOAc, 95:5) gave 3.82
(1.7 g, 98%) as a yellowish oil.
1H NMR (CDCl3): δH 5.35 (1H, d, J = 10.8 Hz, CH2CH, cis), 5.87 (1H, d, J = 17.1 Hz,
CH2CH, trans), 6.77 (1H, dd, J = 17.1, 10.8 Hz CH2CH),   7.09 (1H, d, J = 8.3 Hz, H-5),
7.29 (1H, dd, J = 2.3, 8.3 Hz, H-6), 7.89 (1H, d, J = 2.3 Hz, H-2).
13C NMR (CDCl3): δC 114.7 (CHCH2), 121.8 (C-1), 127.8 (C-5), 131.9 (C-6), 133. 2 (C-2),
135.9 (CHCH2) and 136.9 (C-4).
HRESIMS (positive ionisation mode), m/z found 168.0461 [M+H]+, calculated for
C8H6NO2F 168.0460.







.S(CH3)2 (5.5 mmol, 5M) was added at 0 ºC to a solution of 3.82 (0.90 g, 5.4 mmol) in
dry THF (10 ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0ºC
and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2 (15.2
mmol) were added dropwise over 30 min, then stirred for 8 h at 0 ºC.  Upon completion of
the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the organic layer was
washed with water, brine and dried over MgSO4 and concentrated. Purification by column
chromatography (hexanes:EtOAc, 8:2) gave 3.83 (0.85 g, 85%) yield as a colourless oil.
1H NMR (CDCl3): δH 2.77 (2H, t, J = 6.3 Hz, CH2CH2OH), 3.79 (2H, t, J = 6.3 Hz,
CH2CH2OH), 7.06 (1H, d, J = 8.3 Hz, H-5), 7.25 (1H, dd, J = 2.3, 8.3 Hz, H-6), 7.51 (1H,
d, J = 2.3 Hz, H-2).
13C NMR (CDCl3): δC 38.8 (CH2CH2OH), 63.7 (CH2CH2OH), 116.9 (C-5), 124.2 (C-2),
133.5 (C-3), 134.8 (C-6), 135.6 (C-1) and 157.7 (C-4).
HRESIMS (positive ionisation mode), m/z found 186.0567 [M+H]+, calculated for
C8H8NO3F 186.0566.
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IR: υmax (neat)/cm-1 3340, 2931, 1612, 1530, 1498, 1347, 1246, 1175, 1164, 1082, 1043,





IBX (3.67) (1.4 g, 5 mmol) was dissolved in DMSO (20ml) and the dissolution of IBX
(3.67) required 10-15 min.  The phenylethanol 3.83 (0.80 g, 4.3 mmol) dissolved in DMSO
(5 ml) was added and the reaction was stirred at room temperature for 5 h (TLC). Upon
completion of the reaction the mixture was diluted with water followed by the extraction
with EtOAc, the organic layer was washed several times with water and concentrated to a
give the desired product. Compound 3.84 was isolated as a yellow oil (0.67 g, 85%).
1H NMR (CDCl3): δH 3.66 (2H, d, J = 2.4 Hz, CH2CHO), 7.13 (1H, d, J = 8.4 Hz, H-5),
7.21 (1H, dd, J = 2.4, 8.4 Hz, H-6), 7.51 (1H, d, J = 2.4 Hz, H-2), 9.71 (1H, t, J = 2.4,
CHO).
13C NMR (CDCl3): δC 49.9 (CH2CHO), 117.3 (C-5), 126.2 (C-2), 132.1 (C-1), 135.9 (C-3),
138.9 (C-6), 156.8 (C-4) and 199.7 (CHO).
HRESIMS (positive ionisation mode), m/z found 184.0409 [M+H]+, calculated for
C8H6NO3F 184.0409.





To a mixture of 4-hydroxybenzaldehyde (6.5 g, 53.2 mmol) in dry DMF (20 ml) were
added K2CO3 (14.7 g, 106.5 mmol).  Freshly distilled isopropyl bromide (16.9 ml, 186.3
mmol) was added dropwise and the resulting suspension was stirred at room temperature
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for 19 h.  After evaporation of DMF under vacuum, the solution was poured into 2M HCl
solution (30 ml).  The aqueous solution was extracted several times with CH2Cl2.  The
combined CH2Cl2 extracts were concentrated under reduced pressure to yield 3.86 (8.4 g,
84%) as yellow oil.
1H NMR (CDCl3/ CD3OD) δH: 1.31 (6H, d, J = 6.2 Hz, CHCH3CH3), 4.62 (1H, m, OCH),
6.92 (2H, d, J = 8.8 Hz, H-3,5), 7.76 (2H, d, J = 8.8 Hz, H-2,6), 9.76.17 (1H, s, CHO).
13C NMR (CDCl3): δC 21.1 (2C, CH3CH3), 69.9 (OCH), 115.1 (2C, C-3,5), 128.8 (C-1),
131.6 (2C, C-2,6), 162.9 (C-4) 190.9 (CHO).
HRESIMS (positive ionisation mode), m/z) found 187.0737 [M+Na]+, calculated for
C10H12O2 187.0735.
IR: υmax (neat)/cm-1 3020, 1715, 1686, 1597, 1573, 1252, 1216, 1177, 1156, 1115, 1100,
947, 830, 739, 696.
5.2.32 1-Isopropyloxy-4-vinylbenzene (3.87)
PriO
t-BuOK (1.9 g, 16.7 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (5.2 g, 13.9 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of p-Isopropyloxybenzaldehyde (3.86)  (1.8 g, 10.8 mmol) in dry
THF (5ml).  The mixture was stirred at room temperature for 15 h (TLC).  Upon
completion of the reaction the mixture was concentrated under vacuum and partitioned
between water and Et2O.  The organic layer was washed with water, brine and dried over
MgSO4 and concentrated. Purification by column chromatography (hexanes:EtOAc, 95:5)
gave 3.87 (1.6 g, 90%) as a colourless oil.
1H NMR (CDCl3/ CD3OD): δH 1.28 (6H, d, J = 6.2 Hz, CHCH3CH3), 4.59 (1H, m, OCH),
5.28 (1H, d, J = 10.5 Hz, CH2CH, cis), 5.79 (1H, d, J = 17.3 Hz, CH2CH, trans), 6.48 (1H,
dd, J = 17.3, 10.5 Hz CH2CH), 6.77 (2H, d, J = 8.5 H-2,6), 7.58 (2H, d, J = 8.5 Hz, H-3,5).
13C NMR (CDCl3): δC 20.9 (2C, CH3CH3), 69.5 (OCH), 114.2 (CHCH2), 115.1 (2C, C-
3,5), 128.5 (2C, C-2,6) and 134.8 (CHCH2).
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HRESIMS (positive ionisation mode), m/z found 163.1124 [M+H]+, calculated for
C11H14O 163.1122.





.S(CH3)2 (5.5 mmol, 5M) was added at 0 ºC to a solution of 3.87 (0.80 g, 5.4 mmol) in
dry THF (10ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0 ºC
and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2 (15.2
mmol) were added dropwise over 30 min, then stirred overnight at 0 ºC.  Upon completion
of the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the organic layer was
washed with water, brine and dried over MgSO4 and concentrated. Purification by column
chromatography (hexanes:EtOAc, 8:2)  gave 3.88 (0.78 g, 92%) as a colourless oil.
1H NMR (CDCl3): δH 1.33 (6H, d, J = 6.0 Hz, CHCH3CH3), 2.74 (2H, t, J = 6.4 Hz,
CH2CH2OH), 3.73 (2H, t, J = 6.4 Hz, CH2CH2OH), 4.52 (1H, m, OCH), 6.75 (2H, d, J =
8.6 Hz, H-3,5), 7.46 (2H, d, J = 8.6 Hz, H-2,6).
13C NMR (CDCl3): δC 21.9 (2C, CH3CH3), 38.4 (CH2CH2OH), 64.6 (CH2CH2OH), 69.8
(2C, OCH), 115.8 (2C, C-3,5), 128.5 (2C, C-2,6), 132.8 (C-1), 157.2 (C-4).
HRESIMS (positive ionisation mode), m/z found 181.1229 [M+Na]+, calculated for
C11H16O2 181.1228.





IBX (3.67) (1.4 g, 5 mmol) was dissolved in DMSO (20ml) and the dissolution of IBX
(3.67) required 10-15 min.  The phenylethanol 3.88 (0.68 g, 4.3 mmol) dissolved in DMSO
(5ml) was added, and the reaction was stirred at room temperature for 18 h.  The reaction
mixture was diluted with water followed by the extraction with EtOAc, the organic layer
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was washed several times with water and concentrated to a give the desired product.
Compound 3.89 was isolated as a yellowish oil (0.69 g, 90%).
1H NMR (CDCl3): δH 1.27 (6H, d, J = 9.1 Hz, CH(CH3)2), 3.58 (2H, d, J = 2.4 Hz,
CH2CHO), 4.51 (1H, m, CH(CH3)2), 6.83 (2H, d, J = 8.6 Hz, H-3,5), 6.95 (2H, d, J = 8.6
Hz, H-2,6), 9.70 (1H, t, J = 2.4 Hz, CHO).
13C NMR (CDCl3): δC 21.8 (2C, CH(CH3)2), 49.7 (CH2CHO), 69.9 (CH(CH3)2), 116.5 (2C,
C-3,5), 123.5 (C-1), (2C, C-2,6), 157.5 (C-4) and 199.8 (CHO).
HRESIMS (positive ionisation mode), m/z found 179.1072 [M+H]+, calculated for
C11H14O2 179.1072.
IR: υmax (neat)/cm-1 3277, 2935, 1715, 1592, 1460, 1425, 1365, 1168, 1072, 1055, 930,











To a solution of amine alcohol 3.41 (1.2 g, 4.05 mmol), phenylacetaldehyde 3.45 (0.7 g,
3.5 mmol), 3 Å molecular sieves (1.0 g) in CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20
ml), acetic acid (0.1 eq.) was added dropwise.  The reaction was refluxed for 18 h and
upon completion of the reaction the mixture was diluted with CH2Cl2 and filtered.  The
filtrate was concentrated under reduced pressure and the residue was purified by column
chromatography (hexanes:EtOAc, 9:1) to give 3.104 (1.3 g, 78%) as yellow solid.
1H NMR (CDCl3): δH 0.96 (3H, d, J = 6.4 Hz, CHCH3), 2.16 (1H, dd, J =13.5, 3.2 Hz, H-
4eq), 2.68-3.20 (3H, m, H-α, H-3, H-4), 3.05 (1H, dd, J = 2.4, 10.4 Hz, H-α), 3.18 (1H,
ddd, J = 3.2, 11.1, 13.2, Hz, H-3eq), 3.63 (1H, q, J = 6.4 Hz, CHCH3), 3.65 (3H, s, 7-
OCH3), 3.80 (3H, s, 6-OCH3), 4.35 (1H, dd, J = 3.8 Hz, 10.4, H-1), 5.93 (1H, s, OH), 6.22
(1H, s, H-5), 7.14 (2H, d, J =8.4 Hz, H-11,13), 7.23-7.25 (5H, m, ArH), 7.45 (2H, d, J =
8.4, H-10,14).
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13C NMR (CDCl3): δC 22.4, 22.6, 31.8, 39.6, 53.8, 55.6, 57.7, 61.1, 103.7, 117.9, 119.4,
126.7, 127.3, 128.3, 130.7 (2C), 131.1, 131.6 (2C), 132.1 (2C), 133.4, 140.8, 146.3, 145.7,
150.5.
HRESIMS (positive ionisation mode), m/z found 482.1333 [M+H]+, calculated for
C26H28
79BrNO3 482.1331.
IR: υmax (neat)/cm-1 3591, 3459, 3188, 2987, 2931, 2845, 1678, 1658, 1602, 1562, 1489,
1366, 1258, 1233, 1153, 1120 and 1051.











To a solution of amine alcohol 3.41 (1.4 g, 4.7 mmol), phenylacetaldehyde 3.79 (0.7 g, 2.8
mmol), 3 Å molecular sieves (1.0 g) in CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20 ml),
acetic acid (0.1 eq.) was added dropwise.  The reaction was refluxed for 12 h and upon
completion of the reaction the mixture was diluted with CH2Cl2 and filtered.  The filtrate
was concentrated under reduced pressure and the residue was purified by column
chromatography (hexanes:EtOAc, 9:1) to give 3.111 (1.2 g, 80%) as a colourless oil.
1H NMR (CDCl3): δH 0.98 (3H, d, J = 6.4 Hz, CHCH3), 2.21 (1H, dd, J =13.5, 3.2 Hz, H-
4eq), 2.71-3.29 (3H, m, H-α, H-3, H-4), 3.12 (1H, dd, J = 2.8, 10.3, Hz, H- α), 3.25 (1H,
ddd, J = 3.2, 11.1, 13.2, Hz, H-3eq), 3.66 (1H, q, J = 6.4 Hz, CHCH3), 3.70 (3H, s, 7-
OCH3), 3.92 (3H, s, 6-OCH3), 4.38 (1H, dd, J = 2.8 Hz, 10.3, H-1), 5.97 (1H, s, OH), 6.29
(1H, s, H-5), 7.20 (2H, d, J =8.5 Hz, H-11,13), 7.43-7.65 (5H, m, ArH), 7.45 (2H, d, J =
8.5, H-10,14).
13C NMR (CDCl3): δC 22.7, 23.0, 31.9, 39.9, 54.1, 56.2, 57.9, 61.9, 104.2, 118.2, 119.9,
127.2, 127.9, 128.8, 131.5 (2C), 131.9, 131.8 (2C), 132.9 (2C), 133.8, 141.2, 146.9, 148.2,
151.1.
HRESIMS (positive ionisation mode), m/z found 530.1193 [M+H]+, calculated for
C26H28NO3I 530.1192.
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IR: υmax (neat)/cm-1 3585, 3427, 3190, 2968, 2850, 1670, 1602, 1555, 1470, 1390, 1245,
1175 and 1025.












To a solution of amine alcohol 3.41 (1.3 g, 4.4 mmol), phenylacetaldehyde 3.84 (0.70 g,
3.8 mmol), 3 Å molecular sieves (1.0 g) in CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20
ml), acetic acid (0.1 eq.) was added dropwise.  The reaction was refluxed for 20 h and
upon completion of the reaction the mixture diluted with CH2Cl2 and filtered.  The filtrate
was concentrated under reduced pressure and the residue was purified by column
chromatography (hexanes:EtOAc, 9:1) to give 3.112 (1.3 g, 72%) as a yellow oil.
1H NMR (CDCl3): δH: 0.98 (3H, d, J = 6.4 Hz, CHCH3), 2.20 (1H, dd, J =13.5, 3.2 Hz, H-
4eq),  2.71-3.25 (3H, m, H-α, H-3, H-4), 3.12 (1H, dd, J = 3.6, 10.3, Hz, H- α), 3.25 (1H,
ddd, J = 3.2, 11.1, 13.2, Hz, H-3eq), 3.66 (1H, q, J = 6.4 Hz, CHCH3), 3.71 (3H, s, 7-
OCH3), 3.84 (3H, s, 6-OCH3), 4.37 (1H, dd, J = 3.6, 10.3 Hz, H-1), 5.96 (1H, s, OH), 6.26
(1H, s, H-5), 7.16 (1H, d, J = 8.4 Hz, H-10), 7.26-7.31 (5H, m, ArH), 7.45 (1H, dd, J = 2.4,
8.4 Hz, H-14) 7.13 (1H, d, J = 8.4 Hz, H-11).
13C NMR (CDCl3): δC 22.6, 32.3, 41.3, 45.7, 53.2, 53.9, 55.6, 61.2, 104.9, 116.9, 117.5,
124.5, 127.3, 128.9, 130.9 (2C), 131.5, 131.9 (2C), 132.4 (2C), 133.9, 139.7, 145.7, 146.3,
151.3.
HRESIMS (positive ionisation mode), m/z found 467.1948 [M+H]+, calculated for
C26H27NO5F 467.1947.
IR: υmax (neat)/cm-1 3496, 2944, 3188, 2987, 2865, 1615, 1589, 1505, 1453, 1362, 1235,
1186, 1119, 1069, 908, 820, 729, 699.
[α]D25 = + 52.5 (c = 1.3, CHCl3).












To a solution of amine alcohol 3.41 (1.2 g, 3.9 mmol), phenylacetaldehyde 3.89 (0.60 g,
3.4 mmol), 3 Å molecular sieves (1.0 g) in CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20
ml), acetic acid (0.1 eq.) was added dropwise.  The reaction was refluxed for 24 h and
diluted with CH2Cl2 and filtered.  The filtrate was concentrated under reduced pressure and
the residue was purified by column chromatography (hexanes:EtOAc, 9:1) to give 3.113 as
pale yellow oil (1.1 g, 70%).
1H NMR (CDCl3): δH 0.95 (3H, d, J = 6.5 Hz, CHCH3), 1.35 (6H, d, J = 6.1Hz,
CH(CH3)2), 2.13 (1H, dd, J =13.4, 3.3 Hz, H-4eq), 2.59-3.17 (3H, m, H-α, H-3, H-4), 3.09
(1H, dd, J = 3.5, 10.6, Hz, H- α), 3.22 (1H, ddd, J = 3.3, 11.1, 13.4, Hz, H-3eq), 3.65 (1H,
q, J = 6.9 Hz, CHCH3), 3.80 (3H, s, OCH3), 3.91 (3H, s, OCH3), 4.38 (1H, dd, J = 3.5,
10.6 Hz, H-1), 4.57 (1H, m, CH(CH3)2), 5.91 (1H, s, H-5 or H-8), 6.22 (1H, s, H-5 or H-8),
6.88 (2H, d, J = 8.6, H-10,14), 7.16-7.22 (5H, m, ArH) and 7.27 (2H, d, J = 8.6 Hz, H-
11,13).
13C NMR (CDCl3): δC 22.5 [OCH(CH3)2], 22.5 (CHCH3), 22.6 (C-4), 39.3 (C-α), 39.4 (C-
3), 53.9 (C-1), 55.6 (OCH3), 57.7 (NCHPh), 61.0 (OCH3), 70.0 [OCH(CH3)2], 103.5 (C-5),
115.2 (C-10,14), 118.3 (C-8a), 125.7 -128.3 (C-Ph), 130.6 (C-11,13), 131.1 (C-9), 133.3
(C-4a), 134.1 (quaternary on Ph), 147.3 (C-8), 146.7 (C-7), 150.4 (C-6), 155.9 (C-12).
HRESIMS (positive ionisation mode), m/z found 462.2645 [M+H]+, calculated for
C29H35O4N 462.2644.
IR:  υmax (neat)/cm-1 3582, 3466, 3125, 2965, 2849, 1643, 1655, 1613, 1566, 1231, 1113,
1061, 977, 743, 695.
[α]D25 = + 63.5 (c = 1.0, CHCl3).












A mixture of phenol 3.104 (0.2 g, 0.41 mmol), Cu(OAc)2 (75 mg, 0.41 mmol), arylboronic
acid (0.15 g, 1.2 mmol) and powdered 4 Å molecular sieves (100 mg) were dissolved in
CH2Cl2, and Et3N (2.07 mmol, 0.29 ml) was added.  The resulting coloured heterogeneous
mixture was stirred for 18 h at 25 °C, then filtered and separated by flash chromatography
(hexanes:EtOAc, 9:1) to afford 3.121 (0.16 g, 72%) as a colourless oil.
1H NMR (CDCl3): δH 0.77 (3H, d, J = 6.5 Hz, CHCH3), 2.29 (1H, dd, J =16.5, 4.2 Hz, H-
4), 2.72-2.91 (4H, m, 2x H-α, H-3, H-4), 3.19 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3),
3.61 (1H, q, J = 6.5 Hz, CHCH3), 3.59 (3H, s, 7-OCH3), 3.78 (3H, s, 6-OCH3), 4.01 (1H, t,
J = 5.3, 7.8, H-1), 6.51 (1H, s, H-5), 7.00-7.08 (6H, m, ArH), 7.18 (3H, ArH), 7.36 (2H, d,
J = 8.3), 7.83 (2H, d, J = 8.5 Hz).
13C NMR (CDCl3): δC 21.4, 22.3, 30.7, 38.9, 40.2, 53.3, 55.8, 57.9, 60.3, 109.7, 115.1
(2C), 119.1, 123.8, 126.4, 126.8 (2C), 128.1 (2C), 130.5 (2C), 131.0, 131.1 (2C), 131.5,
131.9, 135.6, 139.8, 144.4, 145.7, 152.2 and 162.5.
HRESIMS (positive ionisation mode), m/z found 558.1645 [M+H]+, calculated for
C32H32
79BrNO3 558.1643.
IR: υmax (neat)/cm-1 (ATR platinum gold) 2955, 2875, 1687, 1615, 1591, 1507, 1470,
1391, 1275, 1157 and 1071.
[α]D25 = + 17.2 (c = 1.1, MeOH).





The mixture of p-fluorobenzaldehyde (3.80) (5.0 g, 40 mmol), phenol (3.124) (3.5 g, 40
mmol) and K2CO3 (0.8 mmol) were dissolved in DMF (10 ml) and heated at reflux for 1 h
under microwave (100 °C).  The reaction ws then cooled to room temperature filtered and
acidified with HCl (pH indicator).  The reaction mixture was extracted with EtOAc (3 x 50
ml), washed with brine and concentrated to a crude solid. Purification by column
chromatography (hexanes:EtOAc, 8:2) gave 3.125 (7.2 g, 90%) yield as a white solid.
1H NMR (CDCl3): H 7.00 (2H, d, J = 8.7 Hz), 7.02 (1H, d, J = 7.8 Hz), 7.16 (2H, t, J =
7.8 Hz) 7.34 (2H, t, J = 7.8 Hz), 7.76 (2H, d, J = 8.7 Hz), 9.85 (1H, s, CHO).
13C NMR (CDCl3): δC 117.6 (2C), 120.4 (2C), 124.9 (2C), 130.1, 131.3, 131.9 (2C), 155.1,
163.2, 190.7 (CHO).
HRESIMS (positive ionisation mode), m/z found 199.0759 [M+H]+, calculated for
C13H10O2 199.0759.
IR: υmax (neat)/cm-1 3421, 2845, 1725, 1688, 1606, 1586, 1505, 1489, 1423, 1287, 1242,
1197, 873 and 686.
5.2.41 1-Phenoxy-4-vinylbenzene (3.126)
O
t-BuOK (1.9 g, 16.7 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (5.2 g, 13.9 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of 3.125 (2.2 g, 10.8 mmol) in dry THF (5ml).  The mixture was
stirred at room temperature for 15 h (TLC). Upon completion of the reaction the mixture
was extracted with EtOAc (3 x 30 ml) and the organic layer was washed with water, brine
and dried over MgSO4 and concentrated.  Purification by column chromatography gave
3.126 (2.0 g, 95%) as a yellow oil.
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1H NMR (CDCl3): δH 5.19 (1H, d, J = 10.4 Hz, cis CH2CH), 5.65 (1H, d, J = 17.4 Hz,
trans CH2CH), 6.64 (1H, dd, J = 17.4, 10.4 Hz CH2CH), 6.89 (2H, d, J = 8.3 Hz ArH),
6.95 (2H, d, J = 8.4 Hz ArH),7.02 (2H, d, J = 8.6 Hz ArH), 7.21 (2H, d, J = 8.5 Hz ArH
13C NMR (CDCl3): δC 112.6, 117.2 (2C), 120.4 (2C), 125.6 (2C), 128.8, 131.2, 131.9 (2C),
135.8, 155.1 and 156.5.
HRESIMS (positive ionisation mode), m/z found 199.0967 [M+H]+, calculated for
C14H12O 197.0966.






.S(CH3)2 (5.5 mmol, 5M) was added at 0 ºC to a solution of 3.126 (1.1 g, 5.4 mmol) in
dry THF (10ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0 ºC
and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2 (15.2
mmol) were added dropwise over 30 min, then stirred overnight at 0 ºC.  Upon completion
of the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the organic layer was
washed with water, brine and dried over MgSO4 and concentrated. Purification by column
chromatography (hexanes:EtOAc, 8:2) gave 3.127 (0.99 g, 85%) as a colourless oil.
1H NMR (CDCl3): δH 2.79 (2H, t, J = 6.6 Hz CH2CH2OH), 3.85 (2H, t, J = 6.6 Hz,
CH2CH2OH), 6.99 (2H, d, J = 8.6 Hz), 7.01 (1H, d, J = 7.8 Hz), 7.14 (2H, t, J = 7.8 Hz)
7.20 (2H, t, J = 7.8 Hz), 7.35 (2H, d, J = 8.6 Hz).
13C NMR (CDCl3): δC 38.5, 65.3, 117.1 (2C), 121.4 (2C), 125.3 (2C), 130.1, 131.3, 131.9
(2C), 153.1 and 156.9.
HRESIMS (positive ionisation mode), m/z found 215.1073 [M+H]+, calculated for
C14H14O2 215.1072.
IR: υmax (neat)/cm-1 2931, 2845, 1725, 1688, 1606, 1586, 1505, 1489, 1423, 1287, 1242,
1197, 873 and 686.





IBX (3.67) (5 mmol) was dissolved in DMSO (20ml) and the dissolution of IBX (3.67)
required 10-15 min.  The phenylethanol 3.127 (0.68 g, 4.3 mmol) dissolved in DMSO
(5ml) was added, and the reaction was stirred at room temperature for 12 h monitored by
TLC. Upon completion of the reaction the mixture was diluted with water followed by the
extraction with EtOAc, the organic layer was washed several times with water and
concentrated to a give the desired product. Compound 3.128 was isolated as a yellow solid
(0.90 g, 98%).
1H NMR (CDCl3): H 3.59 (2H, d, J = 2.2 Hz, CH2CHO), 6.91-6.94 (3H, m, ArH), 7.01-
7.11 (3H, m, ArH), 7.22-7.28 (3H, m, ArH), 9.67 (1H, t, J = 2.5 Hz, CHO).
13C NMR (CDCl3): δC 49.7, 118.6 (2C), 119.2 (2C), 123.4, 126.5, 129.8 (2C), 130.9 (2C),
156.7, 157.0 and 199.2 (CHO).
HRESIMS (positive ionisation mode), m/z found 213.0916 [M+H]+, calculated for
C14H12O2 213.0915.
IR: υmax (neat)/cm-1 2923, 2852, 1731, 1685, 1611, 1581, 1512, 1482, 1422, 1290, 1237,






To a solution of 3,4-dimethoxyphenethylamine (3.129) (0.79 g, 4.3 mmol),
phenylacetaldehyde 3.128 (0.80 g, 3.8 mmol) and the 3 Å molecular sieves (1.0 g) in
CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20 ml), acetic acid (25 mmol) was added
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dropwise.  The reaction was refluxed for 18 h and upon completion of the reaction the
mixture was diluted with CH2Cl2 and filtered.  The filtrate was concentrated under reduced
pressure and the residue was purified by column chromatography (hexanes:EtOAc, 9:1) to
give 3.130 (1.1 g, 75%) as yellow solid.
1H NMR (CDCl3): δH 2.16 (1H, dd, J =13.5, 3.2 Hz, H-4eq), 2.68-3.20 (3H, m, H-α, H-3,
H-4), 3.05 (1H, dd, J = 2.4, 10.4, Hz, H- α), 3.18 (1H, ddd, J = 3.2, 11.1, 13.2, Hz, H-3eq),
3.65 (3H, s, 7-OCH3), 3.80 (3H, s, 6-OCH3), 4.35 (1H, dd, J = 2.8, 10.4 Hz, H-1), 5.99
(1H, s), 6.31 (1H, s), 6.99 (2H, d, J = 8.6), 7.01 (1H, d, J = 7.8), 7.14 (2H, t, J = 7.8 Hz)
7.20 (2H, t, J = 7.8 Hz), 7.35 (2H, d, J = 8.6 Hz).
13C NMR (CDCl3): δC 23.7, 24.5, 32.5, 40.6, 56.2, 59.4, 117.1 (2C), 121.4 (2C), 125.3
(2C), 126.9, 127.8, 128.6, 130.9 (2C), 132.1, 133.7 (2C), 141.2, 146.9, 153.1 and 156.9.
HRESIMS (positive ionisation mode), m/z found 376.1913 [M+H]+, calculated for
C24H25O4N 376.1912.
IR: υmax (neat)/cm-1 2944, 2845, 1662, 1589, 1503, 1487, 1466, 1231, 1199, 1164, 1071,












The mixture of p-fluorobenzaldehyde (3.80) (0.15 g, 1.24 mmol), phenol 3.104 (0.60 g,
1.24 mmol) and K2CO3 (0.8 mmol) were dissolved in DMF (10 ml) and heated at reflux for
1 h under microwave (100 °C).  The reaction was then cooled to room temperature filtered
and acidified with HCl (pH indicator).  The reaction mixture was extracted with EtOAc (3
x 50 ml) was washed with brine and concentrated to a crude solid. Purification by column
chromatography gave 3.131 (0.62 g, 85%) as colorless crystals from chloroform m.p. 145-
146 ºC.
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1H NMR (CDCl3): δH 0.79 (3H, d, J = 6.4 Hz, CHCH3), 2.31 (1H, dd, J =16.8, 4.4, H-4),
2.74-2.93 (4H, m, 2x H-α, H-3, H-4), 3.22 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3), 3.63
(1H, q, J = 6.4 Hz, CHCH3), 3.60 (3H, s, 7-OCH3), 3.81 (3H, s, 6-OCH3), 4.04 (1H, t, J =
5.3, 7.8), 6.53 (1H, s, H-5), 7.01-7.09 (6H, m, ArH), 7.20 (3H, ArH), 7.39 (2H, d, J = 8.1),
7.86 (2H, d, J = 8.6 Hz) and 9.88 (1H, s, CHO).
13C NMR (CDCl3): δC 21.9, 22.8, 31.9, 39.4, 40.4, 53.9, 56.0, 58.0, 60.9, 110.0, 115.3
(2C), 119.6, 124.1, 126.8, 127.1 (2C), 128.3 (2C), 130.7 (2C), 131.1, 131.3 (2C), 131.6,
132.1 (2C), 139.8, 144.4, 145.7, 152.2, 163.0 and 190.7.
HRESIMS (positive ionisation mode), m/z found 586.1594 [M+H]+, calculated for
C33H32
79BrNO4 586.1593.
IR: υmax (neat)/cm-1 (ATR platinum gold) 3479, 2952, 2922, 2855, 1727, 1698, 1686, 1612,
1601, 1582, 1500, 1459, 1377, 1278, 1231, 1157, 1119 and 1071.











t-BuOK (187 mg, 1.67 mmol) was added at 0 oC to a suspension of triphenylphosphonium
methyl iodide (519 mg, 1.39 mmol) in dry THF (10 ml), and stirred for 15 min followed by
addition of a solution of 4-[1-(4-Bromobenzyl)-6,7-dimethoxy-2-(1-phenylethyl)-1,2,3,4-
tetrahydroisoquinolin-8-yloxy]benzaldehyde (3.131) (0.6 g, 1.08 mmol) in dry THF (5ml).
The mixture was stirred at 0 oC for 12 h (TLC).  Upon completion of the reaction the
mixture was concentrated under vacuum and partitioned between water and Et2O.  The
organic layer was washed with water, brine and dried over MgSO4 and concentrated.
Purification by column chromatography (hexanes:EtOAc, 95:5) gave 3.132 (0.59 g, 95%)
as a colorless oil.
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1H NMR (CDCl3): δH 0.80 (3H, d, J = 6.3Hz, CHCH3), 2.33 (1H, dd, J =16.6, 4.2 Hz, H-
4), 2.76-2.96 (4H, m, 2x H-α, H-3, H-4), 3.25 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3),
3.69 (1H, q, J = 6.3 Hz, CHCH3), 3.63 (3H, s, 7-OCH3), 3.84 (3H, s, 6-OCH3), 4.08 (1H, t,
J = 5.3, 7.8 Hz, H-1), 5.19 (1H, d, J = 10.5 Hz CH2CH, cis), 5.62 (1H, d, J = 16.9 Hz
CH2CH, trans), 6.59 (1H, dd, J = 16.9, 10.5 Hz CH2CH), 6.61 (1H, s, H-5), 7.09-7.17 (6H,
m, ArH), 7.25 (3H, ArH), 7.40 (4H, m, ArH).
13C NMR (CDCl3): δC 21.7, 22.9, 32.3, 39.6, 40.4, 53.9, 56.0, 58.0, 60.9, 109.8, 114.6,
115.2 (2C), 119.8, 124.6, 126.9, 127.5 (2C), 128.6 (2C), 129.7 (2C), 131.3, 131.5 (2C),
131.7, 132.4 (2C), 135.9, 140.1, 142.9, 145.9, 152.4 and 163.0.
HRESIMS (positive ionisation mode), m/z found 584.1801 [M+H]+, calculated for
C34H34
79BrNO3 584.1800.
IR: υmax (neat)/cm-1 2931, 1602, 1503, 1490, 1462, 1345, 1278, 1166, 1112, 1071, 987,
835, 765 and 699.













.S(CH3)2 (0.91 mmol, 5M) was added at 0 ºC to a solution of 3.132 (0.52 g, 0.9 mmol)
in dry THF (10ml), and stirred for 4 h at room temperature.  The mixture was cooled to 0
ºC and the solution of NaOH (10.0 mmol) in EtOH/H2O (2:1, 30 ml) followed by H2O2
(2.5 mmol) were added dropwise over 30 min, then stirred overnight at 0 ºC.  Upon
completion of the reaction the mixture was extracted with EtOAc (3 x 30 ml) and the
organic layer was washed with water, brine and dried over MgSO4 and concentrated.
Compound 3.133 was isolated after chromatography (hexanes:EtOAc, 8:2) as a colourless
liquid (0.36 g, 70%).
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1H NMR (CDCl3): δH 0.78 (3H, d, J = 6.3Hz, CHCH3), 2.30 (1H, dd, J =16.6, 4.2 Hz, H-
4), 2.72-2.92 (6H, m, 2x H-α, H-3, H-4, CH2CH2OH), 3.23 (1H, dt, J = 13.6, 11.7, 5.0, 2.0
Hz, H-3), 3.65 (1H, q, J = 6.3 Hz, CHCH3), 3.71 (2H, t, J = 6.3 Hz, CH2CH2OH),  3.76
(3H, s, 7-OCH3), 3.90 (3H, s, 6-OCH3), 4.20 (1H, t, J = 5.3, 7.8, H-1), 6.60 (1H, s, H-5),
7.04-7.11 (6H, m, ArH), 7.19 (3H, ArH), 7.35-44 (4H, m, ArH).
13C NMR (CDCl3): δC 21.6, 32.4, 38.5, 40.5, 46.5, 53.7, 53.9, 58.0, 60.6, 62.8, 109.5,
114.2, 114.9 (2C), 119.5, 124.2, 126.5, 127.3 (2C), 128.2 (2C), 129.3 (2C), 131.1, 131.3
(2C), 131.5, 132.2 (2C), 135.7, 139.7, 142.5, 145.3 and 152.2.
HRESIMS (positive ionisation mode), m/z found 602.1906 [M+H]+, calculated for
C34H36
79BrNO4 602.1905.
IR: υmax (neat)/cm-1 3429, 2938, 1604, 1503, 1490, 1462, 1347, 1276, 1168, 1119, 1071,
989, 824, 774 and 701.












To a suspension of (methoxymethyl)triphenylphosphonium chloride (1.2 g, 3.7 mmol) in
dry THF (10 ml) t-BuOK (0.49 g, 4.4 mmol) was added at 0 oC for 15 min.  Then 3.131
(0.54 g, 0.92 mmol) in dry THF (5 ml) was added, the reaction mixture was stirred for 1 h
at rt. Upon completion of the reaction the mixture was concentrated under vacuum and
partitioned between water and Et2O.  The aqueous layer was extracted with Et2O (2 x 20
ml), the combined organic layer was washed with water and brine, dried and concentrated
under vacuum. Flash column chromatography (hexanes:EtOAc, 7:3) gave 3.134 (0.51 g,
90%) as a yellow oil.
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1H NMR (CDCl3): δH 0.76 (3H, d, J = 6.3 Hz, CHCH3), 2.26 (1H, dd, J =16.6, 4.2, H-4),
2.72 (1H, dd, J = 5.6, 14.1 Hz, H-3), 2.80-2.86 (2H, m, H-α, H-4), 3.01 (1H, dd, J = 5.6,
10.4, H-α), 3.22 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3), 3.62 (1H, q, J = 6.3 Hz,
CHCH3), 3.68 (3H, s, OCH3), 3.74 (3H, s, 7-OCH3), 3.89 (3H, s, 6-OCH3), 4.20 (1H, dd, J
= 2.78, 7.8), 5.20 (1H, d, J = 10.5 Hz, CHOMe, cis), 5.80 (1H, d, J = 16.9 Hz, CHOMe,
trans), 6.19 (1H, d, J = 10.5 Hz, CHCHOMe, cis), 6.59 (1H, dd, J = 16.9, 10.5 Hz,
CH2CH), 6.58 (1H, s, H-5), 6.86 (2H, m, ArH), 6.95 (1H, d, J = 16.9 Hz CHOMe, trans),
7.08-7.21 (8H, m, ArH), 7.39 (2H, ArH), 7.53 (1H, ArH).
13C NMR (CDCl3): δC 22.0, 22.6, 32.5, 39.4, 40.4, 53.8, 56.0, 56.5, 57.9, 60.5, 60.7, 104.5,
105.2, 109.4, 114.5, 115.0 (2C), 119.4, 124.8, 126.3, 127.1 (2C), 128.2 (2C), 129.5 (2C),
130.5, 131.1, 131.4, 135.9, 140.2, 142.9, 145.2, 147.9, 152.1, 156.2 and 156.5.
HRESIMS (positive ionisation mode), m/z found 612.1750 [M+H]+, calculated for
C35H34O
79BrNO4 612.1749.
IR: υmax (neat)/cm-1 2933, 1608, 1505, 1497, 1465, 1335, 1268, 1177, 1118, 1070, 966,
833 and 701.













IBX (3.67) (0.15 g, 0.57 mmol) was dissolved in DMSO (10ml) and the dissolution of IBX
(3.67) required 10-15 min.  The phenylethanol 3.133 (0.34 g, 0.57 mmol) dissolved in
DMSO (5ml) was added and the reaction was stirred at room temperature for 15 h
monitored by TLC.  The reaction was diluted with water followed by the extraction with
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EtOAc, the organic layer was washed several times with water and concentrated to a give
the desired product.  Compound 3.135 was isolated as a colourless solid (0.24 g, 70%).
Method 2: Hydrolysis of 3.134
Formic acid (3 ml) was added to a solution of 3.134 (0.1 g, 0.16 mmol) in CH2Cl2 (10 ml)
The reaction mixture was stirred for 48 hr at the room temperature, then diluted with water
followed by the extraction with CH2Cl2, the organic layer was washed several times with
water and concentrated to give 3.135 (76 mg, 75%) as a colourless solid.
1H NMR (CDCl3): H 0.80 (3H, d, J = 6.4 Hz, CHCH3), 2.32 (1H, dd, J =16.8, 4.4 Hz, H-
4), 2.76-2.93 (4H, m, 2x H-α, H-3, H-4), 3.22 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3),
3.59-363 (3H, m, CH2CHO, CHCH3), 3.62 (3H, s, 7-OCH3), 3.83 (3H, s, 6-OCH3), 4.19
(1H, d, J = 5.3, 7.8 Hz), 6.52 (1H, s, H-5), 6.98-7.12 (11H, m, ArH), 7.45 (2H, ArH),  9.85
(1H, t, J = 2.4 Hz, CHO).
13C NMR (CDCl3): δC 21.9, 22.6, 39.4, 40.4, 53.9, 56.0, 57.9, 60.5, 60.7, 104.5, 109.4,
114.5, 115.0 (2C), 119.4, 126.3, 127.1 (2C), 128.2 (2C), 129.5 (2C), 130.6, 131.1, 131.4,
135.9, 140.3, 143.1, 144.9, 148.2, 152.1, 156.2, 156.5 and 199.9.
HRESIMS (positive ionisation mode), m/z found 601.1750 [M+H]+, calculated for
C34H34
79BrNO4 601.1749.
IR: υmax (neat)/cm-1 3496, 2923, 2852, 1731, 1685, 1611, 1581, 1512, 1482, 1422, 1290,
1237, 1196, 1153, 1070, 933, 873 and 688.
[α]D25 = + 7.6 (c = 1.0, CHCl3).




















To a solution of amine alcohol 3.41 (0.18 g, 0.58 mmol), phenylacetaldehyde 3.135 (0.3 g,
0.50 mmol), 3 Å molecular sieves (0.1 g) in CH2Cl2 and 2,2,2-trifluoroethanol (7:1, v/v, 20
ml), acetic acid (0.1 eq.) was added dropwise.  The reaction was refluxed for 18 h and
upon completion of the reaction the mixture was diluted with CH2Cl2 and filtered.  The
filtrate was concentrated under reduced pressure and the residue was purified by column
chromatography (hexanes:EtOAc, 9:1) to give 3.136 as a colourless solid (0.12 g, 40%).
1H NMR (CDCl3): δH 0.78 (6H, d, J = 6.3 Hz, 2 x CHCH3), 2.13 (2H, m, H-3, H-4), 2.30
(1H, dd, J =16.6, 4.2 Hz, H-4), 2.25-2.45 (4H, m, 2x H-α, H-3, H-4), 2.72-2.92 (4H, m, 2x
H-α, H-3, H-4), 3.23 (1H, dt, J = 13.6, 11.7, 5.0, 2.0 Hz, H-3), 3.65 (2H, q, J = 6.3 Hz, 2 x
CHCH3), 3.65 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3),
4.18 (1H, t, J = 5.3, 7.8), 4.20 (1H, t, J = 5.3, 7.8 Hz, H-1), 6.54 (1H, s, ArH), 6.60 (1H, s,
ArH), 6.79 (2H, d J = 8.4 Hz), 7.04-7.11 (6H, m, ArH), 7.16 (6H, m, ArH), 7.19 (3H,
ArH), 7.35-44 (2H, m, ArH).
13C NMR (CDCl3): δC 31.8, 32.4, 37.8, 38.5, 45.7, 52.9, 53.7, 53.9, 54.3, 57.3, 58.0, 60.6,
61.7, 62.8, 108.6, 109.2, 113.9, 114.2, 115.3 (2C), 118.6, 119.5, 123.9, 124.2, 126.0, 126.5,
127.0, 127.3 (2C), 127.9, 128.2 (2C), 128.9 (2C), 129.3 (2C), 129.9, 131.1 (2C), 131.3,
131.5, 131.9 (2C), 132.2 (2C), 134.9, 135.7, 137.3, 138.3, 139.7, 142.5, 145.3.
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Appendix: NMR spectra of selected compounds
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Plate 3: 1H NMR spectrum of a mixture of regioisomers.
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Plate 10: 1H NMR spectrum of 3.135.
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